Timothy Hughes
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Professor Timothy P. Hughes, MD, FRACP, FRCPA, MBBS, FAAHMS - TITLEHOLDER.
Professor Timothy Hughes is Precision Medicine Theme Leader at SAHMRI
Professor Timothy Hughes is the Precision Medicine Theme Leader at SAHMRI; Beat Cancer Professor at the University of Adelaide and Consultant Haematologist at the RAH. He is also Chair of the International Chronic Myeloid Leukemia Foundation (iCMLf); an inaugural Fellow of the Australian Academy of Health and Medical Sciences (AAHMS)
Professor Hughes had a significant leadership role in the establishment of the molecular response criteria and kinase domain mutation screening guidelines that are used world-wide to monitor response and resistance in chronic myeloid leukaemia (CML). He has been a principal investigator on many of the key Global and Australian CML trials that have shaped the way tyrosine-kinase inhibitors (TKI's) are selected and sequenced. He has been a leader in the area of treatment-free remission (TFR) and influential in the recent recommendations to make TFR a mainstream goal of therapy. He has published over 300 papers with over 54,000 citations.
In recognition of his outstanding contributions to the field, Professor Hughes was awarded an L3 Investigator Grant from the NHMRC (2022-2026) for his project "A curative approach for chronic myeloid leukaemia".
Chronic Myeloid Leukaemia (CML) - Precision Medicine Theme, SAHMRI
Lead: Professor Tim Hughes.
Brief description of research area.
The treatment of chronic myeloid leukaemia (CML) has been one of the most remarkable cancer success stories this century, heralding the widespread application of small molecules to target oncogenic kinases. Insights from CML research in this era have provided guidance for the targeted therapy programs in many other cancers. The improvement in 10-year survival for CML patients from 20% in the 1990s to over 80% today has been achieved with the clinical application of tyrosine kinase inhibitor (TKI) therapy targeting BcrAbl. Despite the improvements in outcomes achieved with TKI therapy, major challenges still confront the CML clinician. Transformation to blast crisis is still seen in -10%, similar numbers are resistant to all TKls and only -50% overall achieve deep molecular responses (DMR). Furtherme>re most CML patients will remain dependent on TKI therapy for life with current approaches. As well as the massive cost burden, this longterm dependence on TKI therapy often leads to impaired quality of life and, in some cases, significant organ damage. Pioneering work from the Bordeaux and Adelaide trial groups has shown that around half of the patients who achieve stable DMR can cease TKI therapy without evidence of molecular relapse, even with long-term follow-up ( defined as achieving treatment-free remission -TFR). By contrast the other half have molecular evidence of recurrence, usually within 6 months of stopping, and have to restart TKI therapy. We have made excellent progress in understanding some of the key drivers of DMR and TFR and are already translating some of these findings into clinical trials to expand opportunity for these optimal outcomes. This emerging knowledge will provide urgently needed criterio for safe TKI cessation and guide the design of future trials to maximise TFR with consequent major benefits for many CML patients. CML is projected to become the most prevalent leukaemia by 2040, so for f'he thousands of CML patients in Australia who are facing lifelong dependence on expensive and debilitating therapy, support for this work is critical.
Research Project 1 – Dr Ilaria Pagani
Title: Identifying and exploiting metabolic dependencies for improved therapeutic outcomes in chronic myeloid leukaemia.
While the treatment of BCR-ABL1 driven chronic myeloid leukaemia (CML) with tyrosine kinase inhibitors (TKI) has been a success story of modern medicine, not all patients respond optimally, with a small but significant minority progressing to fatal blast crisis.
The inability of TKIs to eradicate leukaemic stem and progenitor cells (LSPC) provides a potential pool for subsequent relapse. This is exemplified by the dependence of most CML patients on lifelong TKI treatment, even in patients who achieve molecular responses. Universally, the presence of an activated tyrosine kinase drives metabolic changes, and the perturbation of these metabolic pathways provides potential avenues for exploration of therapeutic interventions. Targeting metabolic pathways may potentiate the effect of TKI therapies particularly in the LSPC compartment.
The aim of the project will be to investigate the metabolic pathways that exists within normal haematopoietic cells (important knowledge to avoid toxicity), and in LSPC including cases sensitive and resistant to TKIs to enable a clear understanding of whether the metabolome of LSPC can be targeted to sensitise this pool to TKI therapy.
This novel and innovative approach will likely provide a combinational treatment strategy with greater efficacy than current approaches, specifically in CML blast crisis.
Project available for: Honours / Mphil / PhD
Location: SAHMRI
Research project start: Semester 1
Special requirements: Police Clearance
Research Project 2 – Dr Ilaria Pagani
Title: Monitoring of minimal residual disease on chronic myeloid leukaemia patients in a setting of treatment free remission.
For patients who have achieved deep molecular responses and have minimal residual disease after treatment, the new goal for clinicians today is to identify candidate patients that can safely cease TKI therapy achieving treatment free remission (TFR). It is estimated that approximately 50% of CML patients may be eligible to stop TKIs, however half of them experience molecular relapse, usually within 6 months, and have to restart therapy. CML is projected to become the most prevalent leukaemia by 2040, therefore is critical to maximise the number of patients achieving TFR. However, unravelling the critical mediators of TFR is a major challenge.
The aim of the project will be to characterise the residual leukaemia population in TFR patients, and understand why some patients relapse and others don’t. One possible line of inquiry involves identifying the lineage of residual CML cells, through a highly sensitive DNA approach. This will involve a characterization of the genomic breakpoint and the development of a patient-specific assay to monitor residual leukaemia on sorted cell populations.
Project available for: Honours / Mphil / PhD
Location: SAHMRI
Research project start: Semester 1
Special requirements: Police Clearance
Research Project 3 - Dr David Yeung, Dr Liu Lu and Dr Ilaria Pagani
Title: Investigating the efficacy of a combination of TKI and a novel allosteric inhibitor asciminib in chronic myeloid leukaemia.
Clinical trials for the treatment of CML are currently underway using asciminib (ABL001), an allosteric inhibitor, alone and in combination with ATP-competitive tyrosine kinase inhibitors (TKIs: imatinib, nilotinib or dasatinib), to inhibit the constitutively active tyrosine kinase Bcr-Abl. The aims of this project are:
- Investigation of the synergistic effect of the combination of TKI and asciminib.
- Understand the signalling pathway changes in BCR-ABL+ cell lines and CML patient cells when combination therapy is given.
- Generation of resistant cell lines in the laboratory setting. This provides a useful tool for predicting and studying patient responses in vivo.
Understanding how these drugs work in synergy will enhance our ability to predict whether patients are likely to respond to combination therapy, and clarify ways to maximise synergism between these agents. In this project, BCR-ABL1+ cell lines will be exposed long term to gradually increasing concentrations of asciminib in combination with TKI. Mechanisms of resistance will be interrogated during resistance development and once overt resistance is observed. We will then examine mechanisms of treatment resistance in vitro, in an attempt to predict emergent disease resistance mechanisms that may arise.
Project available for: Honours / Mphil / PhD
Location: SAHMRI
Research project start: Semester 1
Special requirements: Police Clearance
Research Project 4 - Dr Chung Kok
Title: Developing an artificial intelligence-based algorithm to enable a risk-adapted approach to frontline therapy in chronic myeloid leukaemia (CML).
Chronic myeloid leukaemia (CML) is a model cancer for targeted therapy, driven by an activated mutant kinase. BCR-ABL1 is both necessary and sufficient to cause CML, through the expression of the constitutively active tyrosine kinase Bcr-Abl, targetable using tyrosine kinase inhibitors (TKIs). Despite the excellent progress we have made, major challenges remain. Even with our current choice of 5 TKIs, 15-20% respond poorly to TKI therapy and half of these patients will die from CML-related causes. Approximately 10% patients still fail to respond despite receiving second generation TKIs frontline, which are more potent than the first generation TKI imatinib. This very high-risk (VHR) group would likely be more effectively managed with a “dual targeted” approach from the start of therapy. For this reason, we have focused on developing baseline predictors of treatment failure to first and second generation TKIs, so that subsequent adverse outcomes can be minimized in high-risk cases by using a more intensive approach upfront. However, this approach would not be beneficial for most patients - adding toxicity without clinical benefit in the low-risk (LR) setting. Predictors that are capable of identifying the patients most likely to benefit from the use of a more potent TKI (high-risk (HR)) and the patients who will do poorly with any of the currently available TKIs (VHR) are urgently needed. We have previously published several bioassays that are predictive of response to frontline therapy in CML, however no single assay allows a sufficiently precise classification of patient risk groups to be clinically actionable.
We propose that the most effective approach will be to utilise all of these biomarkers to develop an artificial intelligence (AI) based algorithm to guide front-line therapy. This will enable up-front triaging of CML patients, tailoring therapy to the most appropriate risk-adapted approach. The theme of this proposal, therefore, is maximising the clinical effectiveness of rationally targeted therapies in CML.
HYPOTHESES
High-risk and very high-risk patients can be identified using an artificial-intelligence derived predictive algorithm based on informative biomarkers to
- enable optimal risk-adapted treatment decisions and
- maximise the clinical effectiveness of rationally targeted therapies.
SPECIFIC AIMS
Aim 1. Develop and validate an artificial intelligence (AI) based algorithm by integrating clinical and laboratory information to predict therapy-specific risk of failure in CML
Aim 2. Design interventions in patients identified as very high-risk based on pathways identified as potential actionable targets
Aim 3. Explore the potential use of the AI algorithm in a dynamic setting to enhance clinical utility
Project available for: Honours / Mphil / PhD
Location: SAHMRI
Research project start: Semester 1
Special requirements: Police Clearance
-
Appointments
Date Position Institution name 2019 - ongoing Precision Medicine Theme Leader South Australian Health and Medical Research Institute (SAHMRI) 2015 - 2020 Chair SA Comprehensive Cancer Collaborative (SACCC) 2015 - 2018 Cancer Theme Leader South Australian Health and Medical Research Institute 2013 - ongoing Cancer Council Professor SAHMRI 2013 - ongoing Chair International CML Foundation (iCMLf) 2008 - ongoing Co-founder International CML Foundation (iCMLf) 2008 - 2014 Head, Department of Haematology SA Pathology 1993 - ongoing Consultant Haematologist, , Division of Haematology Royal Adelaide Hospital & SA Pathology 1991 - 1993 Post-Doctoral Fellow Howard Hughes Medical Institute, UCLA, California USA 1989 - 1991 Leukaemia Research Fellow Adult Leukaemia Research Centre, Royal Postgraduate Medical School, Hammersmith Hospital, London UK 1987 - 1988 Haematology Registrar Prince Henry Hospital, Sydney -
Awards and Achievements
Date Type Title Institution Name Country Amount 2019 Award Ramaciotti Medal for Excellence in Biomedical Research Ramaciotti Australia - 2018 Achievement Clarivate top 1% of cited scientists in their field internationally Clarivate Australia - 2017 Award GSK Award for Research Excellence, Research Australia Health & Medical Research Awards Research Australia Health & Medical Research Australia - 2017 Award Goldman Prize, International CML Foundation (iCMLf) – outstanding lifetime contribution to the management of CML International CML Foundation (iCMLf) Australia - 2015 Research Award CIC on Top Ranked NHMRC Program Grant assessed in 2013 NHMRC Australia - 2015 Fellowship Inaugural Fellow of the Australian Academy of Health and Medical Sciences (AAHMS) Australian Academy of Health and Medical Sciences (AAHMS) Australia - 2015 Achievement Carl De Gruchy Award, HSANZ for lifetime achievements HSANZ Australia - 2015 Award The World’s Most Influential Scientific Minds 2015, “Clinical Medicine” Thomson Reuters Australia - 2014 Award Top 1% of highly cited Scientists in 2014 Thomson Reuters Australia - 2011 Research Award NHMRC Ten of the Best Research Projects NHMRC Australia - -
Education
Date Institution name Country Title 1993 University of New South Wales Australia Doctor of Medicine 1988 Fellowship of the Royal Australasian College of Physicians Australia FRACP 1988 Fellowship of the Royal College of Pathologists of Australia Australia FRCPA 1981 The University of New South Wales Australia MBBS Hons -
Research Interests
-
Journals
Year Citation 2025 Hughes, T. P., Yong, A. S. M., & Ross, D. M. (2025). The evolution of treatment-free remission. Blood, 145(9), 921-930.
Scopus12024 Eadie, L. N., Lagonik, E., Page, E. C., Schutz, C. E., Heatley, S. L., McClure, B. J., . . . White, D. L. (2024). Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy. Blood, 144(9), 1022-1026.
Europe PMC12024 Hochhaus, A., Wang, J., Kim, D. W., Kim, D. D. H., Mayer, J., Goh, Y. T., . . . Hughes, T. P. (2024). Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. New England Journal of Medicine, 391(10), 885-898.
Scopus34 Europe PMC242024 Chee, L., Lee, N., Grigg, A., Chen, M., Schwarer, A., Szer, J., . . . Shanmuganathan, N. (2024). Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia. Internal Medicine Journal, 54(7), 1214-1218.
Scopus1 Europe PMC12024 Yeung, D. T., Shanmuganathan, N., Reynolds, J., Branford, S., Walia, M., Yong, A. S. M., . . . Viiala, N. (2024). Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study. Blood, 144(19), 1993-2001.
Scopus7 Europe PMC22024 Lim, K., Kan, W. L., Nair, P. C., Kutyna, M., Lopez, A. F., Hercus, T., . . . Thomas, D. (2024). CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting. PLoS One, 19(9), e0310641-1-e0310641-19.
2024 Hochhaus, A., Cortes, J. E., & Hughes, T. P. (2024). Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. Reply. The New England journal of medicine, 391(23), 2275-2276.
2024 Hughes, T. P., Saglio, G., Geissler, J., Kim, D. W., Lomaia, E., Mayer, J., . . . Cortes, J. E. (2024). Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study. Journal of Hematology and Oncology, 17(1), 12 pages.
Scopus2 Europe PMC12024 Kantarjian, H., Branford, S., Breccia, M., Cortes, J., Haddad, F. G., Hochhaus, A., . . . Xavier-Mahon, F. (2024). Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?. Leukemia, 38(5), 947-950.
Scopus62024 Cortes, J. E., Sasaki, K., Kim, D. W., Hughes, T. P., Etienne, G., Mauro, M. J., . . . Rea, D. (2024). Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia, 38(7), 1522-1533.
Scopus16 Europe PMC32024 Holmgren, A., Akkouh, I., O'Connell, K. S., Osete, J. R., Bjornstad, P. M., Djurovic, S., & Hughes, T. (2024). Bipolar patients display stoichiometric imbalance of gene expression in post-mortem brain samples. MOLECULAR PSYCHIATRY, 29(4), 1128-1138.
2023 Osete, J. R., Akkouh, I. A., Ievglevskyi, O., Vandenberghe, M., de Assis, D. R., Ueland, T., . . . Djurovic, S. (2023). Characterization of lithium (Li) treated human cortical spheroids (hCS). MOLECULAR PSYCHIATRY, 28(7), 2621.
2023 Leow, B. C. S., Kok, C. H., Yeung, D. T., Hughes, T. P., White, D. L., & Eadie, L. N. (2023). The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism. Sci Rep, 13(1), 1-12.
2023 Pagani, I. S., Shanmuganathan, N., Dang, P., Saunders, V. A., Grose, R., Kok, C. H., . . . Ross, D. M. (2023). Lineage-specific detection of residual disease predicts relapse in chronic myeloid leukemia patients stopping therapy. Blood, 142(25), 2192-2197.
Scopus4 WoS12023 Kok, C. H., Saunders, V. A., Dang, P., Shanmuganathan, N., White, D., Branford, S., . . . Hughes, T. P. (2023). Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib. Blood Cancer Journal, 13(1), 1-9.
Scopus12023 Shanmuganathan, N., & Hughes, T. P. (2023). Accelerated-phase CML: de novo and transformed. Hematology (United States), 2023(1), 459-468.
2023 Torsvik, A., Brattbakk, H. -R., Trentani, A., Holdhus, R., Stansberg, C., Bartz-Johannessen, C. A., . . . Steen, V. M. (2023). Patients with schizophrenia and bipolar disorder display a similar global gene expression signature in whole blood that reflects elevated proportion of immature neutrophil cells with association to lipid changes. TRANSLATIONAL PSYCHIATRY, 13(1), 12 pages.
Europe PMC72023 Irani, Y. D., Hughes, A., Kok, C. H., Clarson, J., Yeung, D. T., Ross, D. M., . . . Yong, A. S. M. (2023). Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha. British Journal of Haematology, 202(6), 1127-1136.
Scopus4 WoS1 Europe PMC22023 Osete, J. R., Akkouh, I. A. A., Ievglevskyi, O., Vandenberghe, M., de Assis, D. R., Ueland, T., . . . Djurovic, S. (2023). Transcriptional and functional effects of lithium in bipolar disorder iPSC-derived cortical spheroids. MOLECULAR PSYCHIATRY, 28(7), 3033-3043.
WoS1 Europe PMC162023 Cortes, J. E., Hochhaus, A., Takahashi, N., Larson, R. A., Issa, G. C., Bombaci, F., . . . Hughes, T. P. (2023). Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncology, 18(38), 4161-4170.
Scopus8 Europe PMC32023 Irani, Y. D., Kok, C. H., Clarson, J., Shanmuganathan, N., Branford, S., Yeung, D. T., . . . Yong, A. S. (2023). Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia. Blood Advances, 7(11), 2364-2374.
Scopus10 WoS1 Europe PMC62023 Radich, J. P., Wall, M., Branford, S., Campbell, C. D., Chaturvedi, S., DeAngelo, D. J., . . . Druker, B. J. (2023). Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis. Haematologica, 108(6), 1567-1578.
Scopus2 WoS2 Europe PMC22023 Hochhaus, A., Réa, D., Boquimpani, C., Minami, Y., Cortes, J. E., Hughes, T. P., . . . Mauro, M. J. (2023). Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia, 37(3), 617-626.
Scopus82 WoS15 Europe PMC362023 Shanmuganathan, N., Wadham, C., Shahrin, N., Feng, J., Thomson, D., Wang, P., . . . Branford, S. (2023). Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention. Haematologica, 108(9), 2380-2395.
Scopus6 WoS2 Europe PMC42023 Mauro, M. J., Hughes, T. P., Kim, D. W., Rea, D., Cortes, J. E., Hochhaus, A., . . . Lang, F. (2023). Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia, 37(5), 1048-1059.
Scopus25 WoS4 Europe PMC182022 Holmgren, A., Hansson, L., Bjerkaas-Kjeldal, K., Impellizzeri, A. A. R., Gilfillan, G. D., Djurovic, S., & Hughes, T. (2022). Mapping the expression of an <i>ANK3</i> isoform associated with bipolar disorder in the human brain. TRANSLATIONAL PSYCHIATRY, 12(1), 8 pages.
WoS1 Europe PMC12022 Krull, F., Akkouh, I., Hughes, T., Bettella, F., Athanasiu, L., Smeland, O. B., . . . Andreassen, O. A. (2022). Dose-dependent transcriptional effects of lithium and adverse effect burden in a psychiatric cohort. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 112, 8 pages.
WoS4 Europe PMC42022 O'Connell, K. S., Sonderby, I. E., Frei, O., van der Meer, D., Athanasiu, L., Smeland, O. B., . . . Djurovic, S. (2022). Association between complement component 4A expression, cognitive performance and brain imaging measures in UK Biobank. PSYCHOLOGICAL MEDICINE, 52(15), 3497-3507.
WoS7 Europe PMC142022 Hughes, T. P., Cortes, J. E., Réa, D., Mauro, M. J., Hochhaus, A., Kim, D. W., . . . Mahon, F. X. (2022). CML-466 Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial. Clinical Lymphoma, Myeloma and Leukemia, 22, S300.
Scopus12022 Réa, D., Hochhaus, A., Mauro, M. J., Minami, Y., Lomaia, E., Voloshin, S., . . . Boquimpani, C. (2022). CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update. Clinical Lymphoma, Myeloma and Leukemia, 22, S295-S296.
Scopus1 WoS12022 Hughes, T. P., Cortes, J., Takahashi, N., Larson, R., Issa, G. C., Bombaci, F., . . . Hochhaus, A. (2022). CML-423 Trial in Progress: A Phase III Study of Asciminib vs an Investigator-Selected Tyrosine Kinase Inhibitor (TKI) in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Clinical Lymphoma, Myeloma and Leukemia, 22, S297-S298.
2022 Hughes, T. P., & Shanmuganathan, N. (2022). Management of TKI-resistant chronic phase CML. Hematology. American Society of Hematology. Education Program, 2022(1), 129-137.
Scopus11 WoS3 Europe PMC82022 Page, E. C., Heatley, S. L., Eadie, L. N., McClure, B. J., de Bock, C. E., Omari, S., . . . White, D. L. (2022). HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort. Oncogene, 41(6), 797-808.
Scopus13 WoS5 Europe PMC102022 Shirazi, P. T., Eadie, L. N., Heatley, S. L., Page, E. C., François, M., Hughes, T. P., . . . White, D. L. (2022). Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia. Cancer Gene Therapy, 29(8-9), 1140-1152.
Scopus6 WoS2 Europe PMC52022 Réa, D., & Hughes, T. P. (2022). Development of asciminib, a novel allosteric inhibitor of BCR-ABL1. Critical Reviews in Oncology/Hematology, 171, 11 pages.
Scopus37 WoS12 Europe PMC142022 Adnan Awad, S., Brück, O., Shanmuganathan, N., Jarvinen, T., Lähteenmäki, H., Klievink, J., . . . Mustjoki, S. (2022). Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation. Blood Cancer Journal, 12(4), 4 pages.
Scopus14 WoS7 Europe PMC52022 Yeung, D. T., Shanmuganathan, N., & Hughes, T. P. (2022). Asciminib: a new therapeutic option in chronic-phase CML with treatment failure. Blood, 139(24), 3474-3479.
Scopus31 WoS9 Europe PMC122022 Shanmuganathan, N., Wadham, C., Thomson, D., Shahrin, N. H., Vignaud, C., Obourn, V., . . . Branford, S. (2022). RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid Leukemia.. The Journal of molecular diagnostics : JMD, 24(7), 803-822.
Scopus5 WoS1 Europe PMC32022 Lu, L., Kok, C. H., Dang, P., Branford, S., Saunders, V. A., Shanmuganathan, N., . . . Yeung, D. T. O. (2022). Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission. British Journal of Haematology, 198(3), 600-603.
Scopus6 Europe PMC12022 Shanmuganathan, N., & Hughes, T. P. (2022). Asciminib for chronic myeloid leukaemia: Next questions. British Journal of Haematology, 199(3), 322-331.
Scopus10 WoS4 Europe PMC22022 Poudel, G., Tolland, M. G., Hughes, T. P., & Pagani, I. S. (2022). Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia. Cancers, 14(14), 18 pages.
Scopus31 WoS10 Europe PMC212022 Kutyna, M. M., Kok, C. H., Lim, Y., Tran, E. N. H., Campbell, D., Paton, S., . . . Hiwase, D. K. (2022). A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure. Leukemia, 36(11), 2678-2689.
Scopus14 WoS4 Europe PMC122022 Krishnan, V., Kim, D. D. H., Hughes, T. P., Branford, S., & Ong, S. T. (2022). Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: Toward gene expression-based biomarkers. Haematologica, 107(2), 358-370.
Scopus15 WoS6 Europe PMC92021 El Khawanky, N., Hughes, A., Yu, W., Myburgh, R., Matschulla, T., Taromi, S., . . . Zeiser, R. (2021). Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat Commun, 12(1), 6436-1-6436-20.
Scopus69 WoS30 Europe PMC462021 Réa, D., Mauro, M. J., Boquimpani, C., Minami, Y., Lomaia, E., Voloshin, S., . . . Hochhaus, A. (2021). A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood, 138(21), 2031-2041.
Scopus211 WoS99 Europe PMC1332021 Reis de Assis, D., Szabo, A., Requena Osete, J., Puppo, F., O'Connell, K. S., A. Akkouh, I., . . . Djurovic, S. (2021). Using iPSC Models to Understand the Role of Estrogen in Neuron-Glia Interactions in Schizophrenia and Bipolar Disorder. CELLS, 10(2), 33 pages.
WoS4 Europe PMC62021 Kantarjian, H. M., Hughes, T. P., Larson, R. A., Kim, D. W., Issaragrisil, S., le Coutre, P., . . . Hochhaus, A. (2021). Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021), 35, 2, (440-453), 10.1038/s41375-020-01111-2). Leukemia, 35(7), 2142-2143.
Scopus9 Europe PMC52021 Hughes, T. P., Clementino, N. C. D., Fominykh, M., Lipton, J. H., Turkina, A. G., Moiraghi, E. B., . . . Mahon, F. -X. (2021). Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update.. Leukemia, 35(6), 1631-1642.
Scopus23 WoS15 Europe PMC162021 García-Montolio, M., Ballaré, C., Blanco, E., Gutiérrez, A., Aranda, S., Gómez, A., . . . Di Croce, L. (2021). Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia Cells. Frontiers in Cell and Developmental Biology, 9, 13 pages.
Scopus8 WoS5 Europe PMC72021 Heatley, S. L., Asari, K., Schutz, C. E., Leclercq, T. M., McClure, B. J., Eadie, L. N., . . . White, D. L. (2021). In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy. Leukemia and Lymphoma, 62(5), 1157-1166.
Scopus32021 Kantarjian, H. M., Hughes, T. P., Larson, R. A., Kim, D. W., Issaragrisil, S., le Coutre, P., . . . Hochhaus, A. (2021). Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia, 35(2), 440-453.
Scopus220 WoS120 Europe PMC1192021 Shanmuganathan, N., Pagani, I. S., Ross, D. M., Park, S., Yong, A. S., Braley, J. A., . . . Hughes, T. P. (2021). Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood, 137(9), 1196-1207.
Scopus58 WoS40 Europe PMC272021 Ross, D. M., & Hughes, T. P. (2021). Counterpoint: There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge. British Journal of Haematology, 192(1), 24-27.
Scopus3 WoS3 Europe PMC22021 Akkouh, I. A., Hughes, T., Steen, V. M., Glover, J. C., Andreassen, O. A., Djurovic, S., & Szabo, A. (2021). Transcriptome analysis reveals disparate expression of inflammation-related miRNAs and their gene targets in iPSC-astrocytes from people with schizophrenia. BRAIN BEHAVIOR AND IMMUNITY, 94, 235-244.
WoS6 Europe PMC132021 Szabo, A., Akkouh, I. A., Vandenberghe, M., Osete, J. R., Hughes, T., Heine, V., . . . Djurovic, S. (2021). A human iPSC-astroglia neurodevelopmental model reveals divergent transcriptomic patterns in schizophrenia. TRANSLATIONAL PSYCHIATRY, 11(1), 13 pages.
WoS6 Europe PMC142021 Osete, J. R., Akkouh, I. A., de Assis, D. R., Szabo, A., Frei, E., Hughes, T., . . . Djurovic, S. (2021). Lithium increases mitochondrial respiration in iPSC-derived neural precursor cells from lithium responders. MOLECULAR PSYCHIATRY, 26(11), 6789-6805.
WoS17 Europe PMC242020 Schmitz, U., Shah, J. S., Dhungel, B. P., Monteuuis, G., Luu, P. -L., Petrova, V., . . . Rasko, J. E. J. (2020). Widespread aberrant alternative splicing despite molecular remission in chronic myeloid leukaemia patients. Cancers, 12(12), 3738-1-3738-19.
Scopus10 WoS9 Europe PMC82020 Pagani, I. S., Dang, P., Saunders, V. A., Braley, J., Thieleke, A., Branford, S., . . . Ross, D. M. (2020). Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia. Leukemia and Lymphoma, 61(10), 2527-2529.
Scopus8 WoS4 Europe PMC32020 McClure, B. J., Heatley, S. L., Rehn, J., Breen, J., Sutton, R., Hughes, T. P., . . . White, D. L. (2020). High-risk B-cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapse. British Journal of Haematology, 191(2), 301-304.
Scopus4 WoS1 Europe PMC22020 Thomson, D. W., Shahrin, N. H., Wang, P. P. S., Wadham, C., Shanmuganathan, N., Scott, H. S., . . . Branford, S. (2020). Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia. Leukemia, 34(8), 2051-2063.
Scopus30 WoS22 Europe PMC212020 Shanmuganathan, N., & Hughes, T. P. (2020). What's NEXT for CML-NGS mutation screening. Blood, 135(8), 515-516.
Scopus1 WoS1 Europe PMC12020 Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., . . . Hehlmann, R. (2020). European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia, 34(4), 966-984.
Scopus1064 WoS641 Europe PMC5732020 Turkina, A., Wang, J., Mathews, V., Saydam, G., Jung, C. W., Al Hashmi, H. H., . . . Hughes, T. P. (2020). TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries. British Journal of Haematology, 190(6), 869-876.
Scopus33 WoS29 Europe PMC362020 Mauro, M. J., & Hughes, T. P. (2020). Asciminib in Relapsed Chronic Myeloid Leukemia Reply. NEW ENGLAND JOURNAL OF MEDICINE, 382(14), 1379.
WoS3 Europe PMC22020 Irani, Y. D., Hughes, A., Clarson, J., Kok, C. H., Shanmuganathan, N., White, D. L., . . . Yong, A. S. M. (2020). Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. British Journal of Haematology, 191(3), 433-441.
Scopus60 WoS37 Europe PMC382020 Ross, D. M., & Hughes, T. P. (2020). Treatment-free remission in patients with chronic myeloid leukaemia.. Nature Reviews Clinical Oncology, 17(8), 493-503.
Scopus40 WoS29 Europe PMC232020 Pagani, I. S., Dang, P., Saunders, V. A., Grose, R., Shanmuganathan, N., Kok, C. H., . . . Ross, D. M. (2020). Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. Leukemia, 34(4), 1052-1061.
Scopus40 WoS29 Europe PMC222020 Zhang, Z., Yu, Y., Xie, Y., Hughes, T., Xu, J., Huang, F., & Huang, H. (2020). Catalytic C-C coupling of diazo compounds with arylboronic acids: Using surface modified sewage sludge as catalyst. Green Chemistry, 22(13), 4165-4173.
Scopus7 WoS52020 Hochhaus, A., Boquimpani, C., Rea, D., Minami, Y., Lomaia, E., Voloshin, S., . . . Mauro, M. J. (2020). Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib (BOS) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs). Blood, 136(Supplement_2), 5 pages.
Scopus20 WoS142020 Akkouh, I. A., Ueland, T., Hansson, L., Inderhaug, E., Hughes, T., Steen, N. E., . . . Djurovic, S. (2020). Decreased IL-1β-induced CCL20 response in human iPSC-astrocytes in schizophrenia: Potential attenuating effects on recruitment of regulatory T cells. BRAIN BEHAVIOR AND IMMUNITY, 87, 634-644.
WoS29 Europe PMC262020 Hughes, T., Hansson, L., Akkouh, I., Hajdarevic, R., Bringsli, J. S., Torsvik, A., . . . Djurovic, S. (2020). Runaway multi-allelic copy number variation at the α-defensin locus in African and Asian populations. SCIENTIFIC REPORTS, 10(1), 8 pages.
WoS2 Europe PMC32020 Akkouh, I. A., Skrede, S., Holmgren, A., Ersland, K. M., Hansson, L., Bahrami, S., . . . Hughes, T. (2020). Exploring lithium's transcriptional mechanisms of action in bipolar disorder: a multi-step study. NEUROPSYCHOPHARMACOLOGY, 45(6), 947-955.
WoS16 Europe PMC202019 Dipietro, L., Campbell, W. W., Buchner, D. M., Erickson, K., Powell, K. E., Bloodgood, B., . . . Whitt-Glover, M. C. (2019). Physical Activity, Injurious Falls, and Physical Function in Aging: An Umbrella Review. MEDICINE & SCIENCE IN SPORTS & EXERCISE, 51(6), 1303-1313.
WoS124 Europe PMC1062019 Tavakoli Shirazi, P., Eadie, L. N., Heatley, S. L., Hughes, T. P., Yeung, D. T., & White, D. L. (2019). The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL.. British journal of cancer, 122(4), 455-464.
Scopus8 WoS6 Europe PMC62019 Hughes, T. P., Mauro, M. J., Cortes, J. E., Minami, H., Rea, D., DeAngelo, D. J., . . . Kim, D. -W. (2019). Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.. The New England journal of medicine, 381(24), 2315-2326.
Scopus332 WoS197 Europe PMC1972019 Shanmuganathan, N., & Hughes, T. P. (2019). Early Management of CML. Current Hematologic Malignancy Reports, 14(6), 480-491.
Scopus2 WoS22019 Heraud, C., Basuki, J., Hughes, T. C., & Mueller, M. (2019). Copolymerization of Pentafluorophenylmethacrylate with Hydrophilic Methacrylamide Monomers Induces Premature Hydrolytic Cleavage. Macromolecular Rapid Communications, 40(19), 7 pages.
Scopus5 WoS32019 Shanmuganathan, N., Braley, J. A., Yong, A. S. M., Hiwase, D. K., Yeung, D. T., Ross, D. M., . . . Branford, S. (2019). Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. Blood, 134(1), 85-89.
Scopus25 WoS19 Europe PMC122019 Kok, C. H., Yeung, D. T., Lu, L., Watkins, D. B., Leclercq, T. M., Dang, P., . . . Hughes, T. P. (2019). Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Advances, 3(10), 1610-1621.
Scopus28 WoS24 Europe PMC232019 Branford, S., Kim, D. D. H., Apperley, J. F., Eide, C. A., Mustjoki, S., Ong, S. T., . . . International CML Foundation Genomics Alliance. (2019). Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia, 33(8), 1835-1850.
Scopus110 WoS80 Europe PMC702019 Ross, D. M., Pagani, I. S., Irani, Y. D., Clarson, J., Leclercq, T., Dang, P., . . . Yong, A. S. M. (2019). Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia. British Journal of Haematology, 186(3), e56-e60.
Scopus12 WoS7 Europe PMC82019 Hughes, T. P., Laneuville, P., Rousselot, P., Snyder, D. S., Rea, D., Shah, N. P., . . . Cortes, J. E. (2019). Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for philadelphia chromosome-positive leukemia. Haematologica, 104(1), 93-101.
Scopus66 WoS52 Europe PMC442019 Shanmuganathan, N., Branford, S., Hughes, T. P., & Hiwase, D. (2019). Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI. Blood Advances, 3(3), 370-374.
Scopus7 WoS4 Europe PMC22019 Chhetri, R., Wee, L. Y. A., Sinha, R., Kutyna, M. M., Pham, A., Stathopoulos, H., . . . Hiwase, D. K. (2019). Red cell autoimmunization and alloimmunization in myelodysplastic syndromes: Prevalence, characteristic and significance. Haematologica, 104(10), E451-E454.
Scopus17 WoS12 Europe PMC42018 Witoelar, A., Rongve, A., Almdahl, I. S., Ulstein, I. D., Engvig, A., White, L. R., . . . Andreassen, O. A. (2018). Meta-analysis of Alzheimer's disease on 9,751 samples from Norway and IGAP study identifies four risk loci. SCIENTIFIC REPORTS, 8(1), 8 pages.
WoS26 Europe PMC372018 Nair, S. S., Luu, P. -L., Qu, W., Maddugoda, M., Huschtscha, L., Reddel, R., . . . Clark, S. J. (2018). Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten. Epigenetics & Chromatin, 11(1), 24.
Scopus36 WoS27 Europe PMC252018 Ross, D. M., Burbury, K. L., Grigg, A. P., Hughes, T. P., & Seymour, J. F. (2018). Management of pregnancy in women with chronic myeloid leukemia. Journal of Clinical Oncology, 36(25), 2657-2658.
Scopus2 WoS2 Europe PMC22018 Branford, S., Wang, P., Yeung, D. T., Thomson, D., Purins, A., Wadham, C., . . . Hughes, T. P. (2018). Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood, 132(9), 948-961.
Scopus155 WoS121 Europe PMC1032018 Lu, L., Kok, C. H., Saunders, V., Wang, J., McLean, J., Hughes, T. P., . . . White, D. L. (2018). Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines. Oncotarget, 9(78), 34735-34747.
Scopus16 Europe PMC52018 Pagani, I. S., Dang, P., Kommers, I. O., Goyne, J. M., Nicola, M., Saunders, V. A., . . . Ross, D. M. (2018). BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia. Haematologica, 103(12), 2026-2032.
Scopus33 WoS20 Europe PMC162018 Ross, D., Pagani, I., Shanmuganathan, N., Kok, C., Seymour, J., Mills, A., . . . Hughes, T. (2018). Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia, 32(12), 2572-2579.
Scopus67 WoS46 Europe PMC352018 Shanmuganathan, N., & Hughes, T. P. (2018). Molecular monitoring in CML: how deep? How often? How should it influence therapy?. Blood, 132(20), 2125-2133.
Scopus15 WoS9 Europe PMC82018 Tvorogov, D., Thomas, D., Liau, N. P. D., Dottore, M., Barry, E. F., Lathi, M., . . . Lopez, A. F. (2018). Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. Science Advances, 4(11), 1-12.
Scopus40 WoS34 Europe PMC332018 Shanmuganathan, N., & Hughes, T. P. (2018). Molecular monitoring in CML: how deep? How often? How should it influence therapy?. Hematology, 2018(1), 168-176.
Scopus26 WoS16 Europe PMC142018 Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., . . . Kantarjian, H. M. (2018). Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.. Blood, 132(4), 1-13.
Scopus432 WoS292 Europe PMC2942018 Eadie, L. N., Hughes, T. P., & White, D. L. (2018). Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy. Leukemia, 32(10), 2288-2291.
Scopus11 WoS10 Europe PMC42018 Eadie, L., Saunders, V., Branford, S., White, D., & Hughes, T. (2018). The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro. Oncotarget, 9(17), 13423-13437.
Scopus45 Europe PMC232018 Hiwase, D., Tan, P., D'Rozario, J., Taper, J., Powell, A., Irving, I., . . . Hughes, T. (2018). Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the Phase IIIb ENESTswift study. Leukemia Research, 67, 109-115.
Scopus14 WoS9 Europe PMC62018 McClure, B., Heatley, S., Kok, C., Sadras, T., An, J., Hughes, T., . . . White, D. (2018). Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression. British Journal of Cancer, 118(7), 1000-1004.
Scopus31 WoS25 Europe PMC232018 Eadie, L., Dang, P., Goyne, J., Hughes, T., & White, D. (2018). ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells. PLoS ONE, 13(1), e0192180-1-e0192180-18.
Scopus21 WoS13 Europe PMC142018 Broughton, S., Hercus, T., Nero, T., Kan, W., Barry, E., Dottore, M., . . . Parker, M. (2018). A dual role for the N-terminal domain of the IL-3 receptor in cell signalling. Nature Communications, 9(1), 386-1-386-15.
Scopus33 WoS23 Europe PMC162018 Mahon, F. X., Boquimpani, C., Kim, D. W., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . . . Hughes, T. P. (2018). Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase results from a single-group, phase 2, open-label study. Annals of Internal Medicine, 168(7), 461-470.
Scopus120 WoS88 Europe PMC672018 Hercus, T., Kan, W., Broughton, S., Tvorogov, D., Ramshaw, H., Sandow, J., . . . Lopez, A. (2018). Role of the β common (βc) family of cytokines in health and disease. Cold Spring Harbor Perspectives in Biology, 10(6), a028514.
Scopus36 WoS21 Europe PMC162018 Mahon, F. X., & Hughes, T. P. (2018). Treatment-free remission after second-line nilotinib treatment: In response. Annals of Internal Medicine, 169(7), 510.
Scopus1 WoS12018 Chesterman, J. P., Hughes, T. C., & Amsden, B. G. (2018). Reversibly photo-crosslinkable aliphatic polycarbonates functionalized with coumarin. European Polymer Journal, 105, 186-193.
Scopus33 WoS182018 Li, L., Lu, C., Wang, L., Chen, M., White, J., Hao, X., . . . Hughes, T. C. (2018). Gelatin-Based Photocurable Hydrogels for Corneal Wound Repair. ACS Applied Materials and Interfaces, 10(16), 13283-13292.
Scopus145 WoS111 Europe PMC492018 Whinton, M., Hughes, T. C., Peng, S., & Brook, M. A. (2018). Silicone Microemulsion Structures Are Maintained during Polymerization with Reactive Surfactants. Langmuir, 34(14), 4374-4381.
Scopus8 WoS62018 Segorbe, D., Wilkinson, D., Mizeranschi, A., Hughes, T., Aalokken, R., Vachova, L., . . . Gilfillan, G. D. (2018). An optimized FAIRE procedure for low cell numbers in yeast. YEAST, 35(8), 507-512.
WoS3 Europe PMC22018 Fan, L., Martynenko, A., Doucette, C., Hughes, T., & Fillmore, S. (2018). Microbial Quality and Shelf Life of Blueberry Puree Developed Using Cavitation Technology. JOURNAL OF FOOD SCIENCE, 83(3), 732-739.
WoS11 Europe PMC22018 Hughes, T., Sonderby, I. E., Polushina, T., Hansson, L., Holmgren, A., Athanasiu, L., . . . Djurovic, S. (2018). Elevated expression of a minor isoform of <i>ANK3</i> is a risk factor for bipolar disorder. TRANSLATIONAL PSYCHIATRY, 8(1), 12 pages.
WoS17 Europe PMC212018 Akkouh, I. A., Ueland, T., Andreassen, O. A., Brattbakk, H. -R., Steen, V. M., Hughes, T., & Djurovic, S. (2018). Expression of <i>TCN1</i> in Blood is Negatively Associated with Verbal Declarative Memory Performance. SCIENTIFIC REPORTS, 8(1), 11 pages.
WoS8 Europe PMC42017 Marsikova, J., Wilkinson, D., Hlavacek, O., Gilfillan, G. D., Mizeranschi, A., Hughes, T., . . . Palkova, Z. (2017). Metabolic differentiation of surface and invasive cells of yeast colony biofilms revealed by gene expression profiling. BMC GENOMICS, 18(1), 16 pages.
WoS10 Europe PMC132017 Ge, C., Basuki, J. S., White, J., Hou, R., Peng, Y., Hughes, T. C., & Tan, T. (2017). Photothermal triggered protein release from an injectable polycaprolactone-based microspherical depot. Journal of Materials Chemistry B, 5(20), 3634-3639.
2017 Hu, S., Ren, W., Cai, D., Hughes, T. C., Qin, P., & Tan, T. (2017). A mixed matrix membrane for butanol pervaporation based on micron-sized silicalite-1 as macro-crosslinkers. Journal of Membrane Science, 533, 270-278.
Scopus56 WoS432017 Basuki, J. S., Qie, F., Mulet, X., Suryadinata, R., Vashi, A. V., Peng, Y. Y., . . . Hughes, T. C. (2017). Photo-Modulated Therapeutic Protein Release from a Hydrogel Depot Using Visible Light. Angewandte Chemie - International Edition, 56(4), 966-971.
Scopus85 WoS56 Europe PMC272017 Hughes, T., & Saglio, G. (2017). Expert opinion on the treatment of refractory chronic phase chronic myeloid leukaemia. European Oncology and Haematology, 13(1), 17-23.
Scopus12017 Nicolini, F. E., Basak, G. W., Kim, D. W., Olavarria, E., Pinilla-Ibarz, J., Apperley, J. F., . . . Cortes, J. E. (2017). Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer, 123(15), 2875-2880.
Scopus84 WoS70 Europe PMC532017 Pagani, I. S., Kok, C. H., Saunders, V. A., Van der Hoek, M. B., Heatley, S. L., Schwarer, A. P., . . . Ross, D. M. (2017). A method for next-generation sequencing of paired diagnostic and remission Samples to detect mitochondrial DNA mutations associated with leukemia. The Journal of molecular diagnostics : JMD, 19(5), 711-721.
Scopus6 WoS5 Europe PMC52017 Hughes, T. P., Munhoz, E., Aurelio Salvino, M., Ong, T. C., Elhaddad, A., Shortt, J., . . . Lipton, J. H. (2017). Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd. British Journal of Haematology, 179(2), 219-228.
Scopus16 WoS14 Europe PMC122017 Sadras, T., Heatley, S., Kok, C., McClure, B., Yeung, D., Hughes, T., . . . White, D. (2017). A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH. Cancer Genetics, 216-217, 86-90.
Scopus12 WoS9 Europe PMC92017 Sadras, T., Heatley, S., Kok, C., Dang, P., Galbraith, K., McClure, B., . . . White, D. (2017). Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. Cancer Letters, 408, 92-101.
Scopus17 WoS18 Europe PMC162017 Marum, J., Yeung, D., Purins, L., Reynolds, J., Parker, W., Stangl, D., . . . Branford, S. (2017). ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure. Blood Advances, 1(18), 1369-1381.
Scopus18 WoS11 Europe PMC132017 Hughes, T. P., Leber, B., Cervantes, F., Spector, N., Pasquini, R., Clementino, N. C. D., . . . Lipton, J. H. (2017). Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: Final ENESTcmr randomized trial results. Leukemia, 31(11), 2529-2531.
Scopus40 WoS37 Europe PMC222017 Rasko, J. E. J., & Hughes, T. P. (2017). First Approved Kinase Inhibitor for AML. Cell, 171(5), 981.
Scopus10 WoS7 Europe PMC72017 Heatley, S. L., Sadras, T., Kok, C. H., Nievergall, E., Quek, K., Dang, P., . . . White, D. L. (2017). High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Haematologica, 102(12), e490-e493.
Scopus51 WoS44 Europe PMC252017 Hughes, A., Clarson, J., Gargett, T., Yu, W., Brown, M. P., Lopez, A. F., . . . Yong, A. S. M. (2017). Comment on “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study”. Leukemia Research, 55, 55-57.
Scopus3 WoS3 Europe PMC22017 Hughes, T. P., & Ross, D. M. (2017). Targeted therapies: Remembrance of things past - Discontinuation of second-generation TKI therapy for CML. Nature Reviews Clinical Oncology, 14(4), 201-202.
Scopus6 WoS2 Europe PMC52017 Wang, J., Lu, L., Kok, C., Saunders, V., Goyne, J., Dang, P., . . . White, D. (2017). Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells. Haematologica, 102(5), 843-853.
Scopus11 WoS11 Europe PMC52017 Eadie, L., Hughes, T., & White, D. (2017). Response to 'Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?'. Leukemia, 31(3), 769-770.
2017 Hochhaus, A., Larson, R., Guilhot, F., Radich, J., Branford, S., Hughes, T., . . . Druker, B. (2017). Long-term outcomes of imatinib treatment for chronic myeloid leukemia. New England Journal of Medicine, 376(10), 917-927.
Scopus969 WoS738 Europe PMC6282017 Wylie, A. A., Schoepfer, J., Jahnke, W., Cowan-Jacob, S. W., Loo, A., Furet, P., . . . Sellers, W. R. (2017). The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature, 543(7647), 733-737.
Scopus432 WoS328 Europe PMC2582017 Sopper, S., Mustjoki, S., White, D., Hughes, T., Valent, P., Burchert, A., . . . Wolf, D. (2017). Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. Journal of Clinical Oncology, 35(2), 175-184.
Scopus33 WoS25 Europe PMC182017 Barratt, D., Cox, H., Menelaou, A., Yeung, D., White, D., Hughes, T., & Somogyi, A. (2017). CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patients. Clinical Pharmacokinetics, 56(8), 977-985.
Scopus21 WoS17 Europe PMC152017 Hughes, A., Clarson, J., Tang, C., Vidovic, L., White, D., Hughes, T., & Yong, A. (2017). CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood, 129(9), 1166-1176.
Scopus152 WoS122 Europe PMC982017 Banjar, H., Ranasinghe, D., Brown, F., Adelson, D., Kroger, T., Leclercq, T., . . . Chaudhri, N. (2017). Modelling predictors of molecular response to frontline imatinib for patients with chronic myeloid leukaemia. PLoS ONE, 12(1), 1-23.
Scopus5 WoS3 Europe PMC32017 Eadie, L. N., Dang, P., Saunders, V. A., Yeung, D. T., Osborn, M. P., Grigg, A. P., . . . White, D. L. (2017). The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. Leukemia, 31(1), 75-82.
Scopus54 WoS51 Europe PMC432016 Eadie, L., Hughes, T., & White, D. (2016). ABCB1 Overexpression Is a key initiator of resistance to tyrosine kinase inhibitors in CML cell lines. PLoS ONE, 11(8), e0161470-1-e0161470-18.
Scopus36 WoS26 Europe PMC252016 Deininger, M., Hodgson, J., Shah, N., Cortes, J., Kim, D., Nicolini, F., . . . Branford, S. (2016). Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood, 127(6), 703-712.
Scopus86 WoS73 Europe PMC532016 le Coutre, P., Hughes, T., Mahon, F., Kim, D., Steegmann, J., Shah, N., . . . Cortes, J. (2016). Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials. Leukemia, 30(7), 1593-1596.
Scopus10 WoS11 Europe PMC92016 Parker, W., Yeung, D., Yeoman, A., Altamura, H., Jamison, B., Field, C., . . . Branford, S. (2016). The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Blood, 127(15), 1870-1880.
Scopus59 WoS53 Europe PMC402016 Hochhaus, A., Saglio, G., Hughes, T., Larson, R., Kim, D., Issaragrisil, S., . . . Kantarjian, H. (2016). Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia, 30(5), 1044-1054.
Scopus663 WoS541 Europe PMC4292016 Latham, S., Bartley, P., Budgen, B., Ross, D., Hughes, E., Branford, S., . . . Morley, A. (2016). BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia. Journal of Clinical Pathology, 69(9), 817-821.
Scopus9 WoS9 Europe PMC52016 Nievergall, E., Reynolds, J., Kok, C., Watkins, D., Biondo, M., Busfield, S., . . . White, D. (2016). TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia, 30(6), 1263-1272.
Scopus44 WoS32 Europe PMC242016 Mughal, T., Radich, J., Deininger, M., Apperley, J., Hughes, T., Harrison, C., . . . Daley, G. (2016). Chronic myeloid leukemia: reminiscences and dreams. Haematologica, 101(5), 541-558.
Scopus92 WoS79 Europe PMC552016 Hughes, T., & Ross, D. (2016). Moving treatment-free remission into mainstream clinical practice in CML. Blood, 128(1), 17-23.
Scopus277 WoS236 Europe PMC1792016 Lipton, J., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Assouline, S., . . . Deininger, M. (2016). Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncology, 17(5), 612-621.
Scopus226 WoS172 Europe PMC1402016 Gurr, P. A., Zhang, Z., Hao, X., Hughes, T. C., & Qiao, G. G. (2016). Highly Ordered Honeycomb Film Formation of Linear Polymers by the Breath Figure Technique. Australian Journal of Chemistry, 69(10), 1130-1139.
Scopus4 WoS32016 Luan, B., Friedrich, T., Zhai, J., Streltsov, V. A., Lindsey, B. W., Kaslin, J., . . . Hao, X. (2016). A library of AuNPs modified by RAFT polymers of different charge and chain length: high throughput synthesis and synchrotron XFM imaging using a zebrafish larvae model. RSC Advances, 6(28), 23550-23563.
Scopus7 WoS62016 Sundaram, A. Y. M., Hughes, T., Biondi, S., Bolduc, N., Bowman, S. K., Camilli, A., . . . Gilfillan, G. D. (2016). A comparative study of ChIP-seq sequencing library preparation methods. BMC GENOMICS, 17(1), 12 pages.
WoS16 Europe PMC142016 Tesli, M., Wirgenes, K. V., Hughes, T., Bettella, F., Athanasiu, L., Hoseth, E. S., . . . Andreassen, O. A. (2016). <i>VRK2</i> gene expression in schizophrenia, bipolar disorder and healthy controls. BRITISH JOURNAL OF PSYCHIATRY, 209(2), 114-120.
WoS12 Europe PMC102016 Baroy, T., Pedurupillay, C. R. J., Bliksrud, Y. T., Rasmussen, M., Holmgren, A., Vigeland, M. D., . . . Misceo, D. (2016). A novel mutation in <i>FBXL4</i> in a Norwegian child with encephalomyopathic mitochondrial DNA depletion syndrome 13. EUROPEAN JOURNAL OF MEDICAL GENETICS, 59(6-7), 342-346.
WoS17 Europe PMC82016 Hughes, T., Hansson, L., Sonderby, I. E., Athanasiu, L., Zuber, V., Tesli, M., . . . Djurovic, S. (2016). A Loss-of-Function Variant in a Minor Isoform of <i>ANK3</i> Protects Against Bipolar Disorder and Schizophrenia. BIOLOGICAL PSYCHIATRY, 80(4), 323-330.
WoS26 Europe PMC312015 Baroy, T., Koster, J., Stromme, P., Ebberink, M. S., Misceo, D., Ferdinandusse, S., . . . Frengen, E. (2015). A novel type of rhizomelic chondrodysplasia punctata, RCDP5, is caused by loss of the PEX5 long isoform. HUMAN MOLECULAR GENETICS, 24(20), 5845-5854.
WoS54 Europe PMC422015 Barlow, K. J., Bernabeu, V., Hao, X., Hughes, T. C., Hutt, O. E., Polyzos, A., . . . Moad, G. (2015). Triphenylphosphine-grafted, RAFT-synthesised, porous monoliths as catalysts for Michael addition in flow synthesis. Reactive and Functional Polymers, 96, 89-96.
Scopus19 WoS172015 Fawcett, A. S., Hughes, T. C., Zepeda-Velazquez, L., & Brook, M. A. (2015). Phototunable Cross-Linked Polysiloxanes. Macromolecules, 48(18), 6499-6507.
Scopus48 WoS442015 Peng, S., Hartley, P. G., Hughes, T. C., & Guo, Q. (2015). Enhancing thermal stability and mechanical properties of lyotropic liquid crystals through incorporation of a polymerizable surfactant. Soft Matter, 11(31), 6318-6326.
Scopus10 WoS9 Europe PMC32015 le Coutre, P. D., Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., Paquette, R., Chuah, C., . . . Kantarjian, H. M. (2015). Ponatinib efficacy and safety in heavily pretreated leukemia patients (Pts) in the PACE trial at 3 years. ONCOLOGY RESEARCH AND TREATMENT, 38, 182-183. 2015 Yeung, D., Tang, C., Vidovic, L., White, D., Branford, S., Hughes, T., & Yong, A. (2015). KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy. Blood, 126(25), 2720-2723.
Scopus26 WoS22 Europe PMC182015 Lickliter, J. D., Taylor, K., Szer, J., Grigg, A., Arthur, C., Hughes, T. P., . . . Bradstock, K. (2015). An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: Long-term results of the CMLALL1 trial. Leukemia and Lymphoma, 56(3), 630-638.
Scopus2 WoS2 Europe PMC22015 Ong, J., Yeung, D., Filshie, R., Hughes, T. P., & Nandurkar, H. (2015). Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia. International Journal of Hematology, 102(5), 639-642.
Scopus6 WoS4 Europe PMC42015 White, D. L., & Hughes, T. P. (2015). Living with CML: Is death no longer the end (point)?. Blood, 126(1), 2-4.
Scopus1 WoS1 Europe PMC52015 Watkins, D., Hughes, T., & White, D. (2015). OCT1 and imatinib transport in CML: Is it clinically relevant?. Leukemia, 29(10), 1960-1969.
Scopus50 WoS40 Europe PMC272015 Hughes, T., Saglio, G., Quintás-Cardama, A., Mauro, M., Kim, D., Lipton, J., . . . Hochhaus, A. (2015). BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia, 29(9), 1832-1838.
Scopus62 WoS53 Europe PMC402015 Lu, L., Saunders, V., Leclercq, T., Hughes, T., & White, D. (2015). Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells. Leukemia, 29(8), 1792-1794.
Scopus20 WoS22 Europe PMC162015 Yeung, D., Osborn, M., White, D., Branford, S., Braley, J., Herschtal, A., . . . Hughes, T. (2015). TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood, 125(6), 915-923.
WoS67 Europe PMC482015 Bartley, P., Latham, S., Budgen, B., Ross, D., Hughes, E., Branford, S., . . . Morley, A. (2015). A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia. The Journal of Molecular Diagnostics, 17(2), 185-192.
Scopus22 WoS16 Europe PMC102015 Yeung, D., Moulton, D., Heatley, S., Nievergall, E., Dang, P., Braley, J., . . . White, D. (2015). Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. Leukemia, 29(1), 230-232.
Scopus25 WoS20 Europe PMC142015 Schafranek, L., Nievergall, E., Powell, J., Hiwase, D., Leclercq, T., Hughes, T., & White, D. (2015). Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia. Leukemia, 29(1), 76-85.
Scopus29 WoS27 Europe PMC232015 Liu, Y., Muir, B. W., Waddington, L. J., Hinton, T. M., Moffat, B. A., Hao, X., . . . Hughes, T. C. (2015). Colloidally stabilized magnetic carbon nanotubes providing MRI contrast in mouse liver tumors. Biomacromolecules, 16(3), 790-797.
Scopus16 WoS15 Europe PMC72015 Wan, W., Zhao, Z., Hughes, T. C., Qian, B., Peng, S., Hao, X., & Qiu, J. (2015). Graphene oxide liquid crystal Pickering emulsions and their assemblies. Carbon, 85, 16-23.
Scopus52 WoS432015 Qie, F., Astolfo, A., Wickramaratna, M., Behe, M., Evans, M. D. M., Hughes, T. C., . . . Tan, T. (2015). Self-assembled gold coating enhances X-ray imaging of alginate microcapsules. Nanoscale, 7(6), 2480-2488.
Scopus12 WoS10 Europe PMC32014 Astolfo, A., Qie, F., Kibleur, A., Hao, X., Menk, R. H., Arfelli, F., . . . Hughes, T. C. (2014). A simple way to track single gold-loaded alginate microcapsules using x-ray CT in small animal longitudinal studies. Nanomedicine: Nanotechnology, Biology, and Medicine, 10(8), 1821-1828.
Scopus18 WoS16 Europe PMC122014 Yang, R., Peng, S., Wan, W., & Hughes, T. C. (2014). Azobenzene based multistimuli responsive supramolecular hydrogels. Journal of Materials Chemistry C, 2(43), 9122-9131.
Scopus52 WoS412014 Peng, S., Xu, C., Hughes, T. C., & Zhang, X. (2014). From Nanodroplets by the ouzo effect to interfacial nanolenses. Langmuir, 30(41), 12270-12277.
WoS25 Europe PMC62014 Guidi, G., Hughes, T. C., Whinton, M., Brook, M. A., & Sheardown, H. (2014). The effect of silicone hydrogel contact lens composition on dexamethasone release. Journal of Biomaterials Applications, 29(2), 222-233.
Scopus18 WoS17 Europe PMC42014 Peng, S., Guo, Q., Hartley, P. G., & Hughes, T. C. (2014). Azobenzene moiety variation directing self-assembly and photoresponsive behavior of azo-surfactants. Journal of Materials Chemistry C, 2(39), 8303-8312.
Scopus44 WoS342014 Wan, W., Li, L., Zhao, Z., Hu, H., Hao, X., Winkler, D. A., . . . Qiu, J. (2014). Ultrafast fabrication of covalently cross-linked multifunctional graphene oxide monoliths. Advanced Functional Materials, 24(31), 4915-4921.
Scopus113 WoS932014 Wan, W., Zhao, Z., Hu, H., Hao, X., Hughes, T. C., Ma, H., . . . Qiu, J. (2014). Folding of graphene into elastic nanobelts. Carbon, 76, 46-53.
Scopus12 WoS82014 Yang, R., Peng, S., & Hughes, T. C. (2014). Multistimuli responsive organogels based on a reactive azobenzene gelator. Soft Matter, 10(13), 2188-2196.
Scopus67 WoS61 Europe PMC222014 Peng, S., Guo, Q., Hughes, T. C., & Hartley, P. G. (2014). Reversible photorheological lyotropic liquid crystals. Langmuir, 30(3), 866-872.
Scopus54 WoS40 Europe PMC112014 Barlow, K. J., Hao, X., Hughes, T. C., Hutt, O. E., Polyzos, A., Turner, K. A., & Moad, G. (2014). Porous, functional, poly(styrene-co-divinylbenzene) monoliths by RAFT polymerization. Polymer Chemistry, 5(3), 722-732.
Scopus48 WoS432014 Liu, Y., Hao, X., Waddington, L. J., Qiu, J., & Hughes, T. C. (2014). Surface modification of multiwalled carbon nanotubes with engineered self-assembled raft diblock coatings. Australian Journal of Chemistry, 67(1), 151-158.
Scopus7 WoS62014 Liu, Y., Hughes, T. C., Muir, B. W., Waddington, L. J., Gengenbach, T. R., Easton, C. D., . . . Qiu, J. (2014). Water-dispersible magnetic carbon nanotubes as T<inf>2</inf>-weighted MRI contrast agents. Biomaterials, 35(1), 378-386.
Scopus60 WoS46 Europe PMC212014 Seymour, J. F., Kim, D. W., Rubin, E., Haregewoin, A., Clark, J., Watson, P., . . . Giles, F. J. (2014). A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer Journal, 4(8), e238.
Scopus61 WoS55 Europe PMC332014 Branford, S., Yeung, D., Parker, W., Roberts, N., Purins, L., Braley, J., . . . Hughes, T. (2014). Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood, 124(4), 511-518.
Scopus186 WoS144 Europe PMC1192014 Ross, D. M., & Hughes, T. P. (2014). How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. British Journal of Haematology, 166(1), 3-11.
Scopus42 WoS43 Europe PMC322014 Roberts, K., Li, Y., Payne-Turner, D., Harvey, R., Yang, Y., Pei, D., . . . Mullighan, C. (2014). Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. New England Journal of Medicine, 371(11), 1005-1015.
Scopus1147 WoS927 Europe PMC7682014 Kok, C. H., Leclercq, T., Watkins, D. B., Saunders, V., Wang, J., Hughes, T. P., & White, D. L. (2014). Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients. Leukemia, 28(3), 702-705.
Scopus6 WoS4 Europe PMC52014 Jabbour, E. J., Hughes, T. P., Cortés, J. E., Kantarjian, H. M., & Hochhaus, A. (2014). Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leukemia & Lymphoma, 55(7), 1451-1462.
Scopus34 WoS32 Europe PMC252014 Parker, W., Phillis, S., Yeung, D., Hughes, T., Scott, H., & Branford, S. (2014). Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination. Blood, 124(1), 153-155.
Scopus25 WoS21 Europe PMC182014 Hughes, T., Lipton, J., Spector, N., Cervantes, F., Pasquini, R., Clementino, N., . . . Leber, B. (2014). Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood, 124(5), 729-736.
Scopus83 WoS73 Europe PMC642014 Hughes, T., Hochhaus, A., Kantarjian, H., Cervantes, F., Guilhot, F., Niederwieser, D., . . . Saglio, G. (2014). Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica, 99(7), 1204-1211.
Scopus35 WoS29 Europe PMC232014 Hughes, T., Saglio, G., Kantarjian, H., Guilhot, F., Niederwieser, D., Rosti, G., . . . Hochhaus, A. (2014). Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood, 123(9), 1353-1360.
Scopus228 WoS194 Europe PMC1602014 Olshen, A., Tang, M., Cortes, J., Gonen, M., Hughes, T., Branford, S., . . . Michor, F. (2014). Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. Haematologica, 99(11), 1701-1709.
Scopus14 WoS8 Europe PMC82014 Pritchard, J. R., Lustgarten, S., Hodgson, G., Baccarani, M., Cortes, J. E., Deininger, M. W., . . . Rivera, V. M. (2014). High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib. BLOOD, 124(21), 4 pages. 2014 Baccarani, M., Druker, B., Branford, S., Kim, D., Pane, F., Mongay, L., . . . Guilhot, F. (2014). Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. International Journal of Hematology, 99(5), 616-624.
Scopus45 WoS34 Europe PMC322014 Eadie, L., Hughes, T., & White, D. (2014). Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. Clinical Pharmacology & Therapeutics, 95(3), 294-306.
Scopus71 WoS60 Europe PMC522014 Nievergall, E., Ramshaw, H., Yong, A., Biondo, M., Busfield, S., Vairo, G., . . . Hiwase, D. (2014). Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. Blood, 123(8), 1218-1228.
Scopus89 WoS77 Europe PMC642014 Wirgenes, K. V., Tesli, M., Inderhaug, E., Athanasiu, L., Agartz, I., Melle, I., . . . Djurovic, S. (2014). <i>ANK3</i> gene expression in bipolar disorder and schizophrenia. BRITISH JOURNAL OF PSYCHIATRY, 205(3), 244-+.
WoS27 Europe PMC242013 Zhang, Z., Hughes, T. C., Gurr, P. A., Blencowe, A., Uddin, H., Hao, X., & Qiao, G. G. (2013). The behaviour of honeycomb film formation from star polymers with various fluorine content. Polymer, 54(17), 4446-4454.
Scopus33 WoS302013 Hochhaus, A., Saglio, G., Larson, R., Kim, D., Etienne, G., Rosti, G., . . . Hughes, T. (2013). Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood, 121(18), 3703-3708.
Scopus86 WoS68 Europe PMC542013 Parker, W., Yeoman, A., Jamison, B., Yeung, D., Scott, H., Hughes, T., & Branford, S. (2013). BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance. British Journal of Cancer, 109(6), 1593-1598.
Scopus20 WoS16 Europe PMC122013 Ross, D., Branford, S., Seymour, J., Schwarer, A., Arthur, C., Yeung, D., . . . Hughes, T. (2013). Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood, 122(4), 515-522.
Scopus623 WoS542 Europe PMC4362013 Baccarani, M., Deininger, M., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J., . . . Hehlmann, R. (2013). European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 122(6), 872-884.
Scopus1684 WoS1393 Europe PMC10802013 Branford, S., Yeung, D., Ross, D., Prime, J., Field, C., Altamura, H., . . . Hughes, T. (2013). Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood, 121(19), 3818-3824.
Scopus146 WoS127 Europe PMC1162013 Kok, C., Watkins, D., Leclercq, T., D'Andrea, R., Hughes, T., & White, D. (2013). Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformation. Leukemia, 27(6), 1427-1430.
Scopus12 WoS12 Europe PMC112013 White, H., Hedges, J., Bendit, I., Branford, S., Colomer, D., Hochhaus, A., . . . Labourier, E. (2013). Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. Clinical Chemistry, 59(6), 938-948.
Scopus45 WoS36 Europe PMC312013 Hiwase, D., Saunders, V., Nievergall, E., Ross, D., White, D., & Hughes, T. (2013). Dasatinib targets chronic myeloid leukemia-CD34⁺ progenitors as effectively as it targets mature cells. Haematologica, 98(6), 896-900.
Scopus8 WoS9 Europe PMC72013 White, D., Eadie, L., Saunders, V., Hiwase, D., & Hughes, T. (2013). Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells. Leukemia, 27(5), 1201-1204.
Scopus8 WoS7 Europe PMC62013 Thomas, D., Powell, J., Green, B., Barry, E., Ma, Y., Woodcock, J., . . . Guthridge, M. (2013). Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival. PLoS Biology, 11(3), 1-14.
Scopus19 WoS16 Europe PMC182013 Watkins, D., Hughes, T., White, D., & D'Andrea, R. (2013). NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis. Leukemia, 27(2), 489-490.
Scopus11 WoS8 Europe PMC82013 Vandyke, K., Fitter, S., Drew, J., Fukumoto, S., Schultz, C., Sims, N., . . . Zannettino, A. (2013). Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: Evidence for site-specific skeletal effects. Journal of Clinical Endocrinology and Metabolism, 98(1), 67-76.
Scopus25 WoS22 Europe PMC222013 Eadie, L., Saunders, V., Hughes, T., & White, D. (2013). Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2. Leukemia & Lymphoma, 54(3), 569-578.
Scopus24 WoS21 Europe PMC212013 Schafranek, L., Leclercq, T., White, D., & Hughes, T. (2013). Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy. Leukemia & Lymphoma, 54(1), 198-201.
Scopus28 WoS21 Europe PMC162013 Stein, A., Martinelli, G., Hughes, T., Muller, M., Beppu, L., Gottardi, E., . . . Radich, J. (2013). Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. BMC Cancer, 13(1), 1-10.
Scopus15 WoS13 Europe PMC122013 Hughes, T., & White, D. (2013). Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. Hematology, 2013(1), 168-175.
Scopus46 WoS37 Europe PMC272013 Angelini, S., Soverini, S., Ravegnini, G., Barnett, M., Turrini, E., Thornquist, M., . . . Martinelli, G. (2013). Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica, 98(2), 193-200.
Scopus95 WoS85 Europe PMC712013 Hercus, T., Dhagat, U., Kan, W., Broughton, S., Nero, T., Perugini, M., . . . Lopez, A. (2013). Signalling by the βc family of cytokines. Cytokine & Growth Factor Reviews, 24(3), 189-201.
Scopus82 WoS68 Europe PMC582013 Schafranek, L., Nievergall, E., Powell, J., Hiwase, D., White, D., Hughes, T., & Leclercq, T. (2013). STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a BCR-ABL-dependent, but JAK2-independent manner. Blood, 122(21), 2705.
WoS12013 Jabbour, E., Le Coutre, P., Cortes, J., Giles, F., Bhalla, K., Pinilla-Ibarz, J., . . . Kantarjian, H. (2013). Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia, 27(4), 907-913.
Scopus20 WoS15 Europe PMC152013 Ross, D., O'Hely, M., Bartley, P., Dang, P., Score, J., Goyne, J., . . . Morley, A. (2013). Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients. Leukemia, 27(10), 2105-2107.
Scopus21 WoS15 Europe PMC142013 Gallipoli, P., Stobo, J., Heaney, N., Nicolini, F. E., Clark, R., Wilson, G., . . . Holyoake, T. L. (2013). Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. British Journal of Haematology, 163(5), 674-676.
Scopus10 WoS10 Europe PMC62013 Cortes, J. E., Kim, D. W., Pinilla-Ibarz, J., Le Coutre, P., Paquette, R., Chuah, C., . . . Kantarjian, H. (2013). A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. New England Journal of Medicine, 369(19), 1783-1796.
Scopus961 WoS747 Europe PMC5892013 Abboud, C., Berman, E., Cohen, A., Cortes, J., DeAngelo, D., Deininger, M., . . . Ohno, R. (2013). The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood, 121(22), 4439-4442.
Scopus535 WoS364 Europe PMC3382013 Giles, F. J., Le Coutre, P. D., Pinilla-Ibarz, J., Larson, R. A., Gattermann, N., Ottmann, O. G., . . . Kantarjian, H. M. (2013). Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia, 27(1), 107-112.
Scopus207 WoS170 Europe PMC1282012 Cortes, J., Goldman, J. M., & Hughes, T. (2012). Current issues in chronic myeloid leukemia: Monitoring, resistance, and functional cure. JNCCN Journal of the National Comprehensive Cancer Network, 10(SUPPL.3), S1-S13.
Scopus41 WoS36 Europe PMC282012 Larson, R. A., Hochhaus, A., Hughes, T. P., Clark, R. E., Etienne, G., Kim, D. W., . . . Kantarjian, H. M. (2012). Erratum: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up (Leukemia (2012) 26, 2302; Doi:10.1038/leu.2012.175). Leukemia, 26(10), 2302.
Scopus42012 Hiwase, D. K., & Hughes, T. P. (2012). Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitors. Leukemia and Lymphoma, 53(7), 1251-1252.
Scopus3 WoS1 Europe PMC12012 Larson, R., Hochhaus, A., Hughes, T., Clark, R., Etienne, G., Kim, D., . . . Kantarjian, H. (2012). Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia, 26(10), 2197-2203.
Scopus376 WoS329 Europe PMC2572012 Branford, S. (2012). Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia, 26(9), 2096-2102.
Scopus360 WoS320 Europe PMC2602012 Yin, O., Giles, F., Baccarani, M., le Coutre, P., Chiparus, O., Gallagher, N., . . . Larson, R. (2012). Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemotherapy and Pharmacology, 70(2), 345-350.
Scopus28 WoS21 Europe PMC172012 Blake, S., Hughes, T., & Lyons, A. (2012). Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A. Experimental Hematology, 40(8), 612-621.
Scopus13 WoS10 Europe PMC92012 White, D., Radich, J., Soverini, S., Saunders, V., Frede, A., Dang, P., . . . Hughes, T. (2012). Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. Haematologica, 97(6), 907-914.
Scopus52 WoS45 Europe PMC352012 Yeung, D., & Hughes, T. (2012). Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia. Critical Reviews in Oncogenesis, 17(1), 17-30.
Scopus25 Europe PMC182012 Wang, J., Hughes, T., Kok, C., Saunders, V., Frede, A., Groot Obbink, K., . . . White, D. (2012). Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells. British Journal of Cancer, 106(11), 1772-1778.
Scopus20 WoS18 Europe PMC152012 Branford, S., Yeung, D., Prime, J., Choi, S., Bang, J., Park, J., . . . Hughes, T. (2012). BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management. Blood, 119(18), 4264-4271.
Scopus45 WoS41 Europe PMC282012 Nieborowska-Skorska, M., Kopinski, P., Ray, R., Hoser, G., Ngaba, D., Flis, S., . . . Skorski, T. (2012). Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood, 119(18), 4253-4263.
Scopus147 WoS124 Europe PMC1072012 Jabbour, E., Saglio, G., Hughes, T., & Kantarjian, H. (2012). Suboptimal responses in chronic myeloid leukemia: implications and management strategies. Cancer, 118(5), 1181-1191.
Scopus17 WoS19 Europe PMC162012 Larson, R., Yin, O., Hochhaus, A., Saglio, G., Clark, R., Nakamae, H., . . . le Coutre, P. (2012). Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph plus chronic myeloid leukemia in chronic phase. European Journal of Clinical Pharmacology, 68(5), 723-733.
Scopus94 WoS82 Europe PMC632012 Hercus, T., Broughton, S., Ekert, P., Ramshaw, H., Perugini, M., Grimbaldeston, M., . . . Lopez, A. (2012). The GM-CSF receptor family: mechanism of activation and implications for disease. Growth Factors, 30(2), 63-75.
Scopus61 WoS55 Europe PMC442012 Parker, W., Ho, M., Scott, H., Hughes, T., & Branford, S. (2012). Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. Blood, 119(10), 2234-2238.
Scopus63 WoS56 Europe PMC442012 White, D., & Hughes, T. (2012). Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response. Journal of Clinical Oncology, 2012(10), 1144-1145.
Scopus14 WoS9 Europe PMC82012 Guilhot, F., Hughes, T., Cortes, J., Druker, B., Baccarani, M., Gathmann, I., . . . Wang, Y. (2012). Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica, 2012(5), 731-738.
Scopus107 WoS92 Europe PMC782012 Branford, S., Kim, D., Soverini, S., Haque, A., Shou, Y., Woodman, R., . . . Muller, M. (2012). Initial molecular response at 3 months may predict both response and event-free survival at 24 months in Imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with Nilotinib. Journal of Clinical Oncology, 30(35), 4323-4329.
Scopus86 WoS77 Europe PMC592012 Peng, S., Hartley, P. G., Hughes, T. C., & Guo, Q. (2012). Controlling morphology and porosity of porous siloxane membranes through water content of precursor microemulsion. Soft Matter, 8(40), 10493-10501.
Scopus27 WoS242012 Zhang, Z., Hao, X., Gurr, P. A., Blencowe, A., Hughes, T. C., & Qiao, G. G. (2012). Honeycomb films from perfluoropolyether-based star and micelle architectures. Australian Journal of Chemistry, 65(8), 1186-1190.
Scopus23 WoS222012 Zhang, Z., Hughes, T. C., Gurr, P. A., Blencowe, A., Hao, X., & Qiao, G. G. (2012). Influence of polymer elasticity on the formation of non-cracking honeycomb films. Advanced Materials, 24(31), 4327-4330.
Scopus24 WoS23 Europe PMC52012 Hao, X., Jeffery, J. L., Le, T. P. T., McFarland, G., Johnson, G., Mulder, R. J., . . . Hughes, T. C. (2012). High refractive index polysiloxane as Injectable, in situ curable accommodating intraocular lens. Biomaterials, 33(23), 5659-5671.
Scopus48 WoS45 Europe PMC172012 Wei, Z., Hao, X., Gan, Z., & Hughes, T. C. (2012). One-pot synthesis of hyperbranched glycopolymers by RAFT polymerization. Journal of Polymer Science, Part A: Polymer Chemistry, 50(12), 2378-2388.
Scopus25 WoS202012 Wei, Z., Hao, X., Kambouris, P. A., Gan, Z., & Hughes, T. C. (2012). One-pot synthesis of hyperbranched polymers using small molecule and macro RAFT inimers. Polymer, 53(7), 1429-1436.
Scopus28 WoS252012 Gilfillan, G. D., Hughes, T., Sheng, Y., Hjorthaug, H. S., Straub, T., Gervin, K., . . . Lyle, R. (2012). Limitations and possibilities of low cell number ChIP-seq. BMC GENOMICS, 13(1), 13 pages.
WoS63 Europe PMC462012 Selmer, K. K., Gilfillan, G. D., Stromme, P., Lyle, R., Hughes, T., Hjorthaug, H. S., . . . Undlien, D. E. (2012). A mild form of Mucopolysaccharidosis IIIB diagnosed with targeted next-generation sequencing of linked genomic regions. EUROPEAN JOURNAL OF HUMAN GENETICS, 20(1), 58-63.
WoS21 Europe PMC152011 Evans, M. D. M., Chaouk, H., Wilkie, J. S., Dalton, B. A., Taylor, S., Xie, R. Z., . . . McLean, K. M. (2011). The influence of surface topography of a porous perfluoropolyether polymer on corneal epithelial tissue growth and adhesion. Biomaterials, 32(34), 8870-8879.
Scopus9 WoS10 Europe PMC52011 Lv, Y., Hughes, T. C., Hao, X., Mei, D., & Tan, T. (2011). Preparation of monomeric and polymeric β-cyclodextrin functionalized monoliths for rapid isolation and purification of puerarin from Radix puerariae. Journal of Separation Science, 34(16-17), 2131-2137.
Scopus10 WoS9 Europe PMC32011 Peng, S., Guo, Q., Hughes, T. C., & Hartley, P. G. (2011). In situ synchrotron SAXS study of polymerizable microemulsions. Macromolecules, 44(8), 3007-3015.
Scopus29 WoS262011 Evans, M. D. M., Prakasam, R. K., Vaddavalli, P. K., Hughes, T. C., Knower, W., Wilkie, J. S., . . . Sweeney, D. F. (2011). A perfluoropolyether corneal inlay for the correction of refractive error. Biomaterials, 32(12), 3158-3165.
Scopus14 WoS13 Europe PMC62011 Esposito, N., Colavita, I., Quintarelli, C., Sica, A., Peluso, A., Luciano, L., . . . Pane, F. (2011). SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. Blood, 118(13), 3634-3644.
Scopus47 WoS40 Europe PMC352011 Cortes, J., Hochhaus, A., Hughes, T., & Kantarjian, H. (2011). Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia. Journal of Clinical Oncology, 29(5), 524-531.
Scopus82 WoS71 Europe PMC562011 Stein, A., Bottino, D., Modur, V., Branford, S., Kaeda, J., Goldman, J., . . . Hochhaus, A. (2011). BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib teatment. Clinical Cancer Research, 17(21), 6812-6821.
Scopus38 WoS34 Europe PMC252011 Parker, W., Lawrence, R., Ho, M., Irwin, D., Scott, H., Hughes, T., & Branford, S. (2011). Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after Imatinib resistance is predictive of outcome during subsequent therapy. Journal of Clinical Oncology, 29(32), 4250-4259.
Scopus81 WoS69 Europe PMC622011 Tang, C., Schafranek, L., Watkins, D., Parker, W., Moore, S., Prime, J., . . . Hughes, T. (2011). Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. Leukemia & Lymphoma, 52(11), 2139-2147.
Scopus53 WoS46 Europe PMC382011 Kantarjian, H., Hochhaus, A., Saglio, G., de Souza, C., Flinn, I., Stenke, L., . . . Hughes, T. (2011). Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. The Lancet Oncology, 12(9), 841-851.
Scopus433 WoS377 Europe PMC3242011 Tang, M., Gonen, M., Quintas-Cardama, A., Cortes, J., Kantarjian, H., Field, C., . . . Michor, F. (2011). Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood, 118(6), 1622-1631.
Scopus57 WoS51 Europe PMC402011 Branford, S., & Hughes, T. (2011). Mutational analysis in chronic myeloid leukemia: When and what to do?. Current Opinion in Hematology, 18(2), 111-116.
Scopus20 WoS21 Europe PMC172011 Engler, J., Hughes, T., & White, D. (2011). OCT-1 as a determinant of response to antileukemic treatment. Clinical Pharmacology & Therapeutics, 89(4), 608-611.
Scopus10 WoS9 Europe PMC72011 Engler, J., Zannettino, A., Bailey, C., Rasko, J., Hughes, T., & White, D. (2011). OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. Haematologica: the haematology journal, 96(2), 1-33.
Scopus13 WoS12 Europe PMC112011 Ross, D., Hughes, T., & Vaz de Melo, J. (2011). Do we have to kill the last CML cell?. Leukemia, 25(2), 193-200.
Scopus34 WoS30 Europe PMC232011 Kantarjian, H., Giles, F., Bhalla, K., Pinilla-Ibarz, J., Larson, R., Gattermann, N., . . . le Coutre, P. (2011). Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood, 117(4), 1141-1145.
Scopus325 WoS228 Europe PMC1932011 White, D., & Hughes, T. (2011). Predicting the response of CML patients to tyrosine kinase inhibitor therapy. Current Hematologic Malignancy Reports, 6(2), 88-95.
Scopus7 WoS7 Europe PMC62011 Ross, D. M., Hughes, T. P., & Melo, J. V. (2011). Erratum: Do we have to kill the last CML cell? (Leukemia (2010) (DOI:10.1038/leukemia.2010.197). Leukemia, 25(2), 386.
2010 White, D. L., Saunders, V. A., Dang, P., Engler, J., & Hughes, T. P. (2010). OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1. Leukemia, 24(11), 1962-1965.
Scopus37 WoS34 Europe PMC242010 Osborn, M., & Hughes, T. (2010). Managing imatinib resistance in chronic myeloid leukaemia. Current Opinion in Hematology, 17(2), 97-103.
Scopus16 WoS12 Europe PMC92010 Branford, S., & Hughes, T. (2010). Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood, 116(22), E111-E117.
Scopus149 WoS115 Europe PMC842010 Hughes, T., Hochhaus, A., Branford, S., Muller, M., Kaeda, J., Foroni, L., . . . Radich, J. (2010). Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood, 116(19), 3758-3765.
Scopus430 WoS356 Europe PMC2942010 Bartley, P., Ross, D., Latham, S., Martin-Harris, M., Budgen, B., Wilczek, V., . . . Morley, A. (2010). Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. International Journal of Laboratory Hematology (Print Edition), 32(6 Part 1), E222-E228.
Scopus51 WoS39 Europe PMC342010 Ross, D., Branford, S., Seymour, J., Schwarer, A., Arthur, C., Bartley, P., . . . Hughes, T. (2010). Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia, 24(10), 1719-1724.
Scopus245 WoS203 Europe PMC1742010 Engler, J., Frede, A., Saunders, V., Zannettino, A., White, D., & Hughes, T. (2010). The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cells. Blood, 116(15), 2776-2778.
Scopus20 WoS18 Europe PMC122010 Branford, S., & Hughes, T. (2010). Practical considerations for monitoring patients with chronic myeloid leukemia. Seminars in Hematology, 47(4), 327-334.
Scopus7 WoS5 Europe PMC52010 Fitter, S., Vandyke, K., Schultz, C., White, D., Hughes, T., & Zannettino, A. (2010). Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in Type 2 diabetic CML patients?. Journal of Clinical Endocrinology and Metabolism, 95(8), 3763-3767.
Scopus50 WoS46 Europe PMC412010 Hiwase, D., White, D., Powell, J., Saunders, V., Zrim, S., Frede, A., . . . Hughes, T. (2010). Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia, 24(4), 771-778.
Scopus48 WoS42 Europe PMC332010 Cortes, A., Baccarani, M., Guilhot, F., Druker, B., Branford, S., Kim, D., . . . Hughes, T. (2010). Phase III, randomized, open-label study of daily Imatinib Mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study. Journal of Clinical Oncology, 28(3), 424-430.
Scopus238 WoS221 Europe PMC1792010 Saglio, G., Kim, D., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., . . . Kantarjian, H. (2010). Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 362(24), 2251-2259.
Scopus1451 WoS1248 Europe PMC9482010 White, D., Dang, P., Engler, J., Frede, A., Osborn, M., Saunders, V., . . . Hughes, T. (2010). Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with Imatinib. Journal of Clinical Oncology, 28(16), 2761-2767.
Scopus158 WoS142 Europe PMC1182010 Eadie, L., Hughes, T., & White, D. (2010). Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells. Leukemia, 24(4), 855-857.
Scopus9 WoS8 Europe PMC92010 Engler, J., Frede, A., Saunders, V., Zannettino, A., Hughes, T., & White, D. (2010). Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity. Leukemia, 24(4), 765-770.
Scopus55 WoS52 Europe PMC402010 Vandyke, K., Fitter, S., Dewar, A., Hughes, T., & Zannettino, A. (2010). Dysregulation of bone remodeling by imatinib mesylate. Blood, 115(4), 766-774.
Scopus127 WoS107 Europe PMC822010 Fraser, C., Lousberg, E., Guerin, L., Hughes, T., Brown, M., Diener, K., & Hayball, J. (2010). Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo. Cancer Biology & Therapy, 10(7), 715-727.
Scopus11 WoS10 Europe PMC82010 Hiwase, D., White, D., Zrim, S., Saunders, V., Vaz de Melo, J., & Hughes, T. (2010). Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. Leukemia, 24(3), 658-660.
Scopus27 WoS25 Europe PMC222010 Hochhaus, A., O'Brien, S. G., Guilhot, F., Druker, B. J., Branford, S., Foroni, L., . . . Larson, R. A. (2010). Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia(Leukemia (2009) 23 (1054-1061) DOI: 10.1038/leu.2009.38). Leukemia, 24(5), 1102.
Scopus2 WoS72010 Hochhaus, A., Saglio, A., Kantarjian, H., Haque, A., Shou, Y., Woodman, R. C., . . . Kim, D. (2010). Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page.
2010 Hughes, T. P., le Coutre, P. D., Clark, R. E., Saglio, G., Larson, R. A., Yin, Q., . . . Kantarjian, H. (2010). Population pharmacokinetic (PK) and exposure-response analysis of nilotinib in newly diagnosed Ph plus chronic myeloid leukemia in chronic phase: Results from ENESTnd. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page.
WoS12010 Kim, D., Saglio, G., Martinelli, G., Shou, Y., Stein, A. M., Woodman, R. C., . . . Hochhaus, A. (2010). BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page.
2010 Larson, R. A., le Coutre, P. D., Reiffers, J., Hughes, T. P., Saglio, G., Edrich, P., . . . Hochhaus, A. (2010). Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in ehronic phase (CML-CP): ENESTnd beyond one year. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page.
WoS82010 Lv, Y., Hughes, T. C., Hao, X., Hart, N. K., Littler, S. W., Zhang, X., & Tan, T. (2010). A novel route to prepare highly reactive and versatile chromatographic monoliths. Macromolecular Rapid Communications, 31(20), 1785-1790.
Scopus16 WoS16 Europe PMC22010 Hao, X., Jeffery, J. L., Wilkie, J. S., Meijs, G. F., Clayton, A. B., Watling, J. D., . . . Hughes, T. C. (2010). Functionalised polysiloxanes as injectable, in situ curable accommodating intraocular lenses. Biomaterials, 31(32), 8153-8163.
Scopus46 WoS41 Europe PMC142010 Cass, P., Knower, W., Pereeia, E., Holmes, N. P., & Hughes, T. (2010). Preparation of hydrogels via ultrasonic polymerization. Ultrasonics Sonochemistry, 17(2), 326-332.
Scopus69 WoS52 Europe PMC72009 Elvin, C. M., Brownlee, A. G., Huson, M. G., Tebb, T. A., Kim, M., Lyons, R. E., . . . Werkmeister, J. A. (2009). The development of photochemically crosslinked native fibrinogen as a rapidly formed and mechanically strong surgical tissue sealant. Biomaterials, 30(11), 2059-2065.
Scopus112 WoS96 Europe PMC492009 Drummond, M. W., Heaney, N., Kaeda, J., Nicolini, F. E., Clark, R. E., Wilson, G., . . . Holyoake, T. L. (2009). A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia, 23(6), 1199-1201.
Scopus33 WoS30 Europe PMC222009 Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., . . . Hehlmann, R. (2009). Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. Journal of Clinical Oncology, 27(35), 6041-6051.
Scopus1145 WoS1007 Europe PMC7662009 Muller, M., Cortes, J., Kim, D., Druker, B., Erben, P., Pasquini, R., . . . Hochhaus, A. (2009). Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood, 114(24), 4944-4953.
Scopus255 WoS255 Europe PMC1852009 Fraser, C., Lousberg, E., Kumar, R., Hughes, T., Diener, K., & Hayball, J. (2009). Dasatinib inhibits the secretion of TNF-α following TLR stimulation in vitro and in vivo. Experimental Hematology, 37(12), 1435-1444.
Scopus38 WoS36 Europe PMC292009 Hughes, T., & Branford, S. (2009). Measuring minimal residual disease in chronic myeloid leukemia: Fluorescence in situ hybridization and polymerase chain reaction. Clinical Lymphoma & Myeloma, 9(Supp 3), S266-S271.
Scopus8 WoS3 Europe PMC22009 Kantarjian, H., Pasquini, R., Levy, V., Jootar, S., Holowiecki, J., Hamerschlak, N., . . . Shah, N. (2009). Dasatinib or high-dose Imatinib for chronic-phase chronic myeloid leukemia resistant to Imatinib at a dose of 400 to 600 milligrams daily. Two-year follow-up of a randomized phase 2 study (START-R). Cancer, 115(18), 4136-4147.
Scopus185 WoS159 Europe PMC1242009 Hughes, T., Saglio, G., Branford, S., Soverini, S., Kim, J., Muller, M., . . . Hochhaus, A. (2009). Impact of baseline BCR-ABL mutations on response to Nilotinib in patients with chronic myeloid leukemia in chronic phase. Journal of Clinical Oncology, 27(25), 4204-4210.
Scopus278 WoS245 Europe PMC1942009 Hochhaus, A., Muller, M., Radich, J., Branford, S., Kantarjian, H., Hanfstein, B., . . . Hughes, T. (2009). Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia, 23(9), 1628-1633.
Scopus33 WoS32 Europe PMC242009 Vandyke, K., Dewar, A., Menicanin, D., To, L., Hughes, T., Zannettino, A., & Fitter, S. (2009). Imatinib mesylate causes growth plate closure in vivo. Leukemia, 23(11), 2155-2159.
Scopus37 WoS32 Europe PMC322009 White, D., & Hughes, T. (2009). Predicting the response of CML patients to tyrosine kinase inhibitor therapy. Current Hematologic Malignancy Reports, 4(2), 59-65.
Scopus6 Europe PMC52009 Apperley, J., Cortes, J., Kim, D., Roy, L., Roboz, G., Rosti, G., . . . Stone, R. (2009). Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial. Journal of Clinical Oncology, 27(21), 3472-3479.
Scopus172 WoS149 Europe PMC1062009 Viswanathan, S., Powers, J., Einhorn, W., Hoshida, Y., Ng, T., Toffanin, S., . . . Daley, G. (2009). Lin28 promotes transformation and is associated with advanced human malignancies. Nature Genetics, 41(7), 843-U109.
Scopus726 WoS647 Europe PMC5892009 Hochhaus, A., O'Brien, S., Guilhot, F., Druker, B., Branford, S., Foroni, L., . . . Larson, R. (2009). Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia, 23(6), 1054-1061.
Scopus758 WoS656 Europe PMC5392009 Tojo, A., Usuki, K., Urabe, A., Maeda, Y., Kobayashi, Y., Jinnai, I., . . . Naoe, T. (2009). A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph plus CML or relapsed/refractory Ph plus ALL. International Journal of Hematology, 89(5), 679-688.
Scopus39 WoS37 Europe PMC282009 Vandyke, K., Dewar, A., Farrugia, A., Fitter, S., To, B., Hughes, T., & Zannettino, A. (2009). Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia, 23(5), 994-997.
Scopus49 WoS47 Europe PMC352009 Hughes, T., & Hochhaus, A. (2009). Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy. Seminars in Hematology, 46(2), S11-S15.
Scopus4 WoS4 Europe PMC32009 Blake, S., Lyons, A., & Hughes, T. (2009). Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro. Journal of Cellular and Molecular Medicine, 13(3), 599-601.
Scopus27 WoS24 Europe PMC202009 Khoury, H., Guilhot, F., Hughes, T., Kim, D., & Cortes, J. (2009). Dasatinib treatment for Philadelphia chromosome-positive Leukemias: practical considerations. Cancer, 115(7), 1381-1394.
Scopus43 WoS38 Europe PMC342009 Ross, D., Schafranek, L., Hughes, T., Nicola, M., Branford, S., & Score, J. (2009). Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplification. Cancer Genetics and Cytogenetics, 189(2), 138-139.
Scopus6 WoS5 Europe PMC52009 Fraser, C., Blake, S., Diener, K., Lyons, A., Brown, M., Hughes, T., & Hayball, J. (2009). Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Experimental Hematology, 37(2), 256-265.
Scopus58 WoS53 Europe PMC482009 Branford, S., Vaz de Melo, J., & Hughes, T. (2009). Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?. Blood, 114(27), 5426-5435.
Scopus158 WoS130 Europe PMC1092009 Hughes, T. P., & Branford, S. (2009). Monitoring disease response to tyrosine kinase inhibitor therapy in CML.. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2009(1), 477-487.
Scopus60 Europe PMC262009 Ross, D., Branford, S., Melo, J., & Hughes, T. (2009). Reply to 'What do we mean by sensitivity when we talk about detecting minimal residual disease?' by Steinbach and Debatin. Leukemia, 23(4), 819-820.
Scopus7 WoS8 Europe PMC32009 Hiwase, D., White, D., Saunders, V., Kumar, S., Melo, J., & Hughes, T. (2009). Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL<sup>+</sup> cells. Leukemia, 23(6), 1205-1206.
Scopus17 WoS15 Europe PMC112008 Ross, D. M., & Hughes, T. P. (2008). How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?. Leukemia and Lymphoma, 49(7), 1230-1231.
Scopus2 WoS2 Europe PMC12008 Branford, S., Fletcher, L., Cross, N. C. P., Müller, M. C., Hochhaus, A., Kim, D. W., . . . Hughes, T. (2008). Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood, 112(8), 3330-3338.
Scopus339 WoS307 Europe PMC2392008 Hughes, T. P., Branford, S., White, D. L., Reynolds, J., Koelmeyer, R., Seymour, J. F., . . . Grigg, A. (2008). Impact of early dose intensity on cytogenetic and molecular responses in chronicphase CMLpatients receiving 600 mg/day of imatinib as initial therapy. Blood, 112(10), 3965-3973.
Scopus146 WoS135 Europe PMC1162008 Sweeney, D. F., Vannas, A., Hughes, T. C., Evans, M. D., McLean, K. M., Xie, R. Z., . . . Prakasam, R. K. (2008). Synthetic corneal inlays: Invited Review. Clinical and Experimental Optometry, 91(1), 56-66.
Scopus34 WoS26 Europe PMC122008 le Coutre, P., Ottmann, O., Giles, F., Kim, D., Cortes, J., Gattermann, N., . . . Kantarjian, H. (2008). Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood, 111(4), 1834-1839.
Scopus274 WoS241 Europe PMC1682008 Ross, D., Watkins, D., Hughes, T., & Branford, S. (2008). Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: Implications for defining sensitivity in minimal residual disease. Clinical Chemistry, 54(9), 1568-1571.
Scopus11 WoS10 Europe PMC72008 Blake, S., Hughes, T., Mayrhofer, G., & Lyons, A. (2008). The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clinical Immunology, 127(3), 330-339.
Scopus108 WoS91 Europe PMC762008 Ross, D., & Hughes, T. (2008). Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders. Pathology, 40(3), 231-246.
Scopus9 WoS10 Europe PMC72008 Mullighan, C., Miller, C., Radtke, I., Philips, L., Dalton, J., Ma, J., . . . Downing, J. (2008). BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature, 453(7191), 110-114.
Scopus893 WoS783 Europe PMC6832008 Giles, F., DeAngelo, D., Baccarani, M., Deininger, M., Guilhot, F., Hughes, T., . . . Cortes, J. (2008). Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. Seminars in Oncology, 35(Supp. 1), S1-S17.
Scopus31 WoS23 Europe PMC182008 Blake, S., Lyons, A., Fraser, C., Hayball, J., & Hughes, T. (2008). Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood, 111(8), 4415-4416.
Scopus69 WoS66 Europe PMC562008 Cross, N., Hughes, T., Hochhaus, A., & Goldman, J. (2008). International standardisation of quantitative real-time RT-PCR for BCR-ABL. Leukemia Research, 32(3), 505-506.
Scopus26 WoS23 Europe PMC232008 Fitter, S., Dewar, A., Kostakis, P., To, L., Hughes, T., Roberts, M., . . . Zannettino, A. (2008). Long-term imatinib therapy promotes bone formation in CML patients. Blood, 111(5), 2538-2547.
Scopus145 WoS129 Europe PMC1072008 Hui, C., Sia, H., Mangos, H., Horvath, N., Lewis, I., Hughes, T., . . . Bardy, P. (2008). Daclizumab has poor efficacy in steroid-refractory severe acute graft-versus-host disease: a single centre experience with 12 allograft patients. Bone Marrow Transplantation, 41(4), 409-410.
Scopus6 WoS5 Europe PMC62008 Hughes, T. (2008). Is drug treatment superior to allografting as first-line therapy in chronic myeloid leukemia?. Nature Clinical Practice Oncology, 5(1), 14-15.
Scopus1 Europe PMC12008 Hiwase, D., Saunders, V., Hewett, D., Frede, A., Zrim, S., Dang, P., . . . White, D. (2008). Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clinical Cancer Research, 14(12), 3881-3888.
Scopus168 WoS145 Europe PMC1252008 Hochhaus, A., Baccarani, M., Deininger, M., Apperley, J. F., Lipton, J. H., Goldberg, S. L., . . . Kantarjian, H. M. (2008). Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia, 22(6), 1200-1206.
Scopus324 WoS276 Europe PMC2252008 Cross, N. C. P., Daley, G. Q., Green, A. R., Hughes, T. P., Jamieson, C., Manley, P., . . . Goldman, J. M. (2008). BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: Some common and contrasting features. Leukemia, 22(11), 1975-1989.
Scopus17 WoS16 Europe PMC142007 Shah, N. P., Skaggs, B. J., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., & Sawyers, C. L. (2007). Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. Journal of Clinical Investigation, 117(9), 2562-2569.
Scopus343 WoS317 Europe PMC2562007 Branford, S., Hughes, T., Milner, A., Koelmeyer, R., Schwarer, A., Arthur, C., . . . Taylor, K. (2007). Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-α. Cancer, 110(4), 801-808.
Scopus6 WoS7 Europe PMC32007 Kantarjian, H., Pasquini, R., Hamerschlak, N., Rousselot, P., Holowiecki, J., Jootar, S., . . . Shah, N. (2007). Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial. Blood, 109(12), 5143-5150.
Scopus346 WoS279 Europe PMC2192007 Hochhaus, A., Kantarjian, H. M., Baccarani, M., Lipton, J. H., Apperley, J. F., Druker, B. J., . . . Shah, N. P. (2007). Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood, 109(6), 2303-2309.
Scopus555 WoS465 Europe PMC3562007 Hughes, T., & Branford, S. (2007). Ph<sup>+</sup> ALL: Resistance seeds sown early. Blood, 110(2), 472.
2007 Branford, S., Seymour, J., Grigg, A., Arthur, C., Rudzki, Z., Lynch, K., & Hughes, T. (2007). BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clinical Cancer Research, 13(23), 7080-7085.
Scopus121 WoS105 Europe PMC832007 White, D., Saunders, V., Dang, P., Engler, J., Venables, A., Zrim, S., . . . Hughes, T. (2007). Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood, 110(12), 4064-4072.
Scopus280 WoS255 Europe PMC1962007 White, D., Saunders, V., Grigg, A., Arthur, C., Filshie, R., Leahy, M., . . . Hughes, T. (2007). Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. Journal of Clinical Oncology, 25(28), 4445-4451.
Scopus54 WoS52 Europe PMC482007 White, D., Saunders, V., Quinn, S., Manley, P., & Hughes, T. (2007). Imatinib increases the intracellular concentration of nilotinib which may explain the observed synergy between these drugs. Blood, 109(8), 3609-3610.
Scopus41 WoS44 Europe PMC302007 Hughes, T., Branford, S., & Goldman, J. (2007). Reliability of PCR for BCR-ABL transcripts. Blood, 109(5), 2263-2264.
WoS12007 Hughes, T. P., Gunderson, L. H., Folke, C., Baird, A. H., Bellwood, D., Berkes, F., . . . Worm, B. (2007). Adaptive management of the great barrier reef and the grand canyon world heritage areas. Ambio, 36(7), 586-592.
Scopus80 WoS69 Europe PMC132006 Luke, C., Nguyen, A. M., To, B., Seshadri, R., Hughes, T., Bardy, P., . . . Roder, D. (2006). Myeloid leukaemia treatment and survival - the south australian experience, 1977 to 2002. Asian Pacific Journal of Cancer Prevention, 7(2), 227-233.
Scopus9 Europe PMC82006 Baccarani, M., Saglio, G., Goldman, J., Hochhaus, A., Simonsson, B., Appelbaum, F., . . . Hehlmann, R. (2006). Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 108(6), 1809-1820.
Scopus1132 WoS963 Europe PMC7232006 Hui, C., & Hughes, T. (2006). Autologous stem cell collection and autograft for patients with chronic myeloid leukemia in the era of ABL kinase inhibitors: Back to the bench. Leukemia & Lymphoma, 47(9), 1721-1723.
Scopus1 WoS1 Europe PMC12006 Druker, B., Guilhot, F., O'Brien, S., Gathmann, I., Kantarjian, H., Gattermann, N., . . . Larson, R. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355(23), 2408-2417.
Scopus3057 WoS2619 Europe PMC20732006 Grigg, A., & Hughes, T. (2006). Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era. Biology of Blood and Marrow Transplantation, 12(8), 795-807.
Scopus26 WoS22 Europe PMC162006 White, D., Saunders, V., Dang, P., Engler, J., Zannettino, A., Cambareri, A., . . . Hughes, T. (2006). OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood, 108(2), 697-704.
Scopus387 WoS322 Europe PMC2552006 Dewar, A., Farrugia, A., Condina, M., To, L., Hughes, T., Vernon-Roberts, B., & Zannettino, A. (2006). Imatinib as a potential antiresorptive therapy for bone disease. Blood, 107(11), 4334-4337.
Scopus70 WoS65 Europe PMC542006 Hughes, T., & Branford, S. (2006). Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Reviews, 20(1), 29-41.
Scopus133 WoS107 Europe PMC802006 Ross, D., Branford, S., Moore, S., & Hughes, T. (2006). Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia, 20(4), 664-670.
Scopus63 WoS57 Europe PMC502006 Branford, S., Cross, N., Hochhaus, A., Radich, J., Saglio, G., Kaeda, J., . . . Hughes, T. (2006). Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia, 20(11), 1925-1930.
Scopus178 WoS153 Europe PMC1182006 Branford, S., & Hughes, T. (2006). Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR.. Methods in molecular medicine, 125, 69-92.
Scopus50 Europe PMC322006 Hughes, T. (2006). ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring.. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2006(1), 211-218.
Scopus38 Europe PMC182006 Branford, S., & Hughes, T. (2006). Detection of BCR-ABL mutations and resistance to imatinib mesylate.. Methods in molecular medicine, 125, 93-106.
Scopus69 Europe PMC352006 Ruo, Z. X., Evans, M. D. M., Bojarski, B., Hughes, T. C., Chan, G. Y., Nguyen, X., . . . Sweeney, D. F. (2006). Two-year preclinical testing of perfluoropolyether polymer as a corneal inlay. Investigative Ophthalmology and Visual Science, 47(2), 574-581.
Scopus31 WoS25 Europe PMC162006 Grace, G. Y., Hughes, T. C., McLean, K. M., McFarland, G. A., Nguyen, X., Wilkie, J. S., & Johnson, G. (2006). Approaches to improving the biocompatibility of porous perfluoropolyethers for ophthalmic applications. Biomaterials, 27(8), 1287-1295.
Scopus31 WoS29 Europe PMC42006 Hughes, T., Deininger, M., Hochhaus, A., Branford, S., Radich, J., Kaeda, J., . . . Goldman, J. M. (2006). Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 108(1), 28-37.
Scopus1058 WoS908 Europe PMC6812005 White, D., Saunders, V., Lyons, A., Branford, S., Grigg, A., To, L., & Hughes, T. (2005). In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de-novo CML.. Blood, 106(7), 2520-2526.
Scopus124 WoS109 Europe PMC902005 Dewar, A., Cambareri, A., Zannettino, A., Boog, B., Doherty, K., Hughes, T., & Lyons, A. (2005). Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood, 105(8), 3127-3132.
Scopus273 WoS248 Europe PMC1822005 Dewar, A., Zannettino, A., Hughes, T., & Lyons, A. (2005). Inhibition of c-fms by imatinib - Expanding the spectrum of treatment. Cell Cycle, 4(7), 851-853.
Scopus46 WoS45 Europe PMC362005 Dewar, A., Doherty, K., Hughes, T., & Lyons, A. (2005). Imatinib inhibits the functional capacity of cultured human monocytes. Immunology and Cell Biology, 83(1), 48-56.
Scopus38 WoS37 Europe PMC272005 Michor, F., Hughes, T., Iwasa, Y., Branford, S., Shah, N., Sawyers, C., & Nowak, M. (2005). Dynamics of chronic myeloid leukaemia. Nature, 435(7046), 1267-1270.
Scopus691 WoS619 Europe PMC4492004 Faderl, S., Hochhaus, A., & Hughes, T. (2004). Monitoring of minimal residual disease in chronic myeloid leukemia. Hematology-Oncology Clinics of North America, 18(3), 657-672.
Scopus23 Europe PMC102004 Mollee, P., Arthur, C., Hughes, T., Januszewicz, H., Grigg, A., Bradstock, K., . . . Taylor, K. (2004). Interferon-α-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia. Annals of Oncology, 15(12), 1810-1815.
Scopus6 WoS7 Europe PMC32004 Hochhaus, A., & Hughes, T. (2004). Clinical resistance to imatinib: mechanisms and implications. Hematology-Oncology Clinics of North America, 18(3), 641-657.
Scopus83 WoS70 Europe PMC502004 Branford, S., Rudzki, Z., Parkinson, I., Grigg, A., Taylor, K., Seymour, J., . . . Hughes, T. (2004). Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood, 104(9), 2926-2932.
Scopus204 WoS175 Europe PMC1332004 Szer, J., Durrant, S., Schwarer, A., Bradstock, K., Gibson, J., Arthur, C., . . . Raunow, H. (2004). Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation. Internal Medicine Journal, 34(3), 98-101.
Scopus10 WoS7 Europe PMC42004 Mullighan, C., Heatley, S., Doherty, K., Szabo, F., Grigg, A., Hughes, T., . . . Bardy, P. (2004). Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation. Transplantation, 27(4), 587-596.
Scopus79 WoS72 Europe PMC582004 Ross, D. M., & Hughes, T. P. (2004). Cancer treatment with kinase inhibitors: What have we learnt from imatinib?. British Journal of Cancer, 90(1), 12-19.
Scopus42 WoS33 Europe PMC192003 Hui, C. -H., & Hughes, T. P. (2003). Strategies for the treatment of imatinib-resistant chronic myeloid leukemia.. Clinical advances in hematology & oncology : H&O, 1(9), 538-559.
Europe PMC32003 Favre, G., Beksaç, M., Bacigalupo, A., Ruutu, T., Nagler, A., Gluckman, E., . . . Pagliuca, A. (2003). Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplantation, 32(9), 873-880.
Scopus88 Europe PMC592003 Hughes, T. (2003). Comments on the Hammersmith policy. Seminars in Hematology, 40(2), 111-112.
2003 O'Brien, S., Guilhot, F., Larson, R., Gathmann, I., Baccarani, M., Cervantes, F., . . . Druker, B. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine, 348(11), 994-1004.
Scopus3161 WoS2669 Europe PMC20662003 Branford, S., Rudzki, Z., Harper, A., Grigg, A., Taylor, K., Durrant, S., . . . Hughes, T. (2003). Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia, 17(12), 2401-2409.
Scopus147 WoS122 Europe PMC892003 Roberts, M., Dyson, P., Rawling, C., Thorp, D., Rawling, T., White, D., . . . Hughes, T. (2003). Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD. Cytotherapy, 5(6), 534-541.
Scopus2 WoS2 Europe PMC22003 Hughes, T., & Branford, S. (2003). Molecular monitoring of chronic myeloid leukemia. Seminars in Hematology, 40(2), 62-68.
Scopus75 WoS60 Europe PMC332003 Branford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., . . . Hughes, T. (2003). Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood, 102(1), 276-283.
Scopus687 WoS587 Europe PMC4192003 Dewar, A., Domaschenz, R., Doherty, K., Hughes, T., & Lyons, A. (2003). Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia, 17(9), 1713-1721.
Scopus53 WoS49 Europe PMC352003 Hughes, T., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M., . . . Radich, J. (2003). Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 349(15), 1423-1432.
Scopus1106 WoS957 Europe PMC6962003 Hui, C., Goh, K., White, D., Branford, S., Grigg, A., Seymour, J., . . . Hughes, T. (2003). Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia, 17(5), 821-828.
Scopus40 WoS33 Europe PMC262003 Melo, J. V., Hughes, T. P., & Apperley, J. F. (2003). Chronic myeloid leukemia.. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2003(1), 132-152.
Scopus117 Europe PMC242002 Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., . . . Hughes, T. (2002). High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood, 99(9), 3472-3475.
Scopus587 WoS522 Europe PMC3612002 Mullighan, C., Heatley, S., Doherty, K., Szabo, F., Grigg, A., Hughes, T., . . . Bardy, P. (2002). Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood, 99(10), 3524-3529.
Scopus187 WoS168 Europe PMC1282002 Frost, M., Ferrao, P., Hughes, T., & Ashman, L. (2002). Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Molecular Cancer Therapeutics, 1(12), 1115-1124.
Scopus246 WoS229 Europe PMC1372002 Branford, S., Hughes, T., & Rudzki, Z. (2002). Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene. British Journal of Haematology, 117(4), 875-877.
Scopus25 WoS21 Europe PMC142002 Borg, M., Hughes, T., Horvath, N., Rice, M., & Thomas, A. C. (2002). Renal toxicity after total body irradiation. International Journal of Radiation Oncology Biology Physics, 54(4), 1165-1173.
Scopus55 Europe PMC282001 Mullighan, C. G., Heatley, S., Doherty, K., Szabo, F., Grigg, A. P., Hughes, T. P., . . . Bardy, P. G. (2001). Non-HLA genetic polymorphisms influence risk of acute and chronic graft-versus-host disease, early death and infection following allogeneic haemopoietic stem cell transplantation.. BLOOD, 98(11), 739A-740A.
WoS12001 Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., . . . Hughes, T. (2001). Point mutations clustered within the ATP binding region of BCR-ABL are common in patients with emerging Glivec resistance but not in Glivec non-responsive cases of CML.. BLOOD, 98(11), 769A-770A.
WoS42001 Branford, S., Moore, S., Grigg, A., Szer, J., Arthur, C., Taylor, K., . . . Hughes, T. (2001). Early measurement of BCR-ABL mRNA blood levels may be predictive of subsequent achievement of major cytogenetic response to Glivec in chronic myeloid leukemia.. BLOOD, 98(11), 613A.
WoS42001 Hui, C., Bardy, P., Hughes, T., Horvath, N., & To, L. (2001). Successful salvage of RAEB/AML relapsing early post allograft with FLAG-Ida conditioned mini-allograft: a report of two cases. International Journal of Laboratory Hematology (Print Edition), 23(2), 135-138.
Scopus12001 Lutwyche, J., Keough, R., Hughes, T., & Gonda, T. (2001). Mutation screening of the c-MYB negative regulatory domain in acute and chronic myeloid leukaemia. British Journal of Haematology, 114(3), 632-634.
Scopus9 WoS9 Europe PMC92001 Evans, M. D. M., McLean, K. M., Hughes, T. C., & Sweeney, D. F. (2001). A review of the development of a synthetic corneal onlay for refractive correction. Biomaterials, 22(24), 3319-3328.
Scopus29 WoS24 Europe PMC122000 Collins, D. J., Hughes, T. C., & Johnson, W. M. (2000). Dihydro-1,2,4-triazin-6(1H)-ones. IV Chemical modification of 3-phenyl-4,5-dihydro-1,2,4-triazin-6(1H)-ones. Australian Journal of Chemistry, 53(2), 137-141.
Scopus10 WoS82000 Hughes, T., White, D., Bresatz, S., Forte, M., Lewis, I., & Lyons, A. (2000). Normal and leukemic engraftment in the nod/scid mouse model. Haematologica, 85, 10-11. 2000 Moore, S., McDiarmid, L., & Hughes, T. (2000). Stem cell factor and chronic myeloid leukemia CD34+ cells. Leukemia & Lymphoma, 38(3-4), 211-220.
Scopus10 WoS9 Europe PMC82000 Craddock, C., Bardy, P., Kreiter, S., Johnston, R., Apperley, J., Marks, D., . . . Derigs, G. (2000). Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen. British Journal of Haematology, 111(3), 797-800.
Scopus22 Europe PMC142000 Branford, S., Rudzi, Z., & Hughes, T. (2000). A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemia. British Journal of Haematology, 109(3), 635-637.
Scopus41 WoS38 Europe PMC342000 Szabo, F., Horvath, N., Seimon, S., & Hughes, T. (2000). Inappropriate antidiuretic hormone secretion, abdominal pain and disseminated varicella-zoster virus infection: an unusual triad in a patient 6 months post mini-allogeneic peripheral stem cell transplant for chronic myeloid leukemia. Bone Marrow Transplantation, 26(2), 231-233.
Scopus23 Europe PMC181999 Branford, S., Hughes, T., & Rudzki, Z. (1999). Monitoring chronic myeloid leukaemia therapy by real time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. British Journal of Haematology, 107(-), 587-599.
Scopus2081999 Branford, S., Hughes, T. P., & Rudzki, Z. (1999). Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. BRITISH JOURNAL OF HAEMATOLOGY, 107(3), 587-599.
WoS185 Europe PMC1631999 Gricg, A. P., Szer, J., Beresford, J., Doods, A., Braosiock, K., Durrant, S., . . . Mattiie, J. (1999). Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. British Journal of Haematology, 107(2), 409-418.
Scopus61 Europe PMC471999 Collins, D. J., Hughes, T. C., & Johnson, W. M. (1999). Dihydro-1,2,4-triazin-6(1H)-ones. III oxidation products of 1-Methyl-3-phenyl-4,5-dihydro-1,2,4-triazin-6(1H)-one. Australian Journal of Chemistry, 52(10), 971-975.
Scopus3 WoS21999 Collins, D. J., Hughes, T. C., & Johnson, W. M. (1999). Dihydro-1,2,4-triazin-6(1H)-ones. II synthesis of several methylated 3-phenyl-4,5-dihydro-1,2,4-triazin-6(1H)-ones. Australian Journal of Chemistry, 52(5), 379-385.
Scopus13 WoS71998 Moore, S., Haylock, D. N., Lévesque, J. P., McDiarmid, L. A., Samels, L. M., To, L. B., . . . Hughes, T. P. (1998). Stem cell factor as a single agent induces selective proliferation of the philadelphia chromosome positive fraction of chronic myeloid leukemia CD34<sup>+</sup> cells. Blood, 92(7), 2461-2470.
Scopus40 WoS36 Europe PMC231998 Moore, S., Haylock, D., Levesque, J. P., McDiarmid, L., Samels, L., To, L., . . . Hughes, T. (1998). Stem cell factor as a single agent induces marked proliferation of the philadelphia chromosome positive fraction of CML CD34+ cell. Blood, 92(7), 2461-2470. 1998 Lewis, I., McDiarmid, L., Samels, L., To, L., & Hughes, T. (1998). Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells. Blood, 91(2), 630-640.
Scopus58 WoS57 Europe PMC371997 Iversen, P., Lewis, I., Turczynowicz, S., Hasle, H., Niemeyer, C., Schmiegelow, K., . . . Lopez, A. (1997). Inhibition of GM-CSF prevents dissemination and induces remission of human juvenile myelomonocytic leukemia in engrafted immunodeficient mice.. Blood, 90(12), 4910-4917. 1997 Hughes, T., Grigg, A., Szer, J., Ho, J., Ma, D., Dale, B., . . . Arthur, C. (1997). Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control.. British Journal of Haematology, 96(3), 635-640.
Scopus14 WoS13 Europe PMC71997 White, D., Hutchins, C., Turczynowicz, S., Suttle, J., Haylock, D., Hughes, T., . . . To, L. (1997). Detection of minimal residual disease in an AML patient with trisomy 8 using interphase fish. Pathology, 29(3), 289-293.
Scopus9 WoS10 Europe PMC71997 Lewis, I., Haylock, D., Moore, S., To, L., & Hughes, T. (1997). Peripheral blood is a source of BCR-ABL-negative pre-progenitors in early chronic phase chronic myeloid leukemia.. Leukemia, 11(4), 581-587.
Scopus11 WoS7 Europe PMC21997 Iversen, P. O., Lewis, I. D., Turczynowicz, S., Hasle, H., Niemeyer, C., Schmiegelow, K., . . . Lopez, A. F. (1997). Inhibition of granulocyte-macrophage colony-stimulating factor prevents dissemination and induces remission of juvenile myelomonocytic leukemia in engrafted immunodeficient mice. Blood, 90(12), 4910-4917.
Scopus51 WoS43 Europe PMC241996 Collins, D. J., Hughes, T. C., & Johnson, W. M. (1996). Regiospecific syntheses of the monomethylated 3-phenyldihydro-1,2,4-triazin-6(1H)-ones. Australian Journal of Chemistry, 49(4), 463-468.
Scopus18 WoS141996 Collins, D. J., Hughes, T. C., Johnson, W. M., & Mackay, M. F. (1996). 2-methyl-3-phenyl-2,5-dihydro-1,2,4-triazin-6(1H)-one methanol solvate and 4-methyl-3-phenyl-4,5-dihydro-1,2,4-triazin-6(1H)-one. Acta Crystallographica Section C: Crystal Structure Communications, 52(11), 2865-2868.
Scopus2 WoS11995 Kumar, S., White, D., Takai, S., Turczynowicz, S., Juttner, C., & Hughes, T. (1995). Apoptosis regulatory gene NEDD2 maps to human chromosome segment 7934-35, a region frequently affected in haematological neoplasms. Human Genetics, 95(6), 641-644.
Scopus41 WoS38 Europe PMC231995 White, D., Hutchins, C., Haylock, D., Turczynowics, S., Bishop, A., To, L., . . . Juttner, C. (1995). A direct analysis of FACS-sorted hemopoietic cell fractions using fish. Biotechniques, 18(5), 818-821.
Scopus4 WoS31994 Orr, S. L., Hughes, T. P., Sawyers, C. L., Kato, R. M., Quan, S. G., Williams, S. P., . . . Hood, L. (1994). Isolation of unknown genes from human bone marrow by differential screening and single-pass cDNA sequence determination. Proceedings of the National Academy of Sciences of the United States of America, 91(25), 11869-11873.
Scopus13 Europe PMC71993 Marks, D. I., Cullis, J. O., Ward, K. N., Lacey, S., Szydlo, R., Hughes, T. P., . . . Goldman, J. M. (1993). Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: A comparison of complications in the first 2 years. Annals of Internal Medicine, 119(3), 207-214.
Scopus199 WoS202 Europe PMC1041993 Cross, N. C. P., Hughes, T. P., Feng, L., O'Shea, P., Bungey, J., Marks, D. I., . . . Goldman, J. M. (1993). Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft‐versus‐host disease and relapse. British Journal of Haematology, 84(1), 67-74.
Scopus171 Europe PMC791993 Cross, N. C. P., Feng, L., Chase, A., Bungey, J., Hughes, T. P., & Goldman, J. M. (1993). Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood, 82(6), 1929-1936.
Scopus374 Europe PMC1721993 HANAUER, S. B., KRAWITT, E. L., ROBINSON, M., RICK, G. G., SAFDI, M. A., ALPERT, E., . . . ROI, L. (1993). LONG-TERM MANAGEMENT OF CROHNS-DISEASE WITH MESALAMINE CAPSULES (PENTASA(R)). AMERICAN JOURNAL OF GASTROENTEROLOGY, 88(9), 1343-1351.
WoS49 Europe PMC281992 Cullis, J. O., Jiang, Y. Z., Schwarer, A. P., Hughes, T. P., Barrett, A. J., & Goldman, J. M. (1992). Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation [3]. Blood, 79(5), 1379-1381.
Scopus138 Europe PMC661992 Cullis, J. O., Schwarer, A. P., Hughes, T. P., Hows, J. M., Franklin, I., Morgenstern, G., & Goldman, J. M. (1992). Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T‐depleted donor marrow: feasibility of using busulphan alone for re‐conditioning. British Journal of Haematology, 80(1), 33-39.
Scopus42 Europe PMC171992 Marks, D. I., Hughes, T. P., Szydlo, R., Kelly, S., Cullis, J. O., Schwarer, A. P., . . . Goldman, J. M. (1992). HLA‐identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. British Journal of Haematology, 81(3), 383-390.
Scopus42 Europe PMC171992 Bi, S., Hughes, T., Bungey, J., Chase, A., De Fabritiis, P., & Goldman, J. M. (1992). p53 in chronic myeloid leukemia cell lines. Leukemia, 6(8), 839-842.
Scopus54 Europe PMC281990 Morgan, G. J., Hernandez, A., Chan, L. C., Hughes, T., Martiat, P., & Wiedemann, L. M. (1990). The role of alternative splicing patterns of BCR/ABL transcripts in the generation of the blast crisis of chronic myeloid leukaemia. British Journal of Haematology, 76(1), 33-38.
Scopus46 Europe PMC221990 Hughes, T., & Goldman, J. M. (1990). Improved results with PCR for chronic myeloid leukaemia. The Lancet, 336(8718), 812.
Scopus17 Europe PMC91990 Hughes, T., Janssen, J. W. G., Morgan, G., Martiat, P., Saglio, G., Pignon, J. M., . . . Goldman, J. M. (1990). False-positive results with PCR to detect leukaemia-specific transcript. The Lancet, 335(8696), 1037-1038.
Scopus52 Europe PMC441990 Mackinnon, S., Hows, J., Goldman, J., Arthur, C., Hughes, T., Apperley, J., . . . Waldman, H. (1990). Bone marrow transplantation for chronic myeloid leukemia: The use of histocompatible unrelated volunteer donors. Experimental Hematology, 18(5), 421-425.
Scopus48 Europe PMC201990 Hughes, T., Martiat, P., Morgan, G., Sawyers, C., Witte, O. N., & Goldman, J. M. (1990). Significance of residual leukaemia transcripts after bone marrow transplant for CML. The Lancet, 335(8680), 50.
Scopus16 Europe PMC71990 Hughes, T. M., & Goldman, J. M. (1990). Biological importance of residual leukaemic cells after BMT for CML: Does the polymerase chain reaction help?. Bone Marrow Transplantation, 5(1), 3-6.
Scopus28 Europe PMC141989 Morgan, G. J., Janssen, J. W. G., Guo, A. P., Wiedemann, L. M., Hughes, T., Gow, J., . . . Bartram, C. R. (1989). POLYMERASE CHAIN REACTION FOR DETECTION OF RESIDUAL LEUKAEMIA. The Lancet, 333(8644), 928-929.
Scopus139 Europe PMC731989 Hughes, T. P., Economou, K., Mackinnon, S., Vlitos, M., Arthur, C. K., Guo, A. P., . . . Goldman, J. M. (1989). Slow evolution of chronic myeloid leukaemia relapsing after BMT with T‐cell depleted donor marrow. British Journal of Haematology, 73(4), 462-467.
Scopus37 Europe PMC191989 Kaminski, E., Hows, J., Brookes, P., Mackinnon, S., Hughes, T., Avakian, O., . . . Batchelor, J. R. (1989). Alloreactive cytotoxic T-cell frequency analysis and HLA matching for bone marrow transplants from HLA matched unrelated donors. Transplantation Proceedings, 21(1 III), 2976-2977.
Scopus11 Europe PMC21989 Hughes, T. P., Jones, P., & Rozenberg, M. C. (1989). Hypergammaglobulinemia and the anticardiolipin antibody test. Arthritis & Rheumatism, 32(6), 813.
Scopus17 Europe PMC151989 Kaminski, E., Hows, J., Man, S., Brookes, P., Mackinnon, S., Hughes, T., . . . Batchelor, J. R. (1989). Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation, 48(4), 608-613.
Scopus181 Europe PMC1061983 CLEMENTS, M. L., LEVINE, M. M., RISTAINO, P. A., DAYA, V. E., & HUGHES, T. P. (1983). EXOGENOUS LACTOBACILLI FED TO MAN - THEIR FATE AND ABILITY TO PREVENT DIARRHEAL DISEASE. PROGRESS IN FOOD AND NUTRITION SCIENCE, 7(3-4), 29-37.
WoS75 Europe PMC291978 NALIN, D. R., LEVINE, M. M., RHEAD, J., BERGQUIST, E., RENNELS, M., HUGHES, T., . . . HORNICK, R. B. (1978). CANNABIS, HYPOCHLORHYDRIA, AND CHOLERA. LANCET, 2(8095), 859-862.
WoS40 Europe PMC221933 Irwin, M. R., & Hughes, T. P. (1933). Inheritance as a factor in resistance to an infectious disease VI. The correlation between resistance and the bactericidal power of the whole blood. JOURNAL OF IMMUNOLOGY, 24(4), 343-348.
WoS81931 Irwin, M. R., & Hughes, T. P. (1931). Differences in bactericidal power of the blood within an inbred strain of rats.. PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 29(3), 0295-0297.
WoS61930 Hughes, T. P. (1930). Acid agglutination zones of typical and variant pneumococci. PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 27(8), 804-805.
WoS21927 Webster, L. T., Hughes, T. P., Pritchett, I. W., & Beaudette, F. R. (1927). Pasteurella avisepticurn* - Infection of poultry. PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 25(2), 119-121.
WoS1 -
Books
-
Book Chapters
Year Citation 2021 Branford, S., Shanmuganathan, N., & Hughes, T. P. (2021). Response-Related Predictors of Survival and of Treatment-Free Remission in CML. In Hematologic Malignancies (pp. 245-264). Springer International Publishing.
DOI2016 Ross, D., & Hughes, T. (2016). Discontinuation of therapy and treatment-free remission in CML. In M. Kizaki (Ed.), Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia (pp. 183-193). Japan: Springer.
DOI Scopus12016 Yeung, D., & Hughes, T. (2016). Chronic Myeloid Leukaemia. In A. V. Hoffbrand, & D. R. Higgs (Eds.), Postgraduate Haematology: Seventh Edition (pp. 419-437). Wiley.
DOI Scopus22011 Hiwase, D. K., & Hughes, T. P. (2011). Therapy of Advanced-Stage and Resistant Chronic Myeloid Leukemia. In Leukemias: Principles and Practice of Therapy (pp. 281-295). Wiley.
DOI2008 Hiwase, D. K., & Hughes, T. (2008). Monitoring response to therapy for patients with chronic myeloid leukemia. In Chronic Myeloproliferative Disorders (pp. 103-117). 2007 Hughes, T., & Branford, S. (2007). Monitoring disease response. In J. Melo, & J. Goldman (Eds.), Myeloproliferative disorders. Hematologic Malignancies (pp. 143-164). Berlin: Springer. -
Conference Papers
Year Citation 2023 Ostovaneh, M., Hughes, T., Wu, C. O., McClelland, R., Casanova, R., Bluemke, D. A., . . . Venkatesh, B. A. (2023). DEEP PHENOTYPING OF DEMENTIA IN A MULTI-ETHNIC CARDIOVASCULAR COHORT: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA). In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Vol. 81 (pp. 4021). LA, New Orleans: ELSEVIER SCIENCE INC. 2023 Ding, X., Dalen, K., Hughes, T., & Rasband, M. (2023). Oligodendroglial Ank3 in paranodal maintenance and etiology of bipolar disorder. In JOURNAL OF NEUROCHEMISTRY Vol. 166 (pp. 74-75). WILEY. 2023 Carpanini, S., Torvell, M., Watkins, L., Byrne, R., Hughes, T., Zelek, W., & Morgan, B. P. (2023). Roles of complement dysregulation and membrane attack complex formation in developmental synapse loss. In IMMUNOBIOLOGY Vol. 228 (pp. 72). ELSEVIER GMBH.
DOI2023 Mizuzo, M., Kamiya, T., Miyasaka, Y., Kim, H., Fukui, S., Ishigami, M., . . . Morgan, B. P. (2023). Prevention of terminal pathway activation improves survival in a lethal malarial infection mouse model associated with multiple organ failure. In IMMUNOBIOLOGY Vol. 228 (pp. 3). ELSEVIER GMBH.
DOI2023 Andreassen, O., Osete, J., Akkouh, I., Ievglevskyi, O., Vandenberghe, M., De Assis, D., . . . Djurovic, S. (2023). Transcriptional and Functional Effects of Lithium in Bipolar Disorder iPSC-Derived Cortical Spheroids. In BIOLOGICAL PSYCHIATRY Vol. 93 (pp. S19). ELECTR NETWORK: ELSEVIER SCIENCE INC. 2021 Lassalle, P. P., Meyer, M. L., Heffernan, K. S., Kiefer, A. W., Bates, L. C., Hanson, E. D., . . . Stoner, L. (2021). Associations Between Carotid-femoral And Estimated Pulse Wave Velocity In Older Adults: The Atherosclerosis Risk In Communities (ARIC) Study. In CIRCULATION Vol. 143 (pp. 3 pages). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
DOI2019 Bevan, R., Hughes, T., Good, M., Morgan, P., & Morgan, J. (2019). RETINAL GANGLION CELL MORPHOLOGY ABNORMALITIES IN ALZHEIMER'S DISEASE AND COMPLEMENT ANIMAL MODELS. In MOLECULAR IMMUNOLOGY Vol. 114 (pp. 440). SPAIN, Madrid: PERGAMON-ELSEVIER SCIENCE LTD. 2019 Szabo, A., Akkouh, I. A., Hansson, L., Inderhaug, E., Hughes, T., Ueland, T., . . . Djurovic, S. (2019). Reduced IL-1beta-induced chemokine response in human iPSC-astrocytes in schizophrenia revealed by RNA-sequencing. In BRAIN BEHAVIOR AND IMMUNITY Vol. 81 (pp. 50-51). ACADEMIC PRESS INC ELSEVIER SCIENCE.
DOI2019 Branford, S., Wadham, C., Shanmuganathan, N., Thomson, D., Shahrin, N. U. R. H., Feng, J., . . . Hughes, T. P. (2019). An RNA-Based Next Generation Sequencing (NGS) Strategy Detects More Cancer Gene Mutations Than a DNA-Based Approach for the Prediction and Assessment of Resistance in CML. In BLOOD Vol. 134 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI2019 Saglio, G., Hughes, T. P., Geissler, J., Kapoor, S., Longin, A. -S., Mukherjee, A., & Cortes, J. E. (2019). Randomized, Open-Label, Multicenter, Phase 2 Study of Asciminib (ABL001) As an Add-on to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Have Not Achieved a Deep Molecular Response with Frontline Imatinib. In BLOOD Vol. 134 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS42019 Radich, J. P., Hochhaus, A., Giles, F. J., Ross, D. M., Saglio, G., Hughes, T. P., . . . Mahon, F. -X. (2019). Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib. In BLOOD Vol. 134 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS12019 Hughes, T. P., Saglio, G., Larson, R. A., Kantarjian, H. M., Kim, D. -W., Issaragrisil, S., . . . Hochhaus, A. (2019). Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis. In BLOOD Vol. 134 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS162019 Shanmuganathan, N., Thomson, D., Wadham, C., Saunders, V. A., Shahrin, N. H., Yeung, D. T., . . . Branford, S. (2019). RNA Splicing Defects in Cancer-Linked Genes Indicate Mutation or Focal Gene Deletion and Are Associated with TKI Resistance in CML. In BLOOD Vol. 134 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS12019 Kok, C. H., Liu, L., Yeung, D. T., Saunders, V. A., Dang, P., & Hughes, T. P. (2019). A Combination of <i>CD302</i> gene Expression and 3-Months <i>BCR</i>-<i>ABL1 Level</i> Predicts Inferior Achievement of Deep Molecular Response in CP-CML Patients Treated with Imatinib. In BLOOD Vol. 134 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI2019 Deininger, M. W., Rea, D., Lang, F., Kim, D. -W., Cortes, J. E., Hughes, T. P., . . . Mauro, M. J. (2019). Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 19 (pp. S289-S290). CIG MEDIA GROUP, LP.
DOI2018 Mahon, F. -X., Boquimpani, C., Takahashi, N., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . . . Hughes, T. P. (2018). Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 2 pages). LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS52018 Leow, B. C., Eadie, L., Pagani, I. S., Yeung, D. T., Hughes, T. P., & White, D. L. (2018). Clonal Selection Determines Resultant Dominance of Tyrosine Kinase Inhibitor-Resistant Cells in Chronic Myeloid Leukaemia. In HemaSphere Vol. 2 (pp. 503). Stockholm, Sweden: Lippincott, Williams & Wilkins.
DOI2018 Shanmuganathan, N., Branford, S., Yong, A., Hiwase, D., Yeung, D., Ross, D., & Hughes, T. (2018). Predictors of Success in Treatment-Free Remission: A Single Centre Experience. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 18 (pp. S224). CIG MEDIA GROUP, LP.
DOI2018 Mauro, M. J., Lang, F., Kim, D. -W., Cortes, J. E., Hughes, T. P., Hochhaus, A., . . . DeAngelo, D. J. (2018). Clinical Development of Asciminib (ABL001): A Randomized Phase 3 Study of Asciminib vs Bosutinib in Patients with Chronic Myeloid Leukemia (CML). In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 18 (pp. S223). CIG MEDIA GROUP, LP.
DOI WoS12018 Cortes, J. E., Hughes, T. P., Geissler, J., Hois, S., Quenet, S., Hourcade-Potelleret, F., . . . Saglio, G. (2018). Asciminib (ABL001) in Combination with Imatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Have Not Achieved a Deep Molecular Response with Long-Term Frontline Imatinib: A Randomized, Open-Label, Multicenter, Phase 2 Study. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 18 (pp. S222-S223). CIG MEDIA GROUP, LP.
DOI WoS12018 Hughes, T. P., Boquimpani, C., Takahashi, N., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . . . Mahon, F. -X. (2018). ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 18 (pp. S222). CIG MEDIA GROUP, LP.
DOI WoS32018 Yong, A. S., Shanmuganathan, N., & Hughes, T. (2018). Treatment-Free Remission in CML: Selecting the Best Candidates. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 18 (pp. S3-S5). CIG MEDIA GROUP, LP.
DOI2018 Mauro, M. J., Lang, F., Kim, D. -W., Cortes, J. E., Hughes, T. P., Hochhaus, A., . . . Rea, D. (2018). Clinical development of asciminib (ABL001) in chronic myeloid leukemia (CML): A randomized phase 3 study vs. bosutinib.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY.
DOI2018 Thomson, D., Shahrin, H., Wang, P., Wadham, C., Hughes, T. P., Schreiber, A., & Branford, S. (2018). High Recombination Activating Gene (RAG) Expression and RAG Mediated Recombination Is Associated with Oncogenic Rearrangement Observed with Tyrosine Kinase Inhibitor Resistant CML. In BLOOD Vol. 132 (pp. 4 pages). CA, San Diego: AMER SOC HEMATOLOGY.
DOI WoS12018 Yeung, D. T., Grigg, A. P., Shanmuganathan, N., Cunningham, I., Shortt, J., Rowling, P., . . . Hughes, T. P. (2018). Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study. In BLOOD Vol. 132 (pp. 5 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS52018 Tvorogov, D., Thomas, D., Liau, N. P. D., Dottore, M., Barry, E. F., Lathi, M., . . . Lopez, A. F. (2018). Accumulation of JAK Activation-Loop Phosphorylation Promotes Type I JAK Inhibitor Withdrawal Syndrome in Myelofibrosis. In BLOOD Vol. 132 (pp. 4 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI2018 Rea, D., Lang, F., Kim, D. -W., Cortes, J. E., Hughes, T. P., Minami, H., . . . Mauro, M. J. (2018). Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial. In BLOOD Vol. 132 (pp. 4 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS42017 Cortes, J. E., Hochhaus, A., Kantarjian, H. M., Guilhot, F., Kota, V. K., Hughes, T. P., . . . Jabbour, E. (2017). Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 6 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS142017 Kantarjian, H. M., Pinilla-Ibarz, J., Le Coutre, P. D., Paquette, R., Chuah, C., Nicolini, F. E., . . . Cortes, J. E. (2017). Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS52017 Mueller, M., Baccarani, M., Deininger, M. W. N., Guilhot, F., Hochhaus, A., Hughes, T. P., . . . Cortes, J. E. (2017). Impact of early landmark responses with ponatinib on 4-yr outcomes in CP-CML patients (pts) in PACE, a pivotal phase II trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 6 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS12017 Ross, D. M., Pagani, I. S., Shanmuganathan, N., Seymour, J. F., Mills, A. K., Filshie, R. J., . . . Hughes, T. P. (2017). Long-term Follow-up of the ALLG CML8 TWISTER Study of Treatment-free Remission (TFR) in Patients With Chronic Myeloid Leukemia (CML).. In Blood Vol. 130 (pp. 1597). Atlanta: American Society of Hematology. 2017 Pagani, I., Dang, P., Kommers, I., Goyne, J., Saunders, V., Prime, J., . . . Ross, D. (2017). Comparison of genomic and reverse transcriptase Q-PCR for the monitoring of first-line imatinib treatment: an ALLG CML9 sub-study. In Haematologica. Madrid: Ferrata Storti Foundation. 2017 Shanmuganathan, N., Branford, S., Yeung, D., Hiwase, D. K., Yong, A. S. M., Ross, D. M., & Hughes, T. P. (2017). Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience. In BLOOD Vol. 130 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY. 2017 Cortes, J. E., Nicolini, F. E., Hochhaus, A., le Coutre, P. D., Kim, D. -W., Pinilla-Ibarz, J., . . . Kantarjian, H. M. (2017). Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). In BLOOD Vol. 130 (pp. 4 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS12017 Hughes, T. P., Hochhaus, A., Kim, D. -W., Mahon, F. -X., Giles, F. J., Radich, J. P., . . . Saglio, G. (2017). Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop. In BLOOD Vol. 130 (pp. 4 pages). Atlanta, GA: AMER SOC HEMATOLOGY. 2017 Hochhaus, A., Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., . . . Kantarjian, H. M. (2017). Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study. In BLOOD Vol. 130 (pp. 4 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS32017 Saglio, G., Hughes, T. P., Hochhaus, A., Kim, D. -W., Giles, F. J., Radich, J. P., . . . Mahon, F. -X. (2017). Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop. In BLOOD Vol. 130 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY. 2017 Cortes, J. E., Kantarjian, H. M., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., . . . Mueller, M. C. (2017). 5-Year Updates from the Pivotal Phase 2 Ponatinib PACE Trial: Efficacy, Safety and Landmark Analysis in Heavily Pretreated Patients with Chronic-Phase Chronic Myeloid Leukemia. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 17 (pp. S307-S308). CIG MEDIA GROUP, LP.
DOI2017 Cortes, J. E., Hochhaus, A., Kantarjian, H., Guilhot, F., Kota, V., Hughes, T. P., . . . Jabbour, E. (2017). Effect of Dose Modifications on 5-Year Efficacy of Dasatinib and Imatinib in Newly Diagnosed Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) From DASISION. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 17 (pp. S308-S309). CIG MEDIA GROUP, LP.
DOI2017 Branford, S., Wang, P., Yeung, D., Purins, A., Marum, J. E., Nataren, N., . . . Hughes, T. P. (2017). Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy. In BLOOD Vol. 130 (pp. 4 pages). Atlanta, GA: AMER SOC HEMATOLOGY. 2017 Hughes, T., Boquimpani, C., Takahashi, N., Benyamini, N., Clementino, N. C., Shuvaev, V., . . . Mahon, F. -X. (2017). DURABLE TREATMENT-FREE REMISSION AFTER STOPPING SECOND-LINE NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: ENESTOP 96-WK UPDATE. In HAEMATOLOGICA Vol. 102 (pp. 75). Madrid, SPAIN: FERRATA STORTI FOUNDATION.
WoS72016 Marum, J. E., Wang, P. P. S., Stangl, D., Yeung, D. T., Mueller, M. C., Dietz, C. T., . . . Branford, S. (2016). Novel Fusion Genes at CML Diagnosis Reveal a Complex Pattern of Genomic Rearrangements and Sequence Inversions Associated with the Philadelphia Chromosome in Patients with Early Blast Crisis. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS22016 Pagani, I. S., Kok, C. H., Saunders, V., Goyne, J., McLean, J., VanderHoek, M., . . . Ross, D. M. (2016). The genomic landscape of mitochondrial DNA mutations in chronic myeloid leukaemia.. In European Journal of Human Genetics. Barcelona: Natue Publishing Group. 2016 Mahon, F. -X., Boquimpani, C. M., Takahashi, N., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . . . Hughes, T. P. (2016). Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS22016 Hughes, T. P., Boquimpani, C. M., Takahashi, N., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . . . Mahon, F. -X. (2016). Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS52016 Asari, K., Heatley, S. L., Sadras, T., Leclercq, T. M., Fitter, S., Kok, C. H., . . . White, D. L. (2016). <i>In Vitro</i> Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance Implications for Targeted Therapy. In BLOOD Vol. 128 (pp. 5 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI2016 Jabbour, E. J., Cortes, J. E., Talpaz, M., Baccarani, M., Mauro, M. J., Hochhaus, A., . . . Kantarjian, H. M. (2016). Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation. In BLOOD Vol. 128 (pp. 7 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI2016 Hiwase, D. K., Tan, P., D'Rozario, J., Taper, J., Powell, A. R., Irving, I., . . . Hughes, T. P. (2016). Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb ENES Tswift Study. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI2016 Shanmuganathan, N., Branford, S., Braley, J., Hiwase, D., Yeung, D. T., Ross, D. M., & Hughes, T. P. (2016). For Patients with Sustained MR4-MR4.5, Less Frequent Molecular Monitoring during the First 12 Months after Tyrosine Kinase Inhibitor Cessation Is Viable for Timely Detection of Loss of MMR. In BLOOD Vol. 128 (pp. 7 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI2016 Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Gerber, T., Butcher, B., . . . Hughes, T. P. (2016). Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI2016 Hughes, T. P., Goh, Y. -T., Ottmann, O. G., Minami, H., Rea, D., Lang, F., . . . Kim, D. -W. (2016). Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS22016 Hughes, T. P., Boquimpani, C., Kim, D. -W., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . . . Mahon, F. -X. (2016). Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 4 pages). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS42016 Muller, M. C., Baccarani, M., Deininger, M. W. N., Guilhot, F., Hochhaus, A., Hughes, T. P., . . . Cortes, J. E. (2016). Impact of landmark responses on 3-year (yr) outcomes with ponatinib in heavily pretreated CP-CML patients (pts).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 4 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI2016 Cortes, J. E., Pinilla-Ibarz, J., Le Coutre, P. D., Paquette, R., Chuah, C., Nicolini, F. E., . . . Kantarjian, H. M. (2016). 4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 4 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS22016 Pagani, I. S., Kok, C. H., Wang, J., Saunders, V., Goyne, J., McLean, J., . . . Ross, D. M. (2016). MITOCHONDRIAL DNA MUTATIONS IDENTIFY CLONAL HETEROGENEITY IN CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA Vol. 101 (pp. 234). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. 2016 Lu, L., Saunders, V., Kok, C., Leclercq, T., Hughes, T., & White, D. (2016). MODELLING PONATINIB RESISTANCE IN BCR-ABL1+CELL LINES: IMPLICATIONS FOR PONATINIB THERAPY. In HAEMATOLOGICA Vol. 101 (pp. 182-183). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. 2015 Pritchard, J., Lustgarten, S., Hodgson, J. G., Baccarani, M., Cortes, J. E., Deininger, M. W., . . . Rivera, V. M. (2015). ANALYSIS OF THE RELATIONSHIP BETWEEN DOSE AND BCR-ABL HALVING TIME IN CP-CML PATIENTS TREATED WITH PONATINIB OR IMATINIB. In HAEMATOLOGICA Vol. 100 (pp. 448-449). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION. 2015 Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., . . . Shah, N. P. (2015). Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study. In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Hochhaus, A., Saglio, G., Hughes, T. P., Larson, R. A., Taningco, L., Deng, W., . . . Kantarjian, H. M. (2015). Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP). In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Ottmann, O. G., Alimena, G., DeAngelo, D. J., Goh, Y. -T., Heinrich, M. C., Hochhaus, A., . . . Dong-Wook, K. (2015). ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS192015 Hughes, T. P., Cervantes, F., Spector, N., Leber, B., Branford, S., Glynos, T. A., . . . Lipton, J. H. (2015). Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL). In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Hochhaus, A., Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., . . . Kantarjian, H. M. (2015). Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial. In BLOOD Vol. 126 (pp. 5 pages). Orlando, FL: AMER SOC HEMATOLOGY.
WoS42015 Hughes, T. P., Larson, R. A., Kim, D. W., Issaragrisil, S., le Coutre, P. D., Lobo, C., . . . Kantarjian, H. M. (2015). EFFICACY AND SAFETY OF NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: 6-YEAR FOLLOW-UP OF ENESTND. In HAEMATOLOGICA Vol. 100 (pp. 61). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION. 2015 Cortes, J. E., Kim, D. G., Pinilla-Ibarz, J., Le Coutre, P. D., Paquette, R., Chuah, C., . . . Kantarjian, H. M. (2015). Efficacy and safety of ponatinib in heavily pretreated leukemia patients in the PACE trial: 3-year results.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI2015 Khoury, H. J., Baccarani, M., Guilhot, F., Hochhaus, A., Hughes, T. P., Lipton, J. H., . . . Mauro, M. J. (2015). Elevated blood pressure (BP) and adverse events (AEs) of hypertension (HTN) in ponatinib (PON) leukemia trials.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2015 Branford, S., Wang, P. P. S., Parker, W. T., Yeung, D., Marum, J. E., Stangl, D., . . . Hughes, T. P. (2015). High Incidence of Mutated Cancer-Associated Genes at Diagnosis in CML Patients with Early Transformation to Blast Crisis. In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Hughes, T. P., Cervantes, F., Leber, B., Spector, N., Lipton, J. H., Pasquini, R., . . . Branford, S. (2015). ENESTCMR 4-Y RESULTS: PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND RESIDUAL DISEASE MORE LIKELY TO ACHIEVE DEEP MOLECULAR RESPONSE FOLLOWING SWITCH TO NILOTINIB (NIL). In HAEMATOLOGICA Vol. 100 (pp. 61-62). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION. 2015 Eadie, L. N., Saunders, V. A., Leclercq, T. M., Branford, S., White, D. L., & Hughes, T. P. (2015). The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Yeung, D. T., Parker, W. T., Phillis, S., Georgievski, J., Scott, H. S., Hughes, T. P., & Branford, S. (2015). BCR-ABL Assay Sensitivity of MR4.5 Achieved in >90%, and MR5 in >75% of Samples, through mRNA Selection before qRT-PCR. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Wang, J., Kok, C. H., Leclercq, T. M., Saunders, V. A., D'Andrea, R. J., Hughes, T. P., & White, D. L. (2015). High Peroxisome Proliferator-Activated Receptor-Gamma (PPARγle) Transcriptional Activity Reduces Active Influx of Imatinib and Kinase Inhibition in CML Cells. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Eadie, L. N., Hughes, T. P., & White, D. L. (2015). The Clinical Significance of Early Imatinib Induced ABCB1 Overexpression in Chronic Phase CML Patients: A TIDEL II Sub-Study. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS12015 Marum, J. E., Purins, L., Yeung, D. T., Parker, W. T., Price, D. J., Wang, P. P. S., . . . Branford, S. (2015). Germline Genetic Variation of ASXL1 and BIM Predicts Response to Imatinib and Identifies a Subset of High Sokal Risk Patients with the Greatest Risk of Treatment Failure and Disease Progression. In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI2015 Kok, C. H., Leclercq, T. M., Watkins, D., Yeung, D. T., Saunders, V. A., White, D. L., & Hughes, T. P. (2015). A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Hughes, A., Tang, C., Clarson, J., Vidovic, L., Hughes, T. P., & Yong, A. S. (2015). Chronic Myeloid Leukemia Patients with Deep Molecular Responses to Tyrosine Kinase Inhibitors Have Increased Effector Natural Killer and Cytotoxic T Cell Immune Responses to Leukaemia-Associated Antigens and Concomitant Reduced Immune Suppressors. In BLOOD Vol. 126 (pp. 2 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS42015 Nicolini, F. E., Basak, G. W., Kim, D. -W., Olavarria, E., Pinilla-Ibarz, J., Apperley, J. F., . . . Cortes, J. E. (2015). The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) with the T315I Mutation. In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Hughes, T. P., Salvino, M. A., Chuan, O. T., Elhaddad, A., Abdulkadyrov, K., Shortt, J., . . . Lipton, J. H. (2015). Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study. In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Pritchard, J. R., Lustgarten, S., Hodgson, G., Baccarani, M., Cortes, J. E., Deininger, M. W., . . . Rivera, V. M. (2015). High-Resolution Analysis of the Relationship Between Ponatinib Dose and Molecular Response in CP-CML Patients in the PACE Trial. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 15 (pp. S212). CIG MEDIA GROUP, LP.
DOI2015 Lipton, J. H., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Lustgarten, S., . . . Deininger, M. W. (2015). EPIC: A Phase 3 Trial of Ponatinib Compared With Imatinib in CP-CML Patients. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 15 (pp. S211). CIG MEDIA GROUP, LP.
DOI2015 Baccarani, M., Mauro, M. J., Cortes, J. E., Hochhaus, A., Hughes, T. P., Guilhot, F., . . . Talpaz, M. (2015). LONG-TERM FOLLOW-UP OF PONATINIB EFFICACY AND SAFETY IN PATIENTS (PTS) WITH THE T315I MUTATION IN THE PHASE 1 AND PHASE 2 (PACE) TRIALS. In HAEMATOLOGICA Vol. 100 (pp. 65). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION.
WoS22015 Mueller, M., Baccarani, M., Deininger, M. W., Guilhot, F., Hochhaus, A., Hughes, T. P., . . . Cortes, J. E. (2015). RESPONSES AT EARLY LANDMARK TIME POINTS ARE ASSOCIATED WITH OUTCOMES IN HEAVILY PRETREATED CP-CML PATIENTS (PTS) TREATED WITH PONATINIB. In HAEMATOLOGICA Vol. 100 (pp. 65). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION. 2014 Mauro, M. J., Cortes, J. E., Hochhaus, A., Baccarani, M., Hughes, T. P., Guilhot, F., . . . Talpaz, M. (2014). Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials. In BLOOD Vol. 124 (pp. 4 pages). AMER SOC HEMATOLOGY.
WoS12014 Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., Le Coutre, P., Paquette, R., Chuah, C., . . . Kantarjian, H. M. (2014). Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. In BLOOD Vol. 124 (pp. 5 pages). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS42014 Nicolini, F. E., Cortes, J. E., Kim, D. W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., . . . Hochhaus, A. (2014). CLINICAL IMPACT OF DOSE MODIFICATION AND DOSE INTENSITY ON RESPONSE TO PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) LEUKEMIAS. In HAEMATOLOGICA Vol. 99 (pp. 334). Milan, ITALY: FERRATA STORTI FOUNDATION. 2014 le Coutre, P. D., Kim, D. W., Pinilla-Ibarz, J., Paquette, R., Chuah, C., Nicolini, F. E., . . . Cortes, J. E. (2014). PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME- POSITIVE (PH plus ) LEUKEMIAS RESISTANT OR INTOLERANT TO DASATINIB OR NILOTINIB, OR WITH THE T315I MUTATION: LONGER-TERM FOLLOW-UP OF THE PACE TRIAL. In HAEMATOLOGICA Vol. 99 (pp. 334). Milan, ITALY: FERRATA STORTI FOUNDATION. 2014 Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Lustgarten, S., Trede, N., . . . Lipton, J. H. (2014). EPIC: A PHASE 3 TRIAL OF PONATINIB VS IMATINIB IN PATIENTS (PTS) WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CP-CML). In HAEMATOLOGICA Vol. 99 (pp. 238). Milan, ITALY: FERRATA STORTI FOUNDATION.
WoS72014 Ma, H., Li, L., Hao, X., Hughes, T., & Chen, H. (2014). Cross-linking Bovine lens capsule as a potential corneal endothelium carrier. In INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE Vol. 55 (pp. 2 pages). ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2014 Hughes, T. P., Munhoz, E. C., Elhaddad, A., Chuan, O. T., Abdulkadyrov, K., Shortt, J., . . . Lipton, J. H. (2014). Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis. In BLOOD Vol. 124 (pp. 4 pages). San Francisco, CA: AMER SOC HEMATOLOGY. 2014 Mahon, F. -X., Baccarani, M., Mauro, M. J., Hughes, T. P., Sagilo, G., Savona, M., . . . Hochhaus, A. (2014). Treatment-free remission (TER) following nilotinib (NIL) in patients (pis) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS122014 Larson, R. A., Kim, D. -W., Jootar, S., Pasquini, R., Clark, R. E., Lobo, C., . . . Hughes, T. P. (2014). ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS102014 Hughes, T. P., le Coutre, P. D., Jootar, S., Reiffers, J., Turkina, A. G., Saglio, G., . . . Larson, R. A. (2014). ENESTND 5-YEAR FOLLOW-UP: CONTINUED BENEFIT OF FRONTLINE NILOTINIB (NIL) COMPARED WITH IMATINIB (IM) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP). In HAEMATOLOGICA Vol. 99 (pp. 236-237). Milan, ITALY: FERRATA STORTI FOUNDATION.
WoS92014 Spector, N., Clementino, N. C. D., Dorlhiac-Llacer, P. E., Leber, B., Hughes, T. P., Cervantes, F., . . . Lipton, J. H. (2014). Effect of continued imatinib (IM) in pts with detectable BCR-ABL after ≥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
DOI2014 Lipton, J. H., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Lustgarten, S., . . . Deininger, M. W. N. (2014). EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS22014 Deininger, M. W., Shah, N. P., Cortes, J. E., Kim, D. W., Nicolini, F. E., Talpaz, M., . . . Branford, S. (2014). LONGER-TERM FOLLOW-UP OF THE IMPACT OF BASELINE (BL) MUTATIONS ON PONATINIB RESPONSE AND END OF TREATMENT (EOT) MUTATION ANALYSIS IN PATIENTS (PTS) WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML). In HAEMATOLOGICA Vol. 99 (pp. 533). Milan, ITALY: FERRATA STORTI FOUNDATION. 2014 Branford, S., Kamel-Reid, S., Bendit, I., Etienne, G., Guerci-Bresler, A., Hughes, T. P., . . . Cervantes, F. (2014). EARLY MOLECULAR RESPONSE PREDICTS ACHIEVEMENT OF UNDETECTABLE BCR-ABL IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) TREATED WITH NILOTINIB: 3-YEAR FOLLOW-UP OF ENESTCMR. In HAEMATOLOGICA Vol. 99 (pp. 532). Milan, ITALY: FERRATA STORTI FOUNDATION.
WoS32014 Larson, R. A., Kim, D. -W., Issaragrilsil, S., le Coutre, P., Dorlhiac Llacer, P. E., Etienne, G., . . . Hughes, T. P. (2014). Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd. In BLOOD Vol. 124 (pp. 4 pages). San Francisco, CA: AMER SOC HEMATOLOGY.
DOI WoS22014 Eadie, L. N., Hughes, T. P., & White, D. L. (2014). Increasing expression of the efflux transporter ABCB1 may predispose CML cells to over TKI resistance. In NDLR Abstract Handbook Vol. 122 (pp. 2 pages). Noosa, QLD: AMER SOC HEMATOLOGY.
DOI2014 Hochhaus, A., Pinilla-Ibarz, J., Kim, D. -W., Le Coutre, P. D., Paquette, R., Chuah, C., . . . Cortes, J. E. (2014). Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph plus ) leukemias.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS62014 Mueller, M. C., Baccarani, M., Deininger, M. W., Guilhot, F., Hochhaus, A., Hughes, T. P., . . . Cortes, J. E. (2014). Achieving Early Landmark Response Is Predictive of Outcomes in Heavily Pretreated Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib. In BLOOD Vol. 124 (pp. 4 pages). San Francisco, CA: AMER SOC HEMATOLOGY.
DOI WoS12014 Moad, G., Barlow, K., Hao, X., Hughes, T. C., Hutt, O. E., Polyzos, A., & Turner, K. A. (2014). RAFT-synthesized porous polymer monoliths for flow. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 248 (pp. 1 page). San Francisco, CA: AMER CHEMICAL SOC. 2013 Hughes, T., Cortese, J., Kim, D., Nicolini, F., Talpaz, M., Baccarani, M., . . . Deininger, M. (2013). IMPACT OF BASELINE MUTATIONS ON RESPONSE TO PONATINIB AND END OF TREATMENT MUTATION ANALYSIS IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ( PH plus ) LEUKEMIAS. In HAEMATOLOGICA Vol. 98 (pp. 57). FERRATA STORTI FOUNDATION. 2013 Larson, R. A., Hochhaus, A., Saglio, G., Kim, D. -W., Jootar, S., Le Coutre, P. D., . . . Kantarjian, H. M. (2013). Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
WoS122013 Lipton, J. H., Deininger, M. W. N., Lustgarten, S., Turner, C. D., Rivera, V. M., Clackson, T., . . . Haluska, F. G. (2013). EPIC: A phase III randomized, open-label study of ponatinib versus imatinib in adult patients with newly diagnosed chronic myeloid leukemia in chronic phase.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2013 Saglio, G., Hughes, T. P., Larson, R. A., Issaragrilsil, S., Turkina, A. G., Steegmann, J. L., . . . Hochhaus, A. (2013). Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 2 pages). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2013 Hochhaus, A., Saglio, G., Larson, R., Rosti, G., Flinn, I., Goh, Y., . . . Hughes, T. (2013). NILOTINIB SHOWS SUSTAINED BENEFIT COMPARED WITH IMATINIB IN PATIENTS (PTS) WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTND 4-YEAR FOLLOW-UP (F/U). In HAEMATOLOGICA Vol. 98 (pp. 298-299). FERRATA STORTI FOUNDATION. 2013 Hughes, T., Saglio, G., Quintas-Cardama, A., Mauro, M., Kim, D., Lipton, J., . . . Hochhaus, A. (2013). RESPONSE DYNAMICS AND OUTCOMES IN PATIENTS DEVELOPING MUTATIONS DURING FIRST-LINE TREATMENT WITH DASATINIB OR IMATINIB FOR CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): DASISION 3-YEAR FOLLOW-UP. In HAEMATOLOGICA Vol. 98 (pp. 296-297). FERRATA STORTI FOUNDATION. 2013 Cervantes, F., Hughes, T., Etienne, G., Guerci-Bresler, A., De Souza, C., Moiraghi, B., . . . Leber, B. (2013). CONTINUED DEEPER MOLECULAR RESPONSE WITH NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH DETECTABLE DISEASE ON LONG-TERM IMATINIB: ENESTCMR 24-MONTH RESULTS. In HAEMATOLOGICA Vol. 98 (pp. 56-57). FERRATA STORTI FOUNDATION. 2013 Leber, B., Cervantes, F., Spector, N., Lipton, J. H., Etienne, G., Pasquini, R., . . . Hughes, T. P. (2013). Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY.
DOI WoS42013 Gordon, J. E. A., Bailey, C. G., Rasko, J., Ritchie, W., Watkins, D. B., White, D. L., . . . Hughes, T. P. (2013). MicroRNA Dysregulation in Newly Diagnosed Chronic Myeloid Leukaemia Patients. In BLOOD Vol. 122 (pp. 1 page). New Orleans, LA: AMER SOC HEMATOLOGY.
DOI2013 Kantarjian, H. M., Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., . . . Shah, N. P. (2013). Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY.
DOI WoS52013 Hochhaus, A., Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., . . . Guilhot, F. (2013). Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY.
DOI WoS32013 Le Coutre, P. D., Kim, D. -W., Pinilla-Ibarz, J., Paquette, R., Chuah, C., Nicolini, F. E., . . . Cortes, J. E. (2013). Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs). In BLOOD Vol. 122 (pp. 3 pages). New Orleans, LA: AMER SOC HEMATOLOGY.
DOI WoS32013 le Coutre, P. D., Hughes, T. P., Mahon, F. -X., Kim, D. -W., Steegmann, J. L., Shah, N. P., . . . Cortes, J. E. (2013). Peripheral Arterial Occlusive Disease (PAOD) In Patients (Pts) Receiving Dasatinib: Experience Across Multiple Clinical Trials. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY.
DOI WoS202013 Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., . . . Kantarjian, H. M. (2013). Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY.
DOI WoS32013 Branford, S., Roberts, N., Yeung, D. T., Altamura, H., Parker, W. T., & Hughes, T. P. (2013). Any BCR-ABL Reduction Below 10% At 6 Months Of Therapy Significantly Improves Outcome For CML Patients With a Poor Response At 3 Months. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY.
WoS92013 Saglio, G., Hochhaus, A., Hughes, T. P., Clark, R. E., Nakamae, H., Kim, D. -W., . . . Larson, R. A. (2013). ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY.
DOI WoS162013 Tan, K. J., Moad, G., Turner, K. A., Polyzos, A., Hughes, T. C., Hutt, O. E., & Hao, X. (2013). Monoliths for flow processes synthesised by RAFT polymerization. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 245 (pp. 1 page). New Orleans, LA: AMER CHEMICAL SOC. 2013 White, D., Saunders, V., Eadie, L., David, Y., & Hughes, T. P. (2013). The Depth Of In Vivo Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels. In Blood Vol. 122 (pp. 256). American Society of Hematology.
DOI2013 Eadie, L., Hughes, T. P., & White, D. L. (2013). Increasing expression of the efflux transporter ABCB1 may predispose CML cells to overt TKI resistance. In Blood Vol. 122 (pp. 5157). New Orleans, Louisiana: American Society of Hematology.
DOI2013 Gautier, J. -F., Rea, D., Saglio, G., Hughes, T. P., Kantarjian, H. M., Kemp, C., . . . Breccia, M. (2013). Glucose Metabolism (GM) Changes in Nondiabetic Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib (NIL) or Imatinib (IM). In DIABETES Vol. 62 (pp. A704-A705). AMER DIABETES ASSOC. 2012 Cervantes, C., Hughes, T., Etienne, G., De Souza, C. A., Dorlhiac Llacer, P. E., Schwarer, A., . . . Rea, D. (2012). NILOTINIB INDUCES DEEPER MOLECULAR RESPONSES VS CONTINUED IMATINIB IN PATIENTS WITH PH plus CHRONIC MYELOID LEUKEMIA (CML) WITH DETECTABLE DISEASE AFTER=2 YEARS ON IMATINIB: ENESTCMR 12-MONTH RESULTS. In HAEMATOLOGICA Vol. 97 (pp. 239). FERRATA STORTI FOUNDATION.
WoS12012 Ossenkoppele, G., Le Coutre, P., Steegmann, J. L., Turkina, A., Lobo, C., Shibayama, H., . . . Saglio, G. (2012). RESULTS FROM THE ENESTND EXTENSION STUDY: EFFICACY AND SAFETY OF NILOTINIB 400 MG BID IN PATIENTS WITH PH plus CML-CP AFTER SUBOPTIMAL RESPONSE OR TREATMENT FAILURE TO IMATINIB OR NILOTINIB 300 MG BID. In HAEMATOLOGICA Vol. 97 (pp. 308). FERRATA STORTI FOUNDATION. 2012 Hochhaus, A., Guilhot, F., Al-Ali, K. H., Rosti, G., Nakaseko, C., De Souza, C. A., . . . Hughes, T. (2012). EARLY BCR-ABL TRANSCRIPT LEVELS PREDICT FUTURE MOLECULAR RESPONSE AND LONG-TERM OUTCOMES IN NEWLY-DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: ANALYSIS OF ENESTND 3-YEAR DATA. In HAEMATOLOGICA Vol. 97 (pp. 237-238). FERRATA STORTI FOUNDATION.
WoS42012 Ross, M., Branford, S., Seymour, J., Arthur, C., Schwarer, A., Dang, P., . . . Hughes, T. (2012). FREQUENT AND SUSTAINED DRUG-FREE REMISSION IN THE AUSTRALASIAN CML8 TRIAL OF IMATINIB WITHDRAWAL. In HAEMATOLOGICA Vol. 97 (pp. 74-75). FERRATA STORTI FOUNDATION.
WoS32012 Peng, S., Hughes, T. C., Hartley, P. G., & Guo, Q. (2012). Capturing nanostructure evolution of polymerizable microemulsion by in situ synchrotron SAXS. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 243 (pp. 1 page). San Diego, CA: AMER CHEMICAL SOC. 2012 Clark, R., Reiffers, J., Kim, D. W., Rosti, G., Kurokawa, M., Moiraghi, B., . . . Hochhaus, A. (2012). SUPERIOR EFFICACY OF NILOTINIB COMPARED WITH IMATINIB IN NEWLY DIAGNOSED PATIENTS WITH PH plus CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTND 3-YEAR FOLLOW-UP. In HAEMATOLOGICA Vol. 97 (pp. 237). FERRATA STORTI FOUNDATION. 2012 Kantarjian, H. M., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., . . . Cortes, J. E. (2012). Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial. In BLOOD Vol. 120 (pp. 3 pages). GA, Atlanta: AMER SOC HEMATOLOGY. 2012 Mauro, M. J., Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., . . . Kantarjian, H. M. (2012). Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Treated with Ponatinib in the PACE Trial. In BLOOD Vol. 120 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
DOI WoS52012 Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., . . . Kantarjian, H. M. (2012). A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial. In BLOOD Vol. 120 (pp. 3 pages). GA, Atlanta: AMER SOC HEMATOLOGY.
DOI WoS222012 Kantarjian, H. M., Kim, D. -W., Issaragrisil, S., Clark, R. E., Reiffers, J., Nicolini, F. E., . . . Larson, R. A. (2012). Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia in Chronic Phase (CML-CP). In BLOOD Vol. 120 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
DOI WoS152012 Kantarjian, H., Flinn, I. W., Goldberg, S., Bunworasate, U., Zanichelli, M. A., Nakamae, H., . . . Larson, R. A. (2012). Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u). In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS22012 Lipton, J. H., Hughes, T. P., Leber, B., De Souza, C., Dorlhiac-Llacer, P. E., Steegmann, J. L., . . . Spector, N. (2012). Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS22012 Kim, D. -W., Cortes, J. E., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., . . . Kantarjian, H. M. (2012). Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial. In BLOOD Vol. 120 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
DOI WoS22012 Hochhaus, A., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., . . . Cortes, J. E. (2012). Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph plus ) Leukemia: Results From the PACE Trial. In BLOOD Vol. 120 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
DOI2012 Morley, A., Bartley, P., Latham, S., Budgen, B., Ross, D., Hughes, E., . . . Hughes, T. (2012). DNA-qPCR vs RT-qPCR for Monitoring MRD in Chronic Myeloid Leukemia. In JOURNAL OF MOLECULAR DIAGNOSTICS Vol. 14 (pp. 662-663). Long Beach, CA: ELSEVIER SCIENCE INC. 2011 le Coutre, P. D., Giles, F. J., Pinilla-Ibarz, J., Larson, R. A., Gattermann, N., Ottmann, O. G., . . . Kantarjian, H. M. (2011). Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study. In BLOOD Vol. 118 (pp. 1610). San Diego, CA: AMER SOC HEMATOLOGY.
WoS12011 Pasquini, R., Cortes, J. E., Kantarjian, H. M., Joske, D., Meillon, L. A., Zernovak, O., . . . Kim, D. -W. (2011). Survey of the Frontline Treatment and Management of Chronic Myeloid Leukemia (CML) in a Real-Word Setting: The 3rd Annual Update of the Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry). In BLOOD Vol. 118 (pp. 738). San Diego, CA: AMER SOC HEMATOLOGY. 2011 Nieborowska-Skorska, M., Kopinski, P., Ray, R., Hoser, G., Ngaba, D., Flis, S., . . . Skorski, T. (2011). Targeting Rac2-Mitochondrial Respiratory Chain Complex III Signaling to Prevent Genomic Instability in Leukemia Stem and Progenitor Cells. In BLOOD Vol. 118 (pp. 1176-1177). San Diego, CA: AMER SOC HEMATOLOGY. 2011 Parker, W. T., Ho, M., Scott, H. S., Hughes, T. P., & Branford, S. (2011). Multiple Low Level Mutations Identifies Imatinib Resistant CML Patients At Risk of Poor Response to Second-Line Inhibitor Therapy, Irrespective of the Resistance Profile of the Mutations. In BLOOD Vol. 118 (pp. 54). San Diego, CA: AMER SOC HEMATOLOGY.
WoS12011 Watkins, D. B., Kok, C. H., Hughes, T. P., Slader, C., D'Andrea, R., & White, D. L. (2011). Differential Lineage Involvement Between Very Low and Higher OCT-1 Activity Chronic-Phase CML Patients. In BLOOD Vol. 118 (pp. 727). San Diego, CA: AMER SOC HEMATOLOGY. 2011 Hughes, T. P., Lipton, J. H., Leber, B., Spector, N., Cervantes, F., Pasquini, R., . . . Branford, S. (2011). Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR, After ≥ 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib. In BLOOD Vol. 118 (pp. 278). San Diego, CA: AMER SOC HEMATOLOGY.
WoS12011 Yeung, D. T., Osborn, M., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . Hughes, T. P. (2011). Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial. In BLOOD Vol. 118 (pp. 208). San Diego, CA: AMER SOC HEMATOLOGY.
WoS12011 White, D. L., Saunders, V. A., Frede, A., GrootObbink, K., Slader, C., Yeung, D. T., . . . Hughes, T. P. (2011). The Strategy of Early Nilotinib Switch Based on Failure to Achieve Optimal Molecular Targets on Imatinib May Not Overcome the Negative Impact of a Low OCT-1 Activity in De-Novo CP-CML Patients. In BLOOD Vol. 118 (pp. 735). San Diego, CA: AMER SOC HEMATOLOGY. 2011 Nievergall, E., White, D. L., Ramshaw, H., Lopez, A. F., Hughes, T. P., & Hiwase, D. K. (2011). Antibody-Targeting of IL-3 Receptor-α Increases the Susceptibility of CD34<SUP>+</SUP> CML Progenitors to Dasatinib-Induced Cell Death. In BLOOD Vol. 118 (pp. 1599). San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS12011 Wang, J., Hughes, T. P., Kok, C. H., Saunders, V. A., Frede, A., GrootObbink, K., . . . White, D. L. (2011). Non-Steroidal Anti-Inflammatory Drugs and Imatinib; Drug Interactions That May Impact Efficacy. In BLOOD Vol. 118 (pp. 1493-1494). San Diego, CA: AMER SOC HEMATOLOGY. 2011 Branford, S., Yeung, D. T., Prime, J., Ross, D., & Hughes, T. P. (2011). Imatinib Dose Interruption in Responding CML Patients Is Associated with Characteristic BCR-ABL Kinetics, Which Could Help to Differentiate Non-Adherence From Drug Resistance. In BLOOD Vol. 118 (pp. 55). San Diego, CA: AMER SOC HEMATOLOGY.
WoS12011 White, D. L., Lu, L., Clackson, T. P., Saunders, V. A., & Hughes, T. P. (2011). ATP Dependent Efflux Transporters ABCB1 and ABCG2 Are Unlikely to Impact the Efficacy, or Mediate Resistance to the Tyrosine Kinase Inhibitor, Ponatinib. In BLOOD Vol. 118 (pp. 1180). San Diego, CA: AMER SOC HEMATOLOGY.
WoS12011 Alexander, W., & Shah, N. (2011). American Society of Hematology, 52nd Annual Meeting and Exposition: Dasatinib (Sprycel) versus imatinib (Gleevec) in newly diagnosed chronic-phase chronic myeloid leukemia: The DASISION trial, 18-month follow-up. In P and T Vol. 36 (pp. 100).
Scopus32011 Tuch, B. E., Hughes, T. C., & Evans, M. D. M. (2011). Encapsulated pancreatic progenitors derived from human embryonic stem cells as a therapy for insulin-dependent diabetes. In Diabetes/Metabolism Research and Reviews Vol. 27 (pp. 928-932). Incheon, SOUTH KOREA: WILEY.
DOI Scopus33 WoS30 Europe PMC222010 Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition. In Blood Vol. 116 (pp. 3991). American Society of Hematology.
DOI2010 Klumpen, H., Eechoute, K., Hertzberg, M. S., Schwarer, A. A., Goldstein, D., Hughes, T. P., . . . Gurney, H. (2010). Pharmacogenetic factors predicting the need for a higher dose of imatinib. In JOURNAL OF CLINICAL ONCOLOGY Vol. 28 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY.
DOI2010 Hughes, T. P. (2010). EVOLUTION OF CML TREATMENT: WORKING TOWARDS CURE. In EXPERIMENTAL HEMATOLOGY Vol. 38 (pp. S103). Melbourne, AUSTRALIA: ELSEVIER SCIENCE INC. 2010 Hochhaus, A., Lobo, C., Pasquini, R., Clark, R., Kim, D. W., Issaragrisil, S., . . . Hughes, T. (2010). CONTINUED SUPERIORITY OF NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTND BEYOND 1 YEAR. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 95 (pp. 459). FERRATA STORTI FOUNDATION.
WoS42010 le Coutre, P., Hino, M., Nobile, F., Hochhaus, A., Hughes, T., Kantarjian, H., . . . Clark, R. (2010). RESULTS FROM ENESTND: POPULATION PHARMACOKINETIC (PK) AND EXPOSURE-RESPONSE ANALYSIS OF NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PH<SUP>+</SUP> CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP). In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 95 (pp. 59-60). Barcelona, SPAIN: FERRATA STORTI FOUNDATION.
WoS12010 White, E., Matejtschuk, P., Rigsby, P., Gabert, J., Wang, Y., Branford, S., . . . Cross, N. (2010). ESTABLISHMENT OF THE 1ST WORLD HEALTH ORGANIZATION INTERNATIONAL GENETIC REFERENCE PANEL FOR QUANTITATION OF BCR-ABL MRNA. In HAEMATOLOGICA Vol. 95 (pp. 84-85). Barcelona, SPAIN: FERRATA STORTI FOUNDATION. 2010 White, D. L., Saunders, V., Frede, A., GrootObbink, K., Slader, C., Yeung, D. T., . . . Hughes, T. (2010). Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study. In BLOOD Vol. 116 (pp. 160-161). Orlando, FL: AMER SOC HEMATOLOGY. 2010 Yeung, D. T., Osborn, M., White, D. L., Branford, S., Haswell, L., Slader, C., . . . Hughes, T. (2010). Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial. In BLOOD Vol. 116 (pp. 96). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS102010 White, D. L., Saunders, V., Andrew, M., Rofe, A., Slader, C., Yeung, D. T., . . . Hughes, T. (2010). Imatinib PK: Observations From the TIDEL II Study.. In BLOOD Vol. 116 (pp. 943). Orlando, FL: AMER SOC HEMATOLOGY. 2010 Parker, W., Ho, M., Lawrence, R., Irwin, D., Scott, H., Hughes, T., & Branford, S. (2010). Detection of low level nilotinib or dasatinib resistant BCR-ABL mutations by mass spectrometry in CML patients who fail Imatinib is highly predivtive of their subsequent clonal expansion when treated with the drug for which their mutation confers resistance. In Proceedings of 2010 american society of hematology meeting Vol. 116 (pp. 0 pages). Florida, USA: AMER SOC HEMATOLOGY. 2010 Prime, H., Romeo, G., Phillis, S., Field, C., Jamison, B., Prime, J., . . . Branford, S. (2010). Contrasting response of patients with chronic myeloid leukaemia (CML) and the highly imatinib resistant L248V mutation that may be related to an increased propensity of some patients to form an associated deletion mutant with increased imatinib sensitivity. In Proceedings of Haematology association of australasia annual meeting (pp. 0 pages). Auckland, New Zealand. 2010 Branford, S., Goh, H., Izzo, B., Beppu, L., Ortmann, C., Duniec, K., . . . Hughes, T. (2010). A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate. In Proceedings of 52nd American Society of Hematology Meeting (ASH), as published in Blood Vol. 116 (pp. 389-390). Washington, DC: American Society of Hematology.
WoS12010 Fletcher, L., Prime, J., Phillis, S., Jamison, B., Field, C., Prime, H., . . . Branford, S. (2010). Limiting the variability within a BCR-ABL quantitative PCR (RQ-PCR) assay is essential for optimal concordance of results between laboratories generating BCR-ABL values on an international reporting scale. In Proceedings of Haematology association of australasia annual meeting (pp. 0 pages). New Zealand. 2010 Morley, A., Bartley, P., Ross, D., Latham, S., Budgen, B., Branford, S., & Hughes, T. (2010). Towards DNA-based monitoring of therapy in chronic myeloid leukemia. In Proceedings of 2010 American society of hematology meeting Vol. 116 (pp. 0 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2010 Kim, D., Kim, D., Kim, S., Goh, H., Pane, F., Hughes, T., . . . Hochhaus, A. (2010). Mutation analysis of BCR-ABL tyrosine kinase domain in new chronic phase-chronic myeloid leukemia patients with suboptimal response or treatment failure from imatinib treatment. In Proceedings of 2010 American society of hematology meeting Vol. 116 (pp. 0 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2010 Yeung, D., Osborn, M., White, D., Branford, S., Haswell, L., Slader, C., . . . Hughes, T. (2010). Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial. In Proceedings of 2010 American Society of Hematology conference (pp. 1-2). Florida. 2010 Pasquini, R., Cortes, J., Kantarjian, H. M., Joske, D., Meillon, L. A., Mongay, L., . . . Kim, D. -W. (2010). A Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry)-2nd Annual Interim Analysis.. In BLOOD Vol. 116 (pp. 945). Orlando, FL: AMER SOC HEMATOLOGY.
WoS32010 Saglio, G., Larson, R. A., Hughes, T. P., Issaragrisil, S., Turkina, A. G., Marin, D., . . . Hochhaus, A. (2010). Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chrome Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial. In BLOOD Vol. 116 (pp. 1405-1406). Orlando, FL: AMER SOC HEMATOLOGY.
WoS42010 Larson, R. A., Hochhaus, A., Saglio, G., Rosti, G., Lopez, J. L., Stenke, L., . . . Kantarjian, H. M. (2010). Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd.. In BLOOD Vol. 116 (pp. 944-945). Orlando, FL: AMER SOC HEMATOLOGY.
WoS12010 Hochhaus, A., Saglio, G., Larson, R. A., Kim, D. -W., Flinn, I. W., Goh, Y. -T., . . . Hughes, T. P. (2010). Nilotinib Lowers the Incidence of BCR-ABL Mutations and Improves the Molecular Response Kinetics Compared with Imatinib in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML). In BLOOD Vol. 116 (pp. 1406-1407). Orlando, FL: AMER SOC HEMATOLOGY.
WoS12010 Soverini, S., Angelini, S., Turrini, E., Burnett, M., Ravegnini, G., Thornquist, M., . . . Martinelli, G. (2010). Specific Drug Transporter Genotypes Are Significantly Associated with Increased Rates of Major and Complete Molecular Responses In Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Imatinib - A TOPS Correlative Substudy. In BLOOD Vol. 116 (pp. 293-294). Orlando, FL: AMER SOC HEMATOLOGY. 2010 Hughes, T. P., Hochhaus, A., Saglio, G., Kim, D. -W., Jootar, S., le Coutre, P. D., . . . Kantarjian, H. M. (2010). ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP). In BLOOD Vol. 116 (pp. 94-95). Orlando, FL: AMER SOC HEMATOLOGY.
WoS52010 Morley, A., Bartley, P., Ross, D., Latham, S., Budgen, B., Hughes, E., . . . Hughes, T. (2010). Monitoring of CML by DNA qPCR. In JOURNAL OF MOLECULAR DIAGNOSTICS Vol. 12 (pp. 868). San Jose, CA: AMER SOC INVESTIGATIVE PATHOLOGY, INC. 2010 Martinelli, G., Hochhaus, A., Radich, J., Soverini, S., Branford, S., Erben, P., . . . Kim, D. (2010). DETECTION OF NEW MUTATIONS IN NILOTINIB-TREATED PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE. In HAEMATOLOGICA Vol. 95 (pp. 62). Barcelona, SPAIN: FERRATA STORTI FOUNDATION. 2010 Saglio, S., Hughes, T., Kim, D., Hanfstein, B., Gottardi, E., Branford, S., . . . Martinelli, G. (2010). RESPONSE TO NILOTINIB IN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH DIFFERENT BCR-ABL TRANSCRIPT TYPES. In HAEMATOLOGICA Vol. 95 (pp. 342-343). FERRATA STORTI FOUNDATION. 2010 Stein, A., Shou, Y., Bottino, D., Chia, Y., Woodman, R., Martinelli, G., . . . Radich, J. (2010). RAPID INITIAL DECLINE IN BCR-ABL LEVELS IS ASSOCIATED WITH SUPERIOR RESPONSES IN IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) TREATED WITH NILOTINIB. In HAEMATOLOGICA Vol. 95 (pp. 56). Barcelona, SPAIN: FERRATA STORTI FOUNDATION. 2010 Tang, C., Schafranek, L., Watkins, D., Parker, W. T., Prime, J., White, D. L., & Hughes, T. (2010). Modelling of TKI Resistance In CML Cell Lines: Kinase Domain Mutations Usually Arise In the Setting of BCR-ABL Overexpression. In BLOOD Vol. 116 (pp. 1385). Orlando, FL: AMER SOC HEMATOLOGY. 2010 Hiwase, D. K., Engler, J., Saunders, V., White, D. L., & Hughes, T. (2010). In Contrast to Imatinib, Dasatinib Intracellular Concentration In CML-CD34<SUP>+</SUP> Progenitors Is Not Significantly Different Than That Observed In CD34<SUP>-</SUP> Mature Cells.. In BLOOD Vol. 116 (pp. 517). Orlando, FL: AMER SOC HEMATOLOGY. 2010 Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition.. In BLOOD Vol. 116 (pp. 1626-1627). Orlando, FL: AMER SOC HEMATOLOGY.
WoS12010 Hughes, T., Kim, D., Martinelli, G., Branford, S., Mueller, M., Beppu, L., . . . Hochhaus, A. (2010). EARLY MOLECULAR RESPONSE TO NILOTINIB IN PATIENTS WHO FAILED IMATINIB IS ASSOCIATED WITH A HIGHER PROBABILITY OF CYTOGENETIC RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML). In HAEMATOLOGICA Vol. 95 (pp. 54). Barcelona, SPAIN: FERRATA STORTI FOUNDATION.
WoS12010 Kim, D., Kim, S., Goh, H., Pane, F., Hughes, T., Radich, J., . . . Kim, D. (2010). BCR-ABL MUTATION ANALYSIS USING BOTH ASO-PCR AND DIRECT SEQUENCING IN NEW CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH SUBOPTIMAL RESPONSE OR TREATMENT FAILURE FROM IMATINIB TREATMENT. In HAEMATOLOGICA Vol. 95 (pp. 344-345). FERRATA STORTI FOUNDATION. 2009 Saglio, G., Hochhaus, A., Martinelli, G., Gottardi, E., Soverini, S., Branford, S., . . . Kim, D. (2009). DYNAMICS OF CYTOGENETIC AND MOLECULAR RESPONSE TO NILOTINIB IS SIMILAR IN IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) WITH AND WITHOUT BCR-ABL MUTATIONS EXCEPT E255K/V, Y253H, AND F359C/V. In HAEMATOLOGICA Vol. 94 (pp. 261). Berlin, GERMANY: FERRATA STORTI FOUNDATION. 2009 White, D. L., Saunders, V. A., Frede, A., Dang, P., Zrim, S., Osborn, M. P., . . . Hughes, T. (2009). The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial. In BLOOD Vol. 114 (pp. 209-210). New Orleans, LA: AMER SOC HEMATOLOGY. 2009 Osborn, M. P., White, D. L., Saunders, V. A., Cambareri, B., Branford, S., Menelaou, A., . . . Hughes, T. P. (2009). Early Dose-Escalation in Chronic Myeloid Leukaemia Patients with Low Plasma Imatinib Levels Leads to Equivalent BCR-ABL Values and Drug Levels at 6 Months to Those with Optimal Drug Levels: First Analysis From the TIDEL II Trial of De-Novo Patients Treated with 600mg Imatinib.. In BLOOD Vol. 114 (pp. 465). New Orleans, LA: AMER SOC HEMATOLOGY. 2009 Martinelli, G., Kim, D. W., Saglio, G., Branford, S., Erben, P., Gottardi, E., . . . Radich, J. (2009). RESPONSE TO NILOTINIB IS SIMILAR IN IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS IN ACCELERATED PHASE (CML-AP) WITH AND WITHOUT BCR-ABL MUTATIONS EXCEPT E25SK/V, Y253H, AND F359C/V. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 94 (pp. 258-259). Berlin, GERMANY: FERRATA STORTI FOUNDATION.
WoS12009 Deininger, M., O'Brien, S. G., Guilhot, F., Goldman, J. M., Hochhaus, A., Hughes, T. P., . . . Druker, B. J. (2009). International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.. In BLOOD Vol. 114 (pp. 462). New Orleans, LA: AMER SOC HEMATOLOGY.
WoS702009 Larson, R. A., Chia, Y. L., Granvil, C., Guilhot, F., Druker, B. J., O'Brien, S. G., . . . Wang, Y. (2009). Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy. In BLOOD Vol. 114 (pp. 872). New Orleans, LA: AMER SOC HEMATOLOGY.
WoS22009 Soverini, S., Angelini, S., Turrini, E., Pane, F., Quarantelli, F., Hughes, T. P., . . . Martinelli, G. (2009). Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity. In BLOOD Vol. 114 (pp. 1271). New Orleans, LA: AMER SOC HEMATOLOGY. 2009 Radich, J. P., Martinelli, G., Hochhaus, A., Gottardi, E., Soverini, S., Branford, S., . . . Saglio, G. (2009). Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.. In BLOOD Vol. 114 (pp. 464-465). New Orleans, LA: AMER SOC HEMATOLOGY.
WoS12009 Kantarjian, H. M., Giles, F. J., Bhalla, K. N., Pinilla-Ibarz, J., Larson, R. A., Gattermann, N., . . . le Coutre, P. D. (2009). Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.. In BLOOD Vol. 114 (pp. 464). New Orleans, LA: AMER SOC HEMATOLOGY.
WoS142009 Branford, S., Kim, D. -W., Soverini, S., Gottardi, E., Beppu, L., Mueller, M. C., . . . Hochhaus, A. (2009). Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP). In BLOOD Vol. 114 (pp. 1275-1276). New Orleans, LA: AMER SOC HEMATOLOGY.
WoS12009 Branford, S., Hochhaus, A., Mueller, M., Bahceci, E., Ploughman, L., Mukhopadhyay, J., & Hughes, T. (2009). Analysis of Molecular Data and the Emergence of Mutations for Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) Patients Treated with Dasatinib After Imatinib Failure.. In BLOOD Vol. 114 (pp. 1270-1271). New Orleans, LA: AMER SOC HEMATOLOGY. 2009 Hughes, T. (2009). Reduction of bcr-abl transcript levels with imatinib (Gleevec) in chronic myeloid leukemia (Chronic Phase). In P and T Vol. 34 (pp. 96-97). 2009 Kim, D. -W., Granvil, C., Demirhan, E., Reynolds, J., Jin, Y., Wang, Y., . . . Guilhot, F. (2009). Comparison of Steady-State Imatinib (IM) Trough Levels, Clinical Response, and Safety Between Caucasian and Asian Patients with Chronic Lyeloid Leukemia in Chronic Phase (CML-CP) Treated with 400mg and 800mg Daily Doses of IM in the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) Study.. In BLOOD Vol. 114 (pp. 462-463). New Orleans, LA: AMER SOC HEMATOLOGY.
WoS12009 Baccarani, M., Druker, B. J., Cortes-Franco, J., Hughes, T. P., Kim, D. -W., Pane, F., . . . Guilhot, F. (2009). 24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP). In BLOOD Vol. 114 (pp. 142-143). New Orleans, LA: AMER SOC HEMATOLOGY.
WoS122009 Hiwase, D. K., White, D. L., Powell, J. A., Saunders, V. A., Zrim, S., Frede, A., . . . Hughes, T. (2009). Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells. In BLOOD Vol. 114 (pp. 1258-1259). New Orleans, LA: AMER SOC HEMATOLOGY. 2009 Osborn, M. P., Branford, S., White, D. L., Seymour, J. F., Columbus, R., Taylor, K., . . . Hughes, T. P. (2009). Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.. In BLOOD Vol. 114 (pp. 461-462). New Orleans, LA: AMER SOC HEMATOLOGY. 2009 Esposito, N., Quintarelli, C., Colavita, I., Izzo, B., Peluso, A. L., Ruoppolo, M., . . . Pane, F. (2009). Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph plus Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients. In BLOOD Vol. 114 (pp. 871-872). New Orleans, LA: AMER SOC HEMATOLOGY. 2009 Engler, J. R., Frede, A., Saunders, V. A., Zannettino, A. C. W., White, D. L., & Hughes, T. P. (2009). OCT-1 Activity in CML CD34+Cells Is Not Predictive of Molecular Response to Imatinib Treatment in CP-CML Patients, Despite the Strong Predictive Value of MNC OCT-1 Activity. In BLOOD Vol. 114 (pp. 861). New Orleans, LA: AMER SOC HEMATOLOGY. 2009 Angelini, S., Soverini, S., Turrini, E., Perini, G., Pane, F., Hughes, T., . . . Baccarani, M. (2009). ASSOCIATION BETWEEN GENOTYPES AND RESPONSE TO THE TREATMENT IN A SUBSET OF PREVIOUSLY UNTREATED CHRONIC MYELOID LEUKEMIA PATIENTS ENROLLED INTO THE TOPS TRIAL. In BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY Vol. 105 (pp. 78). WILEY-BLACKWELL PUBLISHING, INC. 2008 Modur, V., Bottino, D. C., Branford, S., Krahnke, T., Pane, F., Rudoltz, M., . . . Barrett, J. C. (2008). Mathematical Simulation of BCR-ABL Real Time Quantitative Polymerase Chain Reaction (RQ-PCR) for Chronic Myeloid Leukemia (CML) Response Monitoring Provides Insight on the Basis of International Standardization. In BLOOD Vol. 112 (pp. 740). San Francisco, CA: AMER SOC HEMATOLOGY. 2008 Hochhaus, A., Mueller, M. C., Cortes, J., Kim, D. W., Matloub, Y., Ploughman, L., & Hughes, T. (2008). DASATINIB EFFICACY AFTER IMATINIB FAILURE BY DOSING SCHEDULE AND BASELINE BCR-ABL MUTATION STATUS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP). In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 93 (pp. 371-372). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.
WoS62008 Hughes, T. (2008). Molecular diagnosis and monitoring of CML: a paradigm for haematological malignancy. In INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY Vol. 30 (pp. 3-4). WILEY-BLACKWELL. 2008 White, D. L., Saunders, V. A., Dang, P., Frede, A., Eadie, L., Soverini, S., . . . Hughes, T. (2008). CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study. In Blood Vol. 112 (pp. 3187). American Society of Hematology.
DOI2008 Hughes, T., Bates, J., Beattie, D., Hao, X., Jarrett, R., Jeffery, J., . . . Rajapaksha, J. (2008). Property optimisation of a fluoropolymer corneal inlay by factorial design. In 8th World Biomaterials Congress 2008 Vol. 3 (pp. 1282). 2008 Hao, X., Donovan, L., Ho, A., Hughes, T. C., Jeffery, J. L., Le, T., . . . Fernandez, V. (2008). Polysiloxane soft gels as in-situ curable accommodating implant. In 8th World Biomaterials Congress 2008 Vol. 3 (pp. 1288). 2008 Hughes, T., Bates, J., Beattie, D., Hao, X., Johnson, G., Le, T., . . . Wilkie, J. (2008). Control of topography of porous perfluoropolyethers using radical concentration during polymerisation. In 8th World Biomaterials Congress 2008 Vol. 3 (pp. 1281). 2008 Hao, X., Aly, M., Ho, A., Hughes, T. C., Jeffery, J. L., Le, T., . . . Ziebarth, N. (2008). High refractive index polysiloxanes as in-situ curable accommodating implant. In 8th World Biomaterials Congress 2008 Vol. 3 (pp. 1287). 2008 Heaney, N. B., Drummond, M., Kaeda, J., Nicolini, F., Clark, R., Wilson, G., . . . Holyoake, T. (2008). A pilot study of continuous imatinib versus pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 141 (pp. 50-51). Glasgow, SCOTLAND: BLACKWELL PUBLISHING. 2008 Engler, J. R., Frede, A., Zannettino, A. C. W., White, D. L., & Hughes, T. P. (2008). Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients. In BLOOD Vol. 112 (pp. 80). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS22008 Hiwase, D. K., White, D. L., Saunders, V. A., Melo, J. V., Kumar, S., & Hughes, T. P. (2008). Short-Term Intense Bcr-Abl Kinase Inhibition Is Adequate to Trigger Cell Death in CML Cell Lines but Not in CML-CD34+Cells Unless They Are Growth Factor Deprived. In BLOOD Vol. 112 (pp. 397). San Francisco, CA: AMER SOC HEMATOLOGY. 2008 Esposito, N., Colavita, I., Quarantelli, F., Izzo, B., Luciano, L., Del Vecchio, L., . . . Pane, F. (2008). A decreased Level of Shp1 provides an additive survival advantage to the Ph plus Cells of CML Patients and may account for Resistance to Imatinib Treatment. In BLOOD Vol. 112 (pp. 1093). San Francisco, CA: AMER SOC HEMATOLOGY. 2008 White, D., Dang, P., Obbink, K. G., Frede, A., Kok, C., Hughes, T. P., & D'Andrea, R. (2008). Enhancing the Functional Activity of the OCT-1 Influx Pump May Overcome the Negative Impact of Low OCT-1 Activity in Imatinib Treated CML Patients. In BLOOD Vol. 112 (pp. 268-269). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS12008 Cross, C., Hochhaus, A., Mueller, M., Saglio, G., Branford, S., Hughes, T., . . . White, H. (2008). DEVELOPMENT OF PROTOTYPE REFERENCE MATERIALS FOR BCR-ABL QUANTITATIVE RT-PCR. In HAEMATOLOGICA Vol. 93 (pp. 54). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. 2008 Cortes, J., Baccarani, M., Guilhot, F., Druker, B. J., Branford, S., Kim, D. -W., . . . Hughes, T. P. (2008). A Phase III, Randomized. Open-Label Study of 400 Mg Versus 800 Mg of Imatinib Mesylate (1M) in Patients (pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints: 1-Year Results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study. In BLOOD Vol. 112 (pp. 130-131). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS142008 White, D., Saunders, V., Quinn, S., & Hughes, T. (2008). PATIENT-SPECIFIC IC50 ASSAYS IN IMATINIB-RESISTANT CIVIL PATIENTS ARE HIGHLY VARIABLE AND MAY BE CLINICALLY RELEVANT. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 93 (pp. 41). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. 2008 Cortes, J. G., Baccarani, M., Guilhot, F., Druker, B. J., Yu, R., Rudoltz, M., . . . Hughes, T. (2008). FIRST REPORT OF THE TOPS STUDY: A RANDOMIZED PHASE III TRIAL OF 400MG VS 800MG IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED, PREVIOUSLY UNTREATED CML IN CHRONIC PHASE USING MOLECULAR ENDPOINTS. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 93 (pp. 160). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.
WoS62008 Mullighan, C. G., Radtke, I., Zhang, J., Phillips, L. A., Su, X., Ma, J., . . . Downing, J. R. (2008). Genome-Wide Analysis of Genetic Alterations in Chronic Myelogenous Leukemia. In BLOOD Vol. 112 (pp. 397-398). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS62008 Vandyke, K., Dewar, A., Diamond, P., Fitter, S., Farrugia, A. N., To, L. B., . . . Zannettino, A. C. W. (2008). Dasatinib (Sprycel™) Inhibits Oteoclast Activity <i>in Vitro</i> and <i>in Vivo</i> Via a C-Fms-Dependent and C-Src-Independent Mechanism. In BLOOD Vol. 112 (pp. 1102-1103). San Francisco, CA: AMER SOC HEMATOLOGY. 2008 Morley, A. A., Bartley, P., Ross, D. M., Latham, S., Martin-Harris, H., Budgen, B., . . . Hughes, T. (2008). DNA-Based Monitoring of Minimal Residual Disease(MRD) in Chronic Myeloid Leukemia(CML). In BLOOD Vol. 112 (pp. 406). San Francisco, CA: AMER SOC HEMATOLOGY. 2008 Shah, N. P., Kantarjian, H. M., Kim, D. W., Réa, D., Dorlhiac-Llacer, P. E., Milone, J. H., . . . Hochhaus, A. (2008). Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. In Journal of Clinical Oncology Vol. 26 (pp. 3204-3212). Vienna, AUSTRIA: AMER SOC CLINICAL ONCOLOGY.
DOI Scopus447 WoS391 Europe PMC3142008 O'Brien, S. G., Guilhot, F., Goldman, J. M., Hochhaus, A., Hughes, T. P., Radich, J. P., . . . Larson, R. A. (2008). International Randomized Study of Interferon Versus ST1571 (IRIS) 7-year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib (IM). In BLOOD Vol. 112 (pp. 76). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS1302008 Mueller, M. C., Cortes, J., Kim, D. -W., Druker, B. J., Erben, P., Pasquini, R., . . . Hochhaus, A. (2008). Dasatinib Efficacy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Pre-Existing BCR-ABL Mutations. In BLOOD Vol. 112 (pp. 171-172). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS52008 Hochhaus, A., Mueller, M. C., Radich, J., Branford, S., Hanfstein, B., Rousselot, P., . . . Hughes, T. P. (2008). Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib. In BLOOD Vol. 112 (pp. 400). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS42008 Esposito, N., Quarantelli, F., Luciano, L., Izzo, B., Peluso, A. L., Picardi, M., . . . Pane, F. (2008). The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial. In BLOOD Vol. 112 (pp. 404). San Francisco, CA: AMER SOC HEMATOLOGY. 2008 Hughes, T. P., Hochhaus, A., Branford, S., Mueller, M. C., Foroni, L., Druker, B. J., . . . Goldman, J. M. (2008). Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP). In BLOOD Vol. 112 (pp. 129-130). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS102008 Guilhot, F., Hughes, T. P., Cortes, J., Wang, Y., Hayes, M., Gichangi, A., . . . Baccarani, M. (2008). Imatinib (IM) Pharmacokinetic (PK) Exposure and Its Correlation with Clinical Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) for 400 Mg and 800 Mg Daily Doses (Tyrosine Kinase Dose Optimization Study [TOPS]). In BLOOD Vol. 112 (pp. 170-171). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS42008 Hochhaus, A., Kim, D. -W., Martinelli, G., Hughes, T. P., Soverini, S., Branford, S., . . . Radich, J. P. (2008). Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP). In BLOOD Vol. 112 (pp. 1103-1104). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS22008 Branford, S., Lawrence, R., Grigg, A., Seymour, J. F., Schwarerl, A., Arthur, C., . . . Hughes, T. (2008). Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response. In BLOOD Vol. 112 (pp. 735-736). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS32008 Branford, S., Lawrence, R., Fletcher, L., Field, C., Rudzki, Z., & Hughes, T. (2008). The Initial Molecular Response of Chronic Phase CML Patients Treated with Second Generation ABL Inhibitor Therapy after Imatinib Failure Can Predict Inadequate Response and Provide Indications for Rational Mutation Screening. In BLOOD Vol. 112 (pp. 128). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS22008 White, D. L., Saunders, V. A., Kalebic, T., & Hughes, T. P. (2008). The IC50 Assay Is Predictive of Molecular Response, and Indicative of Optimal Dose in De-Novo CML Patients. In BLOOD Vol. 112 (pp. 405). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS12008 White, D. L., Saunders, V. A., Dang, P., Frede, A., Eadie, L., Soverini, S., . . . Hughes, T. (2008). CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study. In BLOOD Vol. 112 (pp. 1093-1094). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS32008 Radich, J., Kim, D. -W., Martinelli, G., Soverini, S., Branford, S., Mueller, M., . . . Saglio, G. (2008). RESPONSE TO NILOTINIB IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) ACCORDING TO BCR-ABL MUTATIONS AT BASELINE. In HAEMATOLOGICA Vol. 93 (pp. 55). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.
WoS32007 Branford, S., Fletcher, L., Cross, N. C. P., Hochhaus, A., Mueller, M. C., Kim, D. -W., . . . Hughes, T. (2007). Validation of the international scale for measurement of BCR-ABL by RQ-PCR based on deriving laboratory-specific conversion factors. In BLOOD Vol. 110 (pp. 307A). Atlanta, GA: AMER SOC HEMATOLOGY.
DOI WoS12007 Ross, D., Bartley, P. A., Morley, A. A., Seymour, J. F., Branford, S., & Hughes, T. P. (2007). Detection of patient-specific BCR-ABL genomic dna in cml patients with no detectable BCR-ABL by quantitative reverse transcriptase PCR. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 92 (pp. 212). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION.
WoS12007 Toplin, J., Fuller, C., Fletcher, L., Wong, S., Maslak, P., Cortes, J., . . . Beillard, E. (2007). An MMR control RNA for reliable monitoring of BCR-ABL transcripts in treated CML patients. In BLOOD Vol. 110 (pp. 863A-864A). Atlanta, GA: AMER SOC HEMATOLOGY.
DOI2007 Hughes, T., Saglio, G., Martinelli, G., Kim, D. -W., Soverini, S., Mueller, M., . . . Hochhaus, A. (2007). Responses and disease progression in CML-CP patients treated with nilotinib after imatinib failure appear to be affected by the BCR-ABL mutation status and types. In BLOOD Vol. 110 (pp. 101A). Atlanta, GA: AMER SOC HEMATOLOGY.
DOI WoS132007 Saglio, G., Kim, D. -W., Hochhaus, A., Soverini, S., Erben, P., Branford, S., . . . Radich, J. (2007). Correlation of clinical response to nilotinib with BCR-ABL mutation status in advanced phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or intolerance. In BLOOD Vol. 110 (pp. 576A-577A). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS42007 Stone, R. M., Kantarjian, H. M., Baccarani, M., Lipton, J. H., Hughes, T., Ezzeddine, R., . . . Hochhaus, A. (2007). Efficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180-013). In BLOOD Vol. 110 (pp. 225A). Atlanta, GA: AMER SOC HEMATOLOGY.
DOI WoS142007 Morley, A., Bartley, P., Martin-Harris, H., Latham, S., Ross, D., & Hughes, T. (2007). DNA-based measurement of BCR ABL in chronic myeloid leukemia (CML). In BLOOD Vol. 110 (pp. 865A-866A). Atlanta, GA: AMER SOC HEMATOLOGY.
DOI2007 Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In contrast to imatinib, OCT-1 mediated influx has minimal impact on cellular uptake of dasatinib in CML patients at diagnosis. In BLOOD Vol. 110 (pp. 575A-576A). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS72007 Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.. In Blood Vol. 110 (pp. 1937). American Society of Hematology.
DOI2007 Heaney, N., Drummond, M., Kaeda, J., Nicolini, F., Clark, R., Wilson, G., . . . Holyoake, T. L. (2007). A phase 3 pilot study of continuous imatinib versus pulsed imatinib with or without G-CSF in patients with chronic phase CML who have achieved a complete cytogenetic response to imatinib. In BLOOD Vol. 110 (pp. 313A). Atlanta, GA: AMER SOC HEMATOLOGY.
DOI WoS12007 Lewis, R. D., Jackson, C. L., Morgan, B. P., & Hughes, T. (2007). A role for CD59a in the progression of atherosclerosis: The first direct evidence from an in vivo study. In MOLECULAR IMMUNOLOGY Vol. 44 (pp. 3939). Cardiff, WALES: PERGAMON-ELSEVIER SCIENCE LTD.
DOI2007 White, D., Saunders, V. A., Dang, P., Lynch, K., Manley, P., & Hughes, T. P. (2007). The intracellular concentrations of imatinib and nilotinib, can be substantially altered by interaction with other drugs: Studies with proton pump inhibitors. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 92 (pp. 339). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION. 2006 Hochhaus, A., Ottmann, O. G., Lauber, S., Hughes, T., Verhoef, G., Schwarer, A. P., . . . Gattermann, N. (2006). A phase II study of nilotinib, a novel inhibitor of c-kit, PDGFR, and Bcr-Abl, administered to patients with systemic mastocytosis.. In BLOOD Vol. 108 (pp. 764A). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS22006 Seymour, J. F., Grigg, A., Reynolds, J., Schwarer, A. P., Hermann, R., Taylor, K. M., . . . Hughes, T. (2006). Two year data from a prospective safety study analyzing the consequences of imatinib mesylate inhibition of sensitive kinases other than bcr-abl in patients with previously untreated chronic phase CML.. In BLOOD Vol. 108 (pp. 609A). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS12006 White, D., Saunders, V., Dang, P., Venables, A., Zrim, S., Reynolds, J., . . . Hughes, T. (2006). Molecular response to imatinib is dependent on dose in CML patients with low OCT-1 influx activity. Patients with high activity may respond equally well to standard or increased dose imatinib.. In BLOOD Vol. 108 (pp. 222A). Orlando, FL: AMER SOC HEMATOLOGY. 2006 White, D., Dang, P., Venables, A., Saunders, V., Zrim, S., Zannettino, A., . . . Hughes, T. (2006). ABCB1 overexpression may predispose imatinib treated CML patients to the development of Abl kinase domain mutations, and may be an important contributor to acquired resistance.. In BLOOD Vol. 108 (pp. 608A). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS22006 Branford, S., Hughes, T., Stylian, S., Schwarer, A. P., Arthur, C., Filshie, R., . . . Taylor, K. M. (2006). Significant reduction of BCR-ABL transcripts after switching to imatinib therapy in patients with CML and complete or near-complete cytogenetic responses to interferon-alpha (IFN).. In BLOOD Vol. 108 (pp. 607A-608A). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS12006 Shah, N. P., Skaggs, B., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., & Sawyers, C. L. (2006). The most common dasatinib-resistant BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia are sensitive to VX-680: Rationale for early combination kinase inhibitor therapy.. In BLOOD Vol. 108 (pp. 617A). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS22006 Hochhaus, A., Erben, P., Branford, S., Radich, J., Kim, D. W., Martinelli, G., . . . Baccarani, M. (2006). Hematologic and cytogenetic response dynamics to nilotinib (AMN107) depend on the type of BCR-ABL mutations in patients with chronic myelogeneous leukemia (CML) after imatinib failure.. In BLOOD Vol. 108 (pp. 225A). Orlando, FL: AMER SOC HEMATOLOGY.
WoS42006 Shah, N. P., Skaggs, B., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., & Sawyers, C. L. (2006). Sequential kinase inhibitor therapy in CML patients can select for cells harboring compound BCR-ABL kinase domain mutations with increased oncogenic potency: Rationale for early combination therapy of ABL kinase inhibitors.. In BLOOD Vol. 108 (pp. 225A-226A). Orlando, FL: AMER SOC HEMATOLOGY.
WoS42006 Branford, S., Cross, N. C. P., Hochhaus, A., Radich, J., Saglio, G., Kim, D. W., . . . Hughes, T. (2006). First results from a collaborative initiative to develop an international scale for the measurement of BCR-ABL by RQ-PCR based on deriving laboratory-specific conversion factors.. In BLOOD Vol. 108 (pp. 221A). Orlando, FL: AMER SOC HEMATOLOGY.
WoS12006 Branford, S., Seymour, J. F., Grigg, A., Arthur, C., Lynch, K., & Hughes, T. (2006). Increasing frequency and marked stability of complete molecular response is observed in imatinib-treated CML patients with long-term follow up.. In BLOOD Vol. 108 (pp. 131A). Orlando, FL: AMER SOC HEMATOLOGY.
WoS42006 Ross, D. M., Hughes, T. P., & Branford, S. (2006). Reverse transcription with a random pentadecamer primer increases the sensitivity of quantitative PCR for BCR-ABL.. In BLOOD Vol. 108 (pp. 662A-663A). Orlando, FL: AMER SOC HEMATOLOGY.
DOI2006 Kaeda, J., Hochhaus, A., Radich, J., Branford, S., So, C., Gathmann, I., . . . Hughes, T. (2006). Patients with chronic phase CML in the IRIS study who receive imatinib mesylate (IM) 2nd line after prior IFN/Ara-C have sustained complete cytogenetic and major molecular response rates similar to 1st line IM patients.. In BLOOD Vol. 108 (pp. 607A). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS22005 Hughes, T. P., Branford, S., Reynolds, J., Koelmeyer, R., Seymour, J., Taylor, K., . . . Grigg, A. (2005). Maintenance of imatinib dose intensity in the first six months of therapy for newly diagnosed patients with CML is predictive of molecular response, independent of the ability to increase dose at a later point.. In BLOOD Vol. 106 (pp. 51A). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS42005 Lyons, A. B., Hughes, T. P., & Viboonjuntra, P. (2005). Production of GM-CSF by CML cells can modulate the anti-proliferative and pro-apoptotic effects of imatinib on CML CD34<SUP>+</SUP> cells. In BLOOD Vol. 106 (pp. 803A). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS12005 Shah, N. P., Nicoll, J. M., Branford, S., Hughes, T. P., Paquette, R. L., Talpaz, M., . . . Sawyers, C. L. (2005). Molecular analysis of dasatinib resistance mechanisms in CML patients identifies novel BCR-ABL mutations predicted to retain sensitivity to imatinib: Rationale for combination tyrosine kinase inhibitor therapy.. In BLOOD Vol. 106 (pp. 318A). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS112005 Roberts, M. M., Ross, D. M., Hughes, T. P., & To, L. B. (2005). Lymphoid foci in bone marrow of patients with chronic myeloid leukaemia treated with imatinib.. In BLOOD Vol. 106 (pp. 568A). Atlanta, GA: AMER SOC HEMATOLOGY.
DOI WoS12005 Sweeney, D. F., Sridhar, M. S., Vannas, A., Pravin, V. K., Kala, R., Hughes, T. C., . . . Xie, R. Z. (2005). Corneal inlays: Results of a 6 month phase 1 clinical trial. In INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE Vol. 46 (pp. 1 page). Ft Lauderdale, FL: ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2004 Sweeney, D. F., Xie, R. Z., Evans, M. D. M., Bojarski, B., Vannas, A., Hughes, T. C., . . . McLean, K. M. (2004). Long-term corneal biocompatibility to Pfpe polymers - Histological findings. In INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE Vol. 45 (pp. U306). Ft Lauderdale, FL: ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2004 Evans, M. D. M., Xie, R. Z., Bojarski, B., Hughes, T. C., McLean, K. M., Wilkie, J. S., . . . Sweeney, D. F. (2004). Long-term corneal biocompatibility of PFPE for an implantable contact lens. In Transactions - 7th World Biomaterials Congress (pp. 116). 2004 Shah, N. P., Branford, S., Hughes, T. P., Nicoll, J. M., Decillis, A. P., & Sawyers, C. L. (2004). Major cytogenetic responses to BMS-354825 in patients with chronic myeloid leukemia are associated with a one to two log reduction in <i>BCR</i>-<i>ABL</i> transcript.. In BLOOD Vol. 104 (pp. 288A). San Diego, CA: AMER SOC HEMATOLOGY.
WoS42004 Hughes, T. C., Chan, G. Y. N., Evans, M. D. M., Johnson, G., Le, T. P. T., McFarland, G., . . . Xie, R. Z. (2004). Perfluoropolyether corneal onlays: Adhesive development. In Transactions - 7th World Biomaterials Congress (pp. 1653). 2004 Hughes, T. C., Chan, G. Y. N., Evans, M. D. M., Johnson, G., Knower, W. S., Le, T. P. T., . . . Xie, R. Z. (2004). Hydrogel-like perfluoropolyethers. In Transactions - 7th World Biomaterials Congress (pp. 1607).
Scopus12004 McLean, K. M., Beumer, G. J., Bojarski, B., Chan, G. Y. N., Chaouk, H., Evans, M. D. M., . . . Xie, R. Z. (2004). Corneal implants for refractive error correction. In Transactions - 7th World Biomaterials Congress (pp. 1605). 2003 Branford, S., Rudzki, Z., Miller, B., Grigg, A., Seymour, J. F., Schwarer, A., . . . Hughes, T. P. (2003). Mutations in the catalytic core (P-Loop) of the BCR-ABL kinase domain of imatinib-treated chronic myeloid leukemia patients in chronic phase are strongly associated with imminent progression to blast crisis.. In BLOOD Vol. 102 (pp. 71A). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY.
WoS32003 Branford, S., Rudzki, Z., Grigg, A., Seymour, J. F., Taylor, K., Herrmann, R., . . . Hughes, T. P. (2003). The incidence of BCR-ABL kinase mutations in chronic myeloid leukemia patients is as high in the second year of imatinib therapy as the first but survival after mutation detection is significantly longer for patients with mutations detected in the second year of therapy.. In BLOOD Vol. 102 (pp. 414A). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY.
WoS62003 Hughes, T. P., Branford, S., Matthews, J., Seymour, J., Taylor, K., Guzzo-Pernell, N., . . . Grigg, A. (2003). Trial of higher dose imatinib with selective intensification in newly diagnosed CML patients in the chronic phase.. In BLOOD Vol. 102 (pp. 31A). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY.
WoS162003 Baccarani, M., Cortes, J., Daley, G. Q., Druker, B. J., Guilhot, F., Hochhaus, A., . . . Mahon, F. X. (2003). Comments on the hammersmith policy. In Seminars in Hematology Vol. 40 (pp. 104-113). Elsevier BV.
DOI2003 Hui, C. H., Goh, K., White, D., Branford, S., Grigg, A., Seymour, J., . . . Hughes, T. P. (2003). Mobilization of CD34+ cells from chronic myeloid leukemia patients achieving CCR on imatinib; safety and efficacy using filgrastim with or without continuation of imatinib. In BONE MARROW TRANSPLANTATION Vol. 31 (pp. S50). ISTANBUL, TURKEY: NATURE PUBLISHING GROUP. 2001 Hughes, T. C., Meijs, G. F., Chaouk, H., Steele, J. G., & Johnson, G. (2001). Porous perfluoroalkyl acrylates: A potential ophthalmic biomaterial.. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 222 (pp. U318). AMER CHEMICAL SOC. 2001 Ferrao, P. T., Frost, M. J., Coles, C. J., Domaschenz, R. M., Hughes, T. P., & Ashman, L. K. (2001). Activated mutant D816VKit confers resistance to chemotherapeutic drugs, irradiation and STI 571.. In CLINICAL CANCER RESEARCH Vol. 7 (pp. 3742S). AMER ASSOC CANCER RESEARCH. 2000 Bensinger, W., Cornetta, K., Carabasi, M., Yanovich, S., Hughes, T., Skikne, B., . . . Mills, B. (2000). T cell depleted allogeneic PBSC transplantation using CD34+cell selection.. In BLOOD Vol. 96 (pp. 199A). AMER SOC HEMATOLOGY. 2000 Bardy, P., Grigg, A. P., Szer, J., Roberts, A., Schwarer, A. P., Spencer, A., . . . Hughes, T. P. (2000). Successful engraftment with disease response following sibling allograft with reduced conditioning, T-cell depletion and delayed incremental DLI in CML and MM.. In BLOOD Vol. 96 (pp. 783A). AMER SOC HEMATOLOGY. 1997 Moore, S., Levesque, J. P., Haylock, D. N., McDiarmid, L., Samels, L., To, L. B., . . . Hughes, T. P. (1997). Kit ligand as the sole stimulatory agent induces marked proliferation of CD34+ CML cells without a concomitant increase in adhesion.. In BLOOD Vol. 90 (pp. 1746). W B SAUNDERS CO.
WoS11995 Juttner, C. A., To, L. B., Haylock, D. N., Dyson, P. G., Simmons, P. J., Bayly, J., . . . Thorp, D. (1995). Blood progenitor cells: Biologic and clinical issues. In Bone Marrow Transplantation Vol. 15. 1995 Lewis, L. D., Haylock, D. N., Moore, S., To, L. B., Juttner, C. A., & Hughes, T. P. (1995). Identification of normal primitive progenitors in blood and mobilised blood in chronic myeloid leukaemia.. In BLOOD Vol. 86 (pp. 2085). W B SAUNDERS CO.
WoS11993 Cullis, J. O., Szydlo, R. M., Cross, N. C. P., Marks, D. I., Schwarer, A. P., Hughes, T. P., . . . Goldman, J. M. (1993). Matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia in chronic phase: Comparison of ex vivo and in vivo T-cell depletion. In Bone Marrow Transplantation Vol. 11 (pp. 107-111). England.
Scopus12 Europe PMC41991 Goldman, J. M., & Hughes, T. (1991). Detection and significance of minimal residual disease in patients with leukaemia and lymphoma. In Bone Marrow Transplantation Vol. 7 (pp. 66-69). England.
Scopus3 Europe PMC21991 Hughes, T. P., O'Shea, P., Morgan, G., Martiat, P., & Goldman, J. M. (1991). Persistence of BCR/ABL transcripts after BMT for CML detected by PCR reflects a high risk of relapse. In Bone Marrow Transplantation Vol. 7 (pp. 23). England.
Scopus5 -
Conference Items
Year Citation 2021 Eadie, L., Heatley, S., McClure, B., Rehn, J., Schutz, C., Breen, J., . . . White, D. (2021). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of 4th International T-ALL/T-NHL conference: T-ALL2020: Omics, genetics and therapy. 2021 Eadie, L., Heatley, S., McClure, B., Rehn, J., Schutz, C., Breen, J., . . . White, D. (2021). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of 12th Biennial Childhood Leukemia and Lymphoma Symposium (CLLS). 2020 Poudel, G., Yeung, D., White, D., Hughes, T., & Pagani, I. (2020). Understanding the mechanisms of imatinib resistance in a Ph+ acute lymphoblastic leukaemia cell line. Poster session presented at the meeting of The 59th ASMR National Scientific Conference. 2020 Eadie, L., Heatley, S., McClure, B., Schutz, C., Breen, J., Hughes, T., . . . White, D. (2020). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of Australian & New Zealand Children’s Haematology/Oncology Group. 2020 Eadie, L. N., Rehn, J., Heatley, S. L., McClure, B. J., Schutz, C. S., Breen, J., . . . White, D. L. (2020). Next Generation Genomic Analyses in T-ALL Patients Identify Recurrent and Novel Genomic Abnormalities. Poster session presented at the meeting of BLOOD. ELECTR NETWORK: AMER SOC HEMATOLOGY.
DOI WoS12019 Yeung, D. T., Grigg, A., Shanmuganathan, N., Solterbeck, A. C., White, D. L., Branford, S., . . . Hughes, T. P. (2019). Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY.
DOI2019 El Khawanky, N., Hughes, A., Yu, W., Taromi, S., Clarson, J., Lopez, A. F., . . . Zeiser, R. (2019). Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS42019 Eadie, L., Heatley, S. L., McClure, B. J., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploration of the Genomic Diversity in T-ALL Patients Using mRNA Sequencing. Poster session presented at the meeting of 1st European Society of Haematology (ESH) Translational Conference on ALL. Berlin, Germany. 2019 Eadie, L., Heatley, S. L., McClure, B. J., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploration of the Genomic Diversity in T-ALL Patients Using mRNA Sequencing. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia. 2019 Heatley, S. L., McClure, B. J., Eadie, L. N., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploring the genomic diversity of AYA and adult high-risk B-ALL cases by mRNA sequencing. Poster session presented at the meeting of SAHMRI Annual Scientific Meeting. Adelaide, South Australia. 2019 Yeung, D. T., Shanmuganathan, N., Grigg, A., Cunningham, I., Shortt, J., Rowling, P., . . . Hughes, T. P. (2019). Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS22019 Talpaz, M., Cortes, J., Lang, F., Kim, D. -W., Rea, D., Mauro, M. J., . . . Hughes, T. P. (2019). Combination of Asciminib, a Novel and Specific BCR-ABL1 Inhibitor, Plus Imatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
DOI WoS32019 Hughes, T. P. (2019). CML Case Studies: Impact of Comorbidities. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
DOI2019 DeAngelo, D. J., Mauro, M. J., Kim, D. -W., Cortes, J., Rea, D., Hughes, T. P., . . . Lang, F. (2019). Combination of Asciminib plus Nilotinib or Asciminib plus Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
DOI WoS42019 Mahon, F. -X., Boquimpani, C., Takahashi, N., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . . . Hughes, T. P. (2019). ENESTop 192-Weeks Results: Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
DOI WoS42019 Hughes, T. P., Boquimpani, C., Takahashi, N., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . . . Mahon, F. -X. (2019). ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
WoS72018 Shanmuganathan, N., Branford, S., Yong, A. S. M., Hiwase, D. K., Yeung, D. T., Ross, D. M., & Hughes, T. P. (2018). The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS52018 Asari, K., Leclercq, T., Srihari, S., Fitter, S., Yeung, D., Hughes, T., . . . White, D. L. (2018). in vitro modelling of Ph-like ALL uncovers novel genomic alterations associated with TKI-resistance as a consequence of targeted therapy. Poster session presented at the meeting of Childhood Leukaemia and Lymphoma Symposium. Helsinki, Finland. 2018 Heatley, S. L., Mayne, B. T., McClure, B. J., Kok, C., Sadras, T., Dang, P., . . . White, D. L. (2018). Exploring the genomic diversity of AYA and adult high-risk B-ALL cases by mRNA sequencing. Poster session presented at the meeting of 23rd Congress of European Hematology Association. Stockholm, Sweden. 2018 Heatley, S. L., McClure, B. J., Kok, C., Sadras, T., Dang, P., Galbraith, K., . . . White, D. L. (2018). Exploring the genomic diversity of adult and AYA cases with high-risk B-ALL by mRNA sequencing. Poster session presented at the meeting of NDLR. 2018 Pagani, I. S., Kok, C., Saunders, V., Schwarer, A., Hughes, T. P., White, D. L., & Ross, D. M. (2018). Association of mitochondrial DNA (mtDNA) mutations at diagnosis with treatment response in chronic myeloid leukaemia (CML) patients. Poster session presented at the meeting of NDLR. 2018 Lu, L., Kok, C., Saunders, V., Nievergall, E., White, D. L., & Hughes, T. P. (2018). TGF-α predicts TKI treated CML patients who fail to achieve early molecular response. Poster session presented at the meeting of NDLR. 2018 Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of APG Student Awards. 2018 Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification of ruxolitinib resistance mutations in Pro-B cells driven by a high-risk JAK2 fusion in B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of ASMR. 2018 Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and Characterisation of Ruxolitinib Resistant Mutations in JAK2-rearranged B-cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of AGTA. 2018 Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification of mutations that cause ruxolitinib resistance in Pro-B cells driven by a high-risk B-ALL JAK2-fusion.. Poster session presented at the meeting of ANZCHOG. 2018 Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of SAHMRI Scientific Seminar. 2018 Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of EMBL Australia Postgraduate Symposium. 2017 El-Khawanky, N., Hughes, A., Yu, W., Clarson, J., Lopez, A. F., Brown, M., . . . Yong, A. (2017). CD123 Chimeric Antigen Receptor T-cells in Chronic and Acute Myeloid Leukaemia: pre-clinical in vitro studies. Poster session presented at the meeting of HAA. 2017 El-Khawanky, N., Hughes, T. P., Clarson, J., Yu, W., White, D. L., & Yong, A. (2017). Anti-CD123 Chimeric Antigen Receptor (CAR) T-cells in Chronic and Acute Myeloid Leukaemia: pre-clinical in vitro studies. Poster session presented at the meeting of ASMR. 2017 McClure, B. J., Heatley, S. L., Kok, C., Sadras, T., An, J., Quek, K., . . . White, D. L. (2017). EP300-ZNF384 is a recurrent fusion gene with distinct gene expression in adolescent/young adult pre-B-ALL patients. Poster session presented at the meeting of ANZCHOG. 2017 Heatley, S. L., Sadras, T., Kok, C., Nievergall, E., Quek, K., Dang, P., . . . White, D. L. (2017). High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk-Adapted Treatment. Poster session presented at the meeting of ANZCHOG. 2017 Asari, K., Sadras, T., Srihari, S., Fitter, S., An, J., Zannettino, A. C., . . . White, D. L. (2017). in vitro Modelling of Ph-like ALL Fusions Uncovers Novel Kinase-domain Mutations as a Mode of TKI-resistance and Potential Consequence of Targeted TKI Therapy. Poster session presented at the meeting of ANZCHOG. 2017 Ross, D. M., Pagani, I. S., Shanmuganathan, N., Seymour, J. F., Mills, A., Filshie, R., . . . Hughes, T. P. (2017). Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML). Poster session presented at the meeting of 59th ASH Annual Meeting & Exposition. 2017 Hughes, A., Clarson, J., White, D. L., Yeung, D., Hughes, T. P., & Yong, A. S. M. (2017). Nilotinib/Interferon-α Combination Rapidly Enhances Leukaemia-Associated Antigen Specific Cytotoxic T-Lymphocyte Immune Responses, Limits Natural Killer Cell Maturation and Triggers B Cell Remodelling. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
WoS42017 Yeung, D., Grigg, A., Shanmuganathan, N., Cunningham, I., Shortt, J., Rowling, P., . . . Hughes, T. P. (2017). Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. 2017 Pagani, I. S., Dang, P., Kommers, I. O., Goyne, J., Saunders, V. A., Prime, J. A., . . . Ross, D. M. (2017). COMPARISON OF GENOMIC DNA AND REVERSE TRANSCRIPTASE Q-PCR FOR THE MONITORING OF FIRST-LINE IMATINIB TREATMENT: AN ALLG CML9 SUB-STUDY. Poster session presented at the meeting of HAEMATOLOGICA. Madrid, SPAIN: FERRATA STORTI FOUNDATION. 2017 Cortes, J. E., Kantarjian, H. M., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., . . . Mueller, M. C. (2017). 5-YR RESULTS FROM THE PIVOTAL PHASE 2 PONATINIB PACE TRIAL: EFFICACY, SAFETY AND LANDMARK ANALYSIS IN HEAVILY PRETREATED PATIENTS (PTS) WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML). Poster session presented at the meeting of HAEMATOLOGICA. Madrid, SPAIN: FERRATA STORTI FOUNDATION. 2017 Hochhaus, A., Jabbour, E., Kantarjian, H., Guilhot, F., Kota, V., Hughes, T. P., . . . Cortes, J. E. (2017). 5-YEAR EFFICACY OF DASATINIB AND IMATINIB IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH DOSE MODIFICATIONS FROM DASISION. Poster session presented at the meeting of HAEMATOLOGICA. Madrid, SPAIN: FERRATA STORTI FOUNDATION. 2017 Downes, C. E., McClure, B. M., Heatley, S. H., Sadras, T. S., Hughes, T. H., Kok, C. K., . . . White, D. W. (2017). Identification and cloning of a novel GOLGA4-JAK2 fusion from an adult patient with B-cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Poster session presented at the ASMR SA Scientific Meeting. Adelaide. 2017 Heatley, S., Sadras, T., Kok, C., Nievergall, E., Quek, K., Dang, P., . . . White, D. (2017). High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Poster session presented at the meeting of Abstracts of the 57th Annual Meeting of the American Society of Hematology, as published in Blood. Orlando, FL: American Society of Hematology.
DOI WoS22016 Mueller, M., Baccarani, M., Deininger, M. W., Guilhot, F., Hochhaus, A., Hughes, T. P., . . . Cortes, J. E. (2016). LANDMARK ANALYSES IN THE PIVOTAL PONATINIB PACE TRIAL: IMPACT OF EARLY RESPONSES ON 3-YEAR OUTCOMES IN HEAVILY PRETREATED CP-CML PATIENTS. Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. 2016 Kok, C. H., Watkins, D., Wang, J., Saunders, V., Goyne, J., Pagani, I., . . . White, D. (2016). HIGH GENE EXPRESSION OF HIST1H2AG AND HIST1H4A REDUCES IMATINIB UPTAKE INTO CML CELLS AND PREDICTS POOR RESPONSE TO FRONTLINE IMATINIB THERAPY. Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. 2016 Hughes, T. P., Boquimpani, C., Takahashi, N., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . . . Mahon, F. X. (2016). RESULTS FROM ENESTOP: TREATMENT-FREE REMISSION (TFR) FOLLOWING SWITCH TO NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP). Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.
WoS52016 Cortes, J. E., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., Nicolini, F. E., . . . Kantarjian, H. M. (2016). LONG-TERM EFFICACY AND SAFETY OF PONATINIB IN HEAVILY PRETREATED LEUKEMIA PATIENTS: 4-YEAR RESULTS FROM THE PIVOTAL PHASE 2 PACE TRIAL. Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.
WoS12016 Sadras, T., Heatley, S., Dang, P., Kok, C., Quek, K., Nievergall, E., . . . White, D. L. (2016). A nine-gene signature defines 2 groups of CRLF2 rearranged B-ALL patients with distinctive genetic features. Poster session presented at the meeting of .. Athens. 2016 Pagani, I. S., Kok, C., Saunders, V., Goyne, J., McLean, J., Vanderhoek, M., . . . Ross, D. (2016). The genomic landscape of mitochondrial DNA mutations in chronic myeloid leukaemia. Poster session presented at the meeting of .. Barcelona, Spain. 2016 Eadie, L., Saunders, V., Branford, S., Hughes, T., & White, D. (2016). Resistance mechanisms of the new allosteric inhibitor ABL001. Poster session presented at the meeting of ,. Houtson, USA. 2016 Eadie, L., Goyne, J., Hughes, T., & White, D. (2016). ABCC6 plays a significant role in the transport of nilotinib in both cells lines and primary patient cells, and may contribute to resistance. Poster session presented at the meeting of ,. Houston, USA. 2016 Saunders, V. A., Wang, J., Lu, L., Eadie, L. N., McLean, J. A., Goyne, J. M., . . . Hughes, T. P. (2016). A Low Concentration of ABL001 Potentiates <i>In Vitro</i> TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS12016 Eadie, L. N., Goyne, J., Hughes, T., & White, D. L. (2016). The ABCC6 Transporter Plays a Significant Role in the Efflux of Nilotinib and Dasatinib, and May Contribute to Tyrosine Kinase Inhibitor Resistance. Poster session presented at the meeting of .. San Diego, USA: AMER SOC HEMATOLOGY.
DOI2016 Eadie, L., Hughes, T., & White, D. (2016). ABCB1 overexpression predicts outcome of CML patients undergoing first-line imatinib treatment. Poster session presented at the meeting of Abstract presented at the New Directions in Leukaemia Research 2016 Meeting. Noosa, QLD. 2016 Eadie, L., Saunders, V., Leclercq, T., Branford, S., White, D. L., & Hughes, T. (2016). Abl001 Is Susceptible To Resistance Mediated By Overexpression Of Drug Transporters Abcb1 and Abcg2. Poster session presented at the meeting of .. Noosa, QLD. 2016 Sadras, T., Heatley, S., Kok, C., Quek, K., Dang, P., Nievergall, E., . . . White, D. L. (2016). CRLF2 rearranged B-ALL cases with a Ph-like gene signature are enriched for JAK2 mutations. Poster session presented at the meeting of .. Noosa, QLD. 2016 Lu, L., Saunders, V., Kok, C., Leclercq, T., Hughes, T., & White, D. (2016). Modelling ponatinib resistance in BCR-ABL1+ cell lines: implications for ponatinib therapy. Poster session presented at the meeting of New Directions in Leukaemia Research 2016. Noosa, QLD. 2016 McClure, B., Heatley, S., Sadras, T., Nievergall, E., Kok, C., Dang, P., . . . White, D. L. (2016). Identification of a significantly high prevalence of relapse in Australian children with Ph-like ALL. Poster session presented at the meeting of .. Noosa, QLD. 2016 Asari, K., Heatley, S., Leclercq, T., Fitter, S., Zannettino, A., Hughes, T., & White, D. L. (2016). In vitro Modelling of Therapeutic Resistance to Elucidate Mechanisms of TKI-Resistant High-Risk ALL. Poster session presented at the meeting of .. Noosa, QLD. 2016 Pagani, I., Kok, C., Saunders, V., Goyne, J., McLean, J., Vanderhoek, M., . . . White, D. L. (2016). Do mitochondrial mutations in chronic myeloid leukaemia identify a pre-leukemic clone?. Poster session presented at the meeting of .. Noosa, QLD. 2016 Eadie, L., Dang, P., Saunders, V., Hughes, T., & White, D. L. (2016). The clinical significance of early imatinib induced ABCB1 overexpression in chronic phase CML patients treated sequentially with imatinib and nilotinib: A TIDEL II sub-study. Poster session presented at the meeting of ,. Adelaide, SA. 2016 White, D. L., McClure, B., Heatley, S., Sadras, T., Quek, K., & Hughes, T. (2016). Investigation of the transforming capacity of a recently identified EP300-ZNF384 fusion gene in adult acute lymphoblastic leukaemia. Poster session presented at the meeting of Poster Session. Adelaide, SA. 2016 Asari, K., Heatley, S., Leclercq, T., Fitter, S., Kok, C. H., Zannettino, A., . . . White, D. L. (2016). Investigating Modes of Therapeutic Resistance via In Vitro Modelling of TKI-resistant High-Risk Philadelphia-chromosome-positive and Philadelphia-chromosome-like Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Poster Session. Adelaide, SA. 2016 Watts, S., Saunders, V., Wee, A., Kutyna, M., White, D. L., Hughes, T., & Hiwase, D. (2016). Understanding the mechanism of secondary resistance to Azacitidine in Myelodysplastic syndromes using the cell-line model MOLM-13. Poster session presented at the meeting of Poster Session. Adelaide, SA. 2016 Kok, C. H., Watkins, D., Wang, J., Saunders, V., Goyne, J., Pagani, I. S., . . . White, D. L. (2016). High Gene Expression of hist1h2ag and hist1h4a Reduces Imatinib Uptake into CML Cells and Predicts Poor Response to Frontline Imatinib Therapy. Poster session presented at the meeting of Poster Session. Melbourne, VIC. 2016 Heatley, S., Sadras, T., McClure, B., Kok, C. H., Dang, P., Nievergall, E., . . . White, D. L. (2016). The Incidence of Ph-like Acute Lymphoblastic Leukaemia (ALL) Increases with Age and is Characterised by Poor Outcome. Poster session presented at the meeting of Poster Session. Melbourne, VIC. 2016 Pagani, I. S., Kok, C. H., Wang, J., Saunders, V., Van der Hoek, M., Heatley, S., . . . Ross, D. (2016). Mitochondrial DNA Mutations at Diagnosis are Linked to Response in TKI treated Chronic Myeloid Leukaemia Patients. Poster session presented at the meeting of Poster Session. Melbourne, VIC. 2016 Watts, S., Wee, A., Saunders, V., Kutyna, M., White, D. L., Hughes, T., & Hiwase, D. (2016). Determining Mechanisms of Resistance to Azacitidine (Aza) in Myelodysplastic (MDS) Syndromes and Acute Myeloid Leukaemia (AML) using an in-vitro model. Poster session presented at the meeting of Poster Session. Melbourne, VIC. 2016 Lu, L., Saunders, V., Kok, C. H., Leclercq, T., Hughes, T., & White, D. L. (2016). Modelling Ponatinib Resistance In BCR-ABL1+ Cell Lines: Implications For Ponatinib Therapy. Poster session presented at the meeting of Poster Session. Adelaide, SA. 2016 Hughes, A., Clarson, J., White, D. L., Ross, D. M., Hughes, T. P., & Yong, A. S. (2016). Enhanced Natural Killer and Cytotoxic T Lymphocyte Responses, with Decreased Monocytic Myeloid Derived Suppressor Cells May Promote Treatment Free Remission in Chronic Myeloid Leukaemia Patients Following Tyrosine Kinase Inhibitor Cessation. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS62015 Guilhot, F., Khoury, H. J., Baccarani, M., Hochhaus, A., Hughes, T. P., Lipton, J. H., . . . Mauro, M. J. (2015). ELEVATED BLOOD PRESSURE (BP) AND ADVERSE EVENTS OF HYPERTENSION (HTN) IN PHASE 1, 2, AND 3 TRIALS OF PONATINIB IN LEUKEMIA. Poster session presented at the meeting of HAEMATOLOGICA. Vienna, AUSTRIA: FERRATA STORTI FOUNDATION.
WoS12015 Cortes, J., Kim, D. W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., . . . Kantarjian, H. M. (2015). PONATINIB EFFICACY AND SAFETY IN HEAVILY PRETREATED LEUKEMIA PATIENTS: 3-YEAR RESULTS OF THE PACE TRIAL. Poster session presented at the meeting of HAEMATOLOGICA. Vienna, AUSTRIA: FERRATA STORTI FOUNDATION.
WoS122015 Mueller, M. C., Baccarani, M., Deininger, M. W., Guilhot, F., Hochhaus, A., Hughes, T. P., . . . Cortes, J. E. (2015). Responses to Ponatinib at early landmark time points are associated with Progression-Free Survival (PFS) and Overall Survival (OS) in heavily pretreated Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) patients (Pts). Poster session presented at the meeting of Oncology Research and Treatment. KARGER. 2015 Foreman, C., Russo, P., Davies, N., Hissaria, P., Hughes, T., Proudman, S., & Limaye, V. (2015). AN AUDIT OF IVIG USE FOR INFLAMMATORY MYOPATHIES IN SOUTH AUSTRALIA. Poster session presented at the meeting of INTERNAL MEDICINE JOURNAL. WILEY-BLACKWELL. 2014 Branford, S., Yeung, D., Ross, D., Parker, W., Braley, J., Seymour, J., & Hughes, T. (2014). The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatment. Poster session presented at the meeting of Abstract of power point presentation at 56th ASH Annual Meeting, published in Blood. San Francisco, California: American Society of Hematology. 2014 Yeung, D. T., Vidovic, L., Tang, C., White, D. L., Branford, S., Hughes, T. P., & Yong, A. S. M. (2014). KIR2DL5B Genotype Independently Predicts Poor Outcomes in CML-CP Patients Switched to Nilotinib after Suboptimal Responses to Imatinib and May Refine Prognosis in Patients with EMR Failure. Poster session presented at the meeting of BLOOD. San Francisco, CA: AMER SOC HEMATOLOGY. 2014 Nievergall, E., Reynolds, J., Kok, C. H., Watkins, D., Biondo, M., Busfield, S. J., . . . Hughes, T. P. (2014). High plasma levels of TGF-α and IL-6 at diagnosis predict early molecular response failure and transformation in CML. Poster session presented at the meeting of Abstract of presentation to 56th ASH Annual Meeting, published in Blood. San Francisco, California: American Society of Hematology.
DOI WoS12014 Branford, S., Ross, D., Yeung, D., Braley, J., & Hughes, T. (2014). Achieving the deep molecular response levels required for an imatinib discontinuation trial is strongly associated with the BCR-ABL level at the first qualifying timepoint. Poster session presented at the meeting of Abstract of power point presentation at 56th ASH Annual Meeting, published in Blood. San Francisco, California: American Society of Hematology.
WoS22014 Parker, W. T., Phillis, S. R., Yeung, D. T., Lawrence, D., Schreiber, A., Wang, P., . . . Branford, S. (2014). Detection of BCR-ABL1 Compound and Polyclonal Mutants in Chronic Myeloid Leukemia Patients Using a Novel Next Generation Sequencing Approach That Minimises PCR and Sequencing Errors. Poster session presented at the meeting of BLOOD. San Francisco, CA: AMER SOC HEMATOLOGY.
DOI WoS42014 Branford, S., Yeung, D., Parker, W. T., Purins, L., Braley, J., Seymour, J. F., . . . Hughes, T. P. (2014). PROGNOSIS FOR CML PATIENTS WITH >10% BCR-ABL AFTER 3 MONTHS OF IMATINIB DEPENDS ON THE INITIAL RATE OF BCR-ABL DECLINE. Poster session presented at the meeting of HAEMATOLOGICA. Milan, ITALY: FERRATA STORTI FOUNDATION. 2014 Kantarjian, H. M., Kim, D. -W., Pinilla-Ibaz, J., Le Coutre, P. D., Paquette, R., Chuah, C., . . . Cortes, J. E. (2014). Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph plus ) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS52014 Lu, L., Saunders, V., Kok, C. H., Leclercq, T., Hughes, T. P., & White, D. L. (2014). Modeling Ponatinib Resistance in <i>BCR-ABL1</i>+ Cell Lines: Implications for Ponatinib Resistance in TKI-Resistant and TKI-naive Patients. Poster session presented at the meeting of BLOOD. AMER SOC HEMATOLOGY. 2014 Deininger, M. W., Cortes, J. E., Kim, D. -W., Nicolini, F. E., Talpaz, M., Baccarani, M., . . . Hughes, T. P. (2014). Impact of Baseline Mutations on Response to Ponatinib and End of Treatment Mutation Analysis in Patients With Chronic Myeloid Leukemia. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
DOI2014 Lipton, J. H., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Assouline, S., . . . Deininger, M. W. (2014). Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML). Poster session presented at the meeting of BLOOD. AMER SOC HEMATOLOGY.
WoS32013 White, D. L., Schafranek, L., Nievergall, E., Powell, J. A., Hiwase, D., Leclercq, T., & Hughes, T. (2013). STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a Bcr-Abl-dependent, but JAK2-independent manner.. Poster session presented at the meeting of American Society of Haematology. New Orleans, USA. 2013 White, D., Saunders, V., Eadie, L., David, Y., & Hughes, T. P. (2013). The Depth Of <i>In Vivo</i> Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels. Poster session presented at the meeting of BLOOD. New Orleans, LA: AMER SOC HEMATOLOGY.
WoS12013 Wang, J., Kok, C. H., D'Andrea, R. J., Hughes, T. P., & White, D. L. (2013). Role Of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) and Its Ligands In The Regulation Of Functional OCT-1 Activity In CML Cells. Poster session presented at the meeting of BLOOD. New Orleans, LA: AMER SOC HEMATOLOGY.
DOI2013 White, D. L., Eadie, L., & Hughes, T. (2013). Increasing Expression of the Efflux Transporter ABCB1 may Predispose CML Cells to Overt TKI Resistance.. Poster session presented at the meeting of American Society of Haematology. New Orleans, USA. 2013 Deininger, M. W. N., Cortes, J. E., Kim, D. -W., Nicolini, F. E., Talpaz, M., Baccarani, M., . . . Hughes, T. P. (2013). Impact of baseline mutations on response to ponatinib and end of treatment mutation analysis in patients with chronic myeloid leukemia.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
WoS42013 Spector, N., Leber, B., Lipton, J. H., De Souza, C., Moiraghi, B., Steegmann, J. L., . . . Rea, D. (2013). Switching patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with residual disease on long-term imatinib (IM) to nilotinib (NIL): ENESTcmr 24-mo follow-up. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2013 Parker, W., Yeoman, A., Altamura, H., Roberts, N., Yeung, D., Jamison, B., . . . Branford, S. (2013). Additional BCR-ABL1 Mutations Identified By Sensitive Mass Spectrometry In Chronic Phase CML Patients With T315I Treated With Ponatinib Are Associated With Relatively Inferior Responses and Outcome. Poster session presented at the meeting of Blood. Amer Soc Hematology. 2013 Hiwase, D., Yeung, D., Carne, L., Ross, D., Grigg, A., & Hughes, T. (2013). Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis. Poster session presented at the meeting of Blood. Amer Soc Hematology.
WoS82013 Deininger, M., Shah, N., Cortes, J., Kim, D. W., Nicolini, F., Talpaz, M., . . . Branford, S. (2013). Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML). Poster session presented at the meeting of Blood. Amer Soc Hematology.
WoS32013 Parker, W., Phillis, S., Yeung, D., Hughes, T., Scott, H., & Branford, S. (2013). PCR-mediated recombination can lead to artificial chimera formation, which may pose as BCR-ABL1 compound mutations. Poster session presented at the meeting of Oral Sessions from the 55th ASH Annual Meeting and Exhibition, as published in Blood. New Orleans, Louisiana: American Society of Hematology. 2012 Branford, S., Ross, D., Prime, J., Field, C., Altamura, H., Yeoman, A., . . . Hughes, T. (2012). Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable <i>BCR</i>-<i>ABL1</i>, a Criterion for Imatinib Discontinuation in Patients with CML. Poster session presented at the meeting of BLOOD. GA, Atlanta: AMER SOC HEMATOLOGY.
DOI WoS62012 Watkins, D. B., Kok, C. H., D'Andrea, R. J., Hughes, T. P., & White, D. L. (2012). Global DNA methylation analysis identifies key pathway differences between poor (low OCT-1 activity) and standard risk CP-CML patients at diagnosis. Poster session presented at the meeting of “Abstracts of the 54th Annual Meeting and Exposition of the American Society of Hematology, as published in Blood. Atlanta, GA: America Society of Hematology. 2012 Nievergall, E., White, D. L., Yong, A. S. M., Ramshaw, H. S., Busfield, S. J., Vairo, G., . . . Hiwase, D. K. (2012). Effective Elimination of CML Progenitor and Stem Cells Through Combination of α-CD123 Antibody-Dependent Cell-Mediated Cytotoxicity and Tyrosine Kinase Inhibitor Treatment. Poster session presented at the meeting of BLOOD. GA, Atlanta: AMER SOC HEMATOLOGY.
DOI2012 Schafranek, L., Nievergall, E., Powell, J. A., Hiwase, D. K., White, D. L., & Hughes, T. P. (2012). Commitment of CML Cells to Apoptotic Cell Death Depends On the Length of Exposure to Das and the Level of STAT5 Activity. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
DOI WoS32012 Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . Hughes, T. P. (2012). Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
DOI WoS82012 Parker, W. T., Yeoman, A. L., Jamison, B. A., Yeung, D. T., Scott, H. S., Hughes, T. P., & Branford, S. (2012). The patient's BCR-ABL1 Kinase Domain Mutation History Is Important for Decisions Regarding Tyrosine Kinase Inhibitor Therapy. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
DOI2012 White, D. L., Saunders, V., Yeung, D., Grigg, A., & Hughes, T. (2012). Early Molecular Response to Imatinib in CP-CML Patients: The Significance of Early Dose Intensity and OCT-1 Activity in Responders and Efficacy of Dose Escalation and Switch to Nilotinib in Non-Responders.. Poster session presented at the meeting of American Society of Haematology. Atlanta, USA. 2012 Delphine, R., Gautier, J. -F., Breccia, M., Saglio, G., Hughes, T. P., Kantarjian, H. M., . . . Hochhaus, A. (2012). Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
DOI WoS42012 Hochhaus, A., Hughes, T. P., Saglio, G., Guilhot, F., Al-Ali, H. K., Rosti, G., . . . Kantarjian, H. M. (2012). Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). Poster session presented at the meeting of BLOOD. GA, Atlanta: AMER SOC HEMATOLOGY.
DOI WoS192012 Cortes, J. E., Pasquini, R., Kantarjian, H. M., Joske, D., Meillon, L. A., Shen, Z., . . . Hughes, T. P. (2012). First-Line Treatment and Management of Chronic Myeloid Leukemia (CML) in Clinical Practice: Update of > 1800 Patients (Pts) in the WORLD CML Registry. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
DOI2012 Kantarjian, H. M., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., . . . Cortes, J. E. (2012). Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
DOI WoS32011 Saglio, G., Kantarjian, H., Reiffers, J., Jootar, S., Kalaycio, M. E., Shibayama, H., . . . Hochhaus, A. (2011). The incidence of BCR-ABL mutations in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) treated with nilotinib or imatinib in ENESTnd: 24-month follow-up. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
DOI WoS22011 Larson, R. A., Kim, D., Rosti, G., Stenke, L., Pasquini, R., Hoenekopp, A., . . . Kantarjian, H. (2011). Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
DOI WoS12011 Soverini, S., Angelini, S., Barnett, M., Ravegnini, G., Pane, F., Hughes, T. P., . . . Martinelli, G. (2011). Pharmacogenetics of drug transporters may be useful to identify chronic myeloid leukemia patients who are less likely to achieve molecular responses to imatinib: Implications for treatment optimization in the era of new tyrosine kinase inhibitors. Poster session presented at the meeting of CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
DOI2011 Yin, O. Q., Giles, F. J., Baccarani, M., le Coutre, P., Chia, Y. L., Gallagher, N., . . . Larson, R. A. (2011). CONCURRENT USE OF PROTON PUMP INHIBITORS (PPI) OR H2-BLOCKERS DID NOT ADVERSELY AFFECT NILOTINIB RESPONSE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML). Poster session presented at the meeting of CLINICAL PHARMACOLOGY & THERAPEUTICS. Dallas, TX: NATURE PUBLISHING GROUP. 2011 Hughes, T. P., Kim, D. -W., Etienne, G., De Souza, C., Kurokawa, M., Kalaycio, M., . . . Hochhaus, A. (2011). The Incidence of BCR-ABL Mutations and Their Impact on Outcome in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib or Imatinib in ENESTnd: 36-Month Follow-up. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
WoS22011 Hochhaus, A., Ossenkoppele, G., Reiffers, J., Yao, M., Shibayama, H., Gatterman, N., . . . Kantarjian, H. M. (2011). Results From the ENESTnd Extension Study: Efficacy and Safety of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Treated with Nilotinib 400 Mg Twice Daily (BID) After Suboptimal Response (SoR) or Treatment Failure (TF) to Imatinib 400 Mg Once Daily (QD) or Nilotinib 300 Mg BID. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY. 2011 Larson, R. A., Bunworasate, U., Turkina, A. G., Goldberg, S. L., Dorlhiac-Llacer, P., Lopez, J. L., . . . Hughes, T. P. (2011). Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
WoS22011 Saglio, G., LeCoutre, P. D., Pasquini, R., Jootar, S., Nakamae, H., Flinn, I. W., . . . Kantarjian, H. M. (2011). Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
WoS12008 Vandyke, K., Dewar, A. L., Davis, A. N., Fiuer, S., Hughes, T. P., To, L. B., & Zannettino, A. C. W. (2008). The tyrosine kinase inhibitor dasatinib decreases osteoclast formation and activity in vitro. Poster session presented at the meeting of 30th Annual Meeting of the American Society for Bone and Mineral Research, as published in Journal of Bone and Mineral Research. Montreal, Canada: Wiley.
DOI
2021 - 2026 Medical Research Future Fund (MRFF) - Research Grants - Precision Medicine for Chronic Myelomonocytic Leukaemia: Phase II Trial Studying the Efficacy of Lenzilumab or High Dose Ascorbate plus Azacitidine Based on Molecular Profiling Compared to Risk-matched Historical Cohort.
2020 Cancer Council SA Beat Cancer Research Project Grant. Developing an artificial intelligence-based algorithm to enable a risk-adapted approach to frontline therapy in chronic myeloid leukaemia (CML)
2018 Australian Cancer Research Fund (ACRF) – Infrastructure: ACRF Centre for Integrated Cancer Systems Biology (ACRFCICSB).
2018 - 2021 NHMRC Project Grant. Chronic Myeloid Leukaemia: Changing the treatment paradigm
2018 - 2022 NHMRC. Principal Research Fellowship. Improving Leukaemia Outcomes
2016 – 2018 Leukemia & Lymphoma Society (US). Translational Research Program Grant
2015 - 2019 NHMRC Program Grant: Cytokine dysregulation in leukaemia
2015 Bristol Meyer Squibb Australia. Correlative Science Proposal Associated with the DIRECT study.
2014 - 2017 Determining the prerequisites for the achievement of treatment-free remission in chronic myeloid leukaemia to facilitate the development of new therapeutic approaches with curative intent.
2014 Bristol Meyer Squibb Australia. Correlative Science Proposal Associated with the REGALLIA clinical trial registry.
2014 Bristol Meyer Squibb Australia. Correlative Science Proposal Associated with the REGALLIA clinical trial registry.
2014 Novartis Australia. Correlative Science Proposal Associated with the ENESTxtnd clinical trial.
2013 - 2015 Screening for recently defined genetic lesions in poor risk adult and childhood ALL, and developing treatment approaches to target causative pathways
2013 - 2017 NHMRC. Practitioner Fellowship
2012 - 2014 NHMRC. Assessment of markers of genomic instability for the prediction of treatment response of chronic myeloid leukaemia
2012 – 2014 NHMRC. Characterisation of a new poor-risk sub-category of chronic phase chronic myeloid leukaemia
2012 – 2014 NHMRC. Development of a treatment algorithm for kinase inhibitor therapy in CML
2011 - 2012 Leukaemia Foundation of Australia. Developing a gene signature to predict the optimal front-line kinase inhibitor for CP-CML patients
2011 - 2013 Novartis Pharmaceuticals Australia. Correlative Science Proposal Associated with the ENESTxtnd clinical trial.
2011 Novartis Pharmaceuticals Australia. Correlative Science Associated with TIDELII Clinical Trial – expansion of patient numbers.
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2023 Co-Supervisor Investigating the role of lipid metabolism in chronic myeloid leukaemia Doctor of Philosophy Doctorate Full Time Miss Molly Gladys Tolland 2021 Co-Supervisor Investigation of current, innovative treatments and the roles of secondary genomic lesions in BCR-ABL1 positive leukaemias Doctor of Philosophy Doctorate Part Time Mr Elias Lagonik 2021 Co-Supervisor Genomic Mechanisms Influencing Outcome In Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Miss Adelina Catherina B. Fernandes -
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2019 - 2023 Principal Supervisor Unravelling Resistance Mechanisms in Philadelphia Positive Leukemias: Targeted Treatment Strategies to Overcome Resistance Doctor of Philosophy Doctorate Full Time Mr Govinda Poudel 2012 - 2014 Principal Supervisor The role of cytokines in governing the expansion of the T315I mutation in Chronic myeloid leukaemia Master of Philosophy (Medical Science) Master Full Time Dr Oi-Lin Lee 2012 - 2016 Co-Supervisor In Vitro Investigation of Intracellular Ponatinib Transport and Modeling Ponatinib Resistence in BCR-ABL1+ Cell Lines: Implications for Therapeutic Strategies Doctor of Philosophy Doctorate Full Time Miss Liu Lu 2012 - 2016 Co-Supervisor Prognostic Markers Associated With Tyrosine Kinase Inhibitor Treatment Response and Maintenance of Treatment Free Remission in Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Prof David Yeung 2010 - 2014 Principal Supervisor Assessment of Critical Survival Mechanisms Exploited by BCR-ABL1+ Cells to Evade Tyrosine Kinase Inhibitor-Induced Death; Determination of Novel Therapeutic Targets in Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Miss Lisa Schafranek 2010 - 2014 Co-Supervisor Defining CP-CML patient subsets associated with poor imatinib uptake and response Doctor of Philosophy Doctorate Full Time Mr Dale Benjamin Watkins 2009 - 2013 Principal Supervisor Nilotinib Efflux and Resistance Development: The Effects of Combination and Concomitant Therapies on the Transport and Efficacy of Nilotinib Doctor of Philosophy Doctorate Full Time Ms Laura Eadie 2008 - 2013 Principal Supervisor Investigating Drugs that Enhance Imatinib Uptake and Factors which Contribute to the Functional Activity of OCT-1 in CML Cells Doctor of Philosophy Doctorate Full Time Miss Jueqiong Wang 2008 - 2012 Principal Supervisor TKI Resistance in CML Cell Lines: Investigating Resistance Pathways Doctor of Philosophy Doctorate Full Time Mrs Carine Tang 2007 - 2011 Principal Supervisor Cell Lineage, Cell Maturity and BCR-ABL: Factors Which Influence Imatinib Uptake in Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Ms Jane Engler 2006 - 2009 Principal Supervisor Minimal Residual Disease in Chronic Myeloid Leukaemia after Imatinib Treatment Doctor of Philosophy Doctorate Full Time Dr David Ross 2005 - 2009 Co-Supervisor Investigating the Effects of ABL Kinase Inhibitors on the Signalling and Function of Normal Leukocytes and Leukemic Cells Doctor of Philosophy Doctorate Full Time Mr Stephen Blake 2004 - 2008 Principal Supervisor Factors which Impact on the Response of CML Patients to ABL Kinase Inhibitor Therapy: A Study of Imatinib and Nilotinib Doctor of Philosophy Doctorate Part Time Prof Deborah Lee White 2001 - 2006 Co-Supervisor GM-CSF Protection of CML CD34+ Cells from the Inhibitory Effect of Imatinib Doctor of Philosophy Doctorate Full Time Mr Pongtep Viboonjuntra
Connect With Me
External Profiles
